Current and emerging antibacterial strategies for periprosthetic joint infection: An overview Authors: Marco Fosca, Veronica Manescu, Iulian Antoniac, Julietta V. Rau Published: 2026 ABSTRACT Periprosthetic Joint Infection (PJI) represents one of the most serious complications following joint arthroplasty, with impactful consequences in the clinic and economy. Characterized by biofilm formation on implant surfaces, PJI poses significant therapeutic challenges due to the limited efficacy of systemic antibiotics and the increasing prevalence of multidrug-resistant bacteria. This review paper presents a comprehensive analysis of current and emerging antibacterial strategies designed to mitigate the risk of infection in total joint arthroplasty (TJA). It spans two decades of literature, from 2003 to 2025, with a particular focus on local antibiotic delivery systems, including bone cements, spacers, beads, and novel biomaterial carriers evaluated across in vitro assays, in vivo animal models, and in vivo clinical trials. A systematic search of the Web of Science Core Collection (1 January 2003–31 December 2025; last search: October 2025) identified 300 records; after de-duplication and screening, 138 studies met inclusion criteria (14 in vitro, 25 animal, 99 clinical). Evidence was synthesized using a clinical-pathway framework comparing PMMA-based strategies with resorbable depots, hydrogels, coatings/nanomaterials, and emerging antibiofilm agents. The performance of PolyMethylMethAcrylate (PMMA)-based Antibiotic-Loaded Bone Cements (ALBCs) is critically assessed, highlighting key limitations such as inconsistent drug release, suboptimal biofilm penetration, and their inability to degrade within the living tissue environment and consequently to not promote osseointegration. In contrast, recent developments in multifunctional scaffolds, bioresorbable polymers, and nanocomposite materials are explored as promising solutions for controlled antibiotic release, improved biocompatibility, and enhanced osseointegration. In addition to analysing drug release kinetics and antibacterial efficacy, this review discusses cytotoxicity, nephrotoxicity, and the systemic impact of locally delivered antibiotics. Particular attention is paid to the balance between therapeutic effectiveness and host safety. Furthermore, strategies against biofilm formation, such as surface modification, antimicrobial peptides, and metal-based coatings, are examined. By organizing the findings into a structured comparative framework, this review provides valuable insight into the advantages, limitations, and translational potential of each approach. Finally, future perspectives are outlined, emphasizing the need for advanced clinical validation of next-generation biomaterials that can simultaneously address infection control and regenerative requirements in orthopaedic surgery. Introduction Periprosthetic Joint Infection (PJI) is a serious complication of Total Joint Arthroplasty (TJA). It is one of the leading causes of implant failure, with serious consequences for patient outcomes and a high cost for healthcare systems. As the global population ages and the demand for joint replacement surgeries continues to rise, the incidence of PJI has become a growing concern in orthopedic and reconstructive medicine [1]. While PJI remains a catastrophic complication of orthopaedic implant surgery, the reported incidence of PJI is generally between 0.8% and 2% in low-risk total joint arthroplasties and even higher in revision arthroplasties. In patients with PJI, mortality rates may be as high as 21% within five years after diagnosis [2]. The genesis of PJI is based on the formation of complex microbial films on the implant surface. While these may sometimes appear as clusters of salivary bacteria or viridans group streptococci due to hematogenous seeding, usually occurring after invasive dental procedures or oral infections, the majority of PJIs are mainly caused by commensal bacteria derived from the skin. Staphylococcus aureus (including Methicillin-Resistant Staphylococcus Aureus (MRSA)), Staphylococcus epidermidis, a variety of multi-drug resistant Gram-negative bacilli, and fungal species (e.g., yeast or molds) are the leading pathogens causing early and delayed infections. Distinguishing between direct inoculation during surgery and hematogenous spread from distant sites, like the oral cavity, is vital for creating effective prophylactic strategies and selecting the right antimicrobial agents for local delivery [3]. Microbial biofilm offers a greater level of microbial resistance to antibiotics and the host immune response than planktonic microbes. The period of early post-operative or peri-operative infection is a “race to the surface” where the host cells and bacteria are in competition to adhere to the device; if bacteria come to the surface first the biofilm starts and the infection becomes irreversible [4]. Once a biofilm is clearly established, it may often be a clinical challenge to eradicate the infection, which usually requires explantation of the implant, prolonged or repeated course of systemic antibiotics, and/or multiple revision arthroplasties to control the infection or to re-establish joint function. The resilience of biofilm-associated infectious diseases necessitates the consideration of infection prevention measures and early preemptive measures in orthopaedic care [5]. PJI pathogenesis is intricately linked with biofilm formation, a process by which bacteria adhere to implant surfaces and encase themselves in a protective extracellular polymeric matrix. This microenvironment not only shields bacteria from host immune responses but also significantly reduces the efficacy of systemic antibiotics. Notably, biofilm-associated bacteria can exhibit antibiotic resistance levels up to 1000 times higher than their planktonic counterparts, underscoring the need for localized and sustained antimicrobial interventions [6,7]. The management of PJI is challenging due to its complicated pathophysiology, which includes biofilm formation on implant surfaces that limits the efficiency of systemic antibiotics [7]. However, emerging concerns regarding antibiotic resistance, subtherapeutic drug release, and inconsistent clinical efficacy have underlined the need to re-evaluate current strategies and explore innovative, multifactorial approaches to infection control and bone regeneration [8]. The increasing frequency of multidrug-resistant bacteria complicates treatment, necessitating major surgical procedures in addition to long-term antibiotic therapy [9]. Traditional treatments for PJI often include a two-stage revision surgery in which the infected implant is removed, and a temporary antibiotic-loaded bone cement spacer is used. These spacers not only give structural support but also function as local drug delivery systems, releasing antibiotics directly to the site of infection [10]. The most used material for spacers is PolyMethylMethAcrylate (PMMA) bone cement, which has been demonstrated to be biocompatible, with the possibility to host antibiotics within its bulk matrix. However, PMMA has significant disadvantages, including inadequate antibiotic release kinetics, low biodegradability, and the possibility of mechanical property degradation when loaded with antibiotics [11]. Antibiotic-loaded bone cements often release antibiotics in the first hours after implantation, followed by a steady, persistent release phase. While this first release is necessary for achieving high local antibiotic concentrations, it is frequently insufficient for eradicating infections [12]. Furthermore, high dosages of antibiotics can damage the cement's mechanical integrity, reducing its usefulness in revision surgeries. The need for more effective and innovative antibacterial approaches is critical, especially given the increased prevalence of antibiotic-resistant bacteria and the limits of traditional methods [13]. Despite the routine clinical use of ALBC since the 1980s, recent consensus among experts highlights several critical concerns surrounding its efficacy and safety. These include a lack of standardized formulations, subtherapeutic antibiotic release over time, the risk of fostering antimicrobial resistance, and adverse host responses such as cytotoxicity or nephrotoxicity. Moreover, most commercially available ALBC formulations lack U.S. Food and Drug Administration (FDA) approval for high-dose use and fail to meet the Minimal Biofilm Eradication Concentration (MBEC) required to eliminate persistent infections [8,14]. The 2019 Biofilm Symposium and the 2018 International Consensus Meeting emphasized the need for robust randomized clinical trials and the development of validated assays for biofilm susceptibility testing [8]. Beyond traditional antibiotics, researchers are now exploring non-antibiotic approaches such as antimicrobial peptides, bacteriophages, quorum-sensing inhibitors, and biofilm-degrading enzymes [15]. Modern advances have aimed to overcome these challenges by developing novel materials and techniques that improve the antibacterial properties of bone cement and spacers while retaining mechanical performance. The use of alternative materials has shown promise in enhancing antibiotic elution profiles, increasing antibacterial activity [16,17], tailored setting times, improved biocompatibility, and mechanical performance [[18], [19], [20], [21]]. Studies have looked at a variety of materials, including hydrogels and biodegradable scaffolds, that provide more controlled and longer antibiotic release than typical PMMA [22]. Materials inherently resistant to bacterial colonization through surface chemistry modulation or nano-topography have shown bactericidal effects without drug incorporation [23,24]. Other authors employed metal ions such as silver, zinc, or copper, known for their broad-spectrum antimicrobial properties [25,26]. Multifunctional scaffolds, capable of simultaneously supporting osseointegration and eliminating infection, represent a frontier in orthopaedic biomaterials research. Despite these advancements, challenges remain in translating experimental findings into clinical practice. These include concerns related to scalability, regulatory approval, long-term safety, and reproducibility of outcomes in various patient populations. Furthermore, the heterogeneity in study designs and outcome measures across the literature complicates the direct comparison of therapeutic efficacy, and the consequent management of PJI requires a multifaceted strategy that goes beyond infection control to encompass bone regeneration, implant integration, and patient-specific considerations. The field of antibacterial strategies in PJI is very broad, multifaceted, and complex. It requires an interconnected multidisciplinary approach, and an exhaustive analysis of all its aspects can result in an overwhelming and incomplete effort. Therefore, the present review tries to focus on the arthroplasty implants based on (but not limited to) a material science point of view, trying to take into account the most relevant aspects. In particular, antibiotic-loaded implants, used for local drug delivery constitute the main purpose of this meta-research. The article choice stage privileged those who reported results from clinical or preclinical stages. Nevertheless, some in vitro studies have been included as they presented an interesting and relevant novelty approach to the PJI issue. Following what has been stated so far, crucial aspects of arthroplasty and PJI, such as surgical procedures and techniques, gene therapy, etc., do not constitute the main focus of this review and will be mentioned only to a limited extent when appropriate to the investigated context. In order to provide a rationalized insight into the complexity of this scenario, our review adopts a structured approach, grouping similar results where applicable and highlighting both convergences and divergences in the literature. The studies included in this review were selected based on their relevance to antibacterial efficacy and their contribution to one or more key aspects: drug release kinetics, systemic and local toxicity, biodegradability, osseointegration, and bone growth potential. This review aims to provide clinicians and researchers with a practical and insightful overview of the current evidence base while also identifying gaps and opportunities for future investigation. Methods The main scope of this review was to highlight current strategies, whether consolidated, emerging, or proposed, to contrast bacterial infections that arise during, or after the arthroplasty surgical protocols. This systematic review was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) recommendations [27]. It is well known that reproducibility is one of the most important steps in the PRISMA 2020. To clarify this aspect, one should address the inclusion criteria using the so-called Population, Intervention, Comparison, Outcomes, Study Design (PICOS) model. Regarding the investigated population, the patients with PJI or animal/in vitro models of PJI were included. The searched intervention consists of mapping and critically synthesizing evidence on local antibacterial strategies for PJI, spanning antibiotic-loaded cements/spacers, resorbable carriers, coatings/nanomaterials, and emerging antibiofilm agents. Regarding the comparisons chosen for investigation, we selected standard PMMA-loaded cements, other carrier types, and, last but not least, systemic antibiotics. The main outcomes that followed were antibacterial efficiency, cytotoxicity, drug release kinetics, infection clearance rate, and systemic impact, such as nephrotoxicity. The study design is presented in detail in Table 1, Table 2 with the main involved steps, and it could be summarized as follows: in vitro, in vivo (animal), and clinical trials (Randomized Controlled Trials (RCTs), cohort studies, or case reports).Table 1Synthetic list of the most relevant aspects of arthroplasty implants in reviewed literature: 1 -Materials used for the implant (or specific spacer, blocks cement commercial model); 2 - Type of study: in vitro, in vivo animal model, in vivo human case; 3 – Quality assessment/Risk of bias; 4 -Effects on cement matrix by additional components, treatments and admixing of drugs; 5 - Drug release, kinetic and elution characteristics; 6 - Antibiotic activity; 7 - Local and systemic cytotoxicity, nephrotoxicity; 8 - Biodegradability – Osseointegration – Bone volume analysis. Unavailable aspects for specific reference are indicated with N/A.Table 1ReferenceMaterials used for the implant (or specific spacer/blocks/cement model)Type of study: in vitro, in vivo animal model, in vivo human caseQuality Assessment/Risk of BiasEffects on the cement matrix from additional components, treatments, and drug admixturesDrug release, kinetic, and elution characteristicsAntibiotic activityLocal and systemic cytotoxicity, nephrotoxicityBiodegradability – Osseointegration - Bone volume analysisAlt et al.Ref [36]PMMA-cement loaded with 1% nanoparticulate silverIn vitro study/PreclinicalModerate quality score (3.4/5) (appraisal criteria:scientific rationale and setup, control group validity, reproducibility, outcome measurement, dynamic validity) – It provides a robust experimental design with appropriate positive and negative controls for evaluating the antimicrobial efficacy of silver nanoparticles in PMMA, it is limited by the absence of blinding in outcome assessment and the use of static in vitro testing conditionsN/AN/AComplete inhibition of bacterial growth against gentamicin-resistant MRSE and MRSA strains, while both unloaded and gentamicin-loaded cements showed no antibacterial activityNo signs of cytotoxicity in three different in vitro tests, indicating a lack of local and systemic cytotoxic effects; however, further in vivo cytotoxicity studies are necessary to confirm these initial findingsN/AHasandoost et al.Ref [29]Glass Polyalkenoate Cement (GPC), calcium sulphate (CaSO4), and PMMAIn vitro study/PreclinicalHigh quality score (4/5) (appraisal criteria: experimental design, material characterization, biological control, mechanical validation, antibacterial scope)- Excellent adherence to ISO 10993-5 standards for cytotoxicity and ISO 9917-1 for mechanical integrity. High certainty regarding the osteoconductivity and biocompatibilityCaSO4 enhances the release of ions such as Ca2+ and Zn2+, while also promoting the formation of pores near the surfaceIncreased release of ions such as Ca2+ and Zn2+ over a maturation period of 30 days in deionized waterN/AN/AN/ATaddei and AffatatoRef [78]-Vancogenx-space knee,-gentamicin sulphate, vancomycin hydrochloride, barium sulphate, benzoyl peroxide, N, N-dimethyl-para-toluidine, and traces of hydroquinoneIn vitro study/PreclinicalHigh quality score (4/5) (appraisal criteria: methodological innovation, comparative rigor, material aging, statistical analysis, standardization). Exceptional molecular characterization using Raman spectroscopy. Provided critical insights into the antibiotic's effect on PMMA polymerization and wear resistance, identifying that vancomycin-loaded spacers maintain better molecular stability during clinical useThe addition of vancomycin hydrochloride to the cement matrix appears to influence the polymerization degree of PMMARelease of vancomycin hydrochloride is minimal, with over 90% of the loaded antibiotics remaining trapped in the PMMA matrixN/AN/AN/AAnagnostakos et al.Ref [30]-Palacos R cement, -antibiotic powders such as gentamicin, vancomycin, teicoplanin, and SynercidIn vitro study/PreclinicalHigh quality score: (4.5/5) – in vitro (appraisal criteria: analytical precision, drug synergy, microbiological link, temporal scope, fluid simulation). Rigorous analytical study characterizing dual-antibiotic elution (GM/VCM) from PMMAAddition of a glycopeptide, such as vancomycin, enhances the release of gentamicin from the cement matrix, suggesting that the ratio of incorporated antibiotics may influence their elutionGentamicin showed superior elution characteristics compared to vancomycin, with a higher percentage of gentamicin released over time, particularly from gentamicin-vancomycin or gentamicin-teicoplanin-loaded spacersGentamicin + vancomycin showed the best antimicrobial activity against Staphylococcus epidermidis and MRSA, while gentamicin + teicoplanin was most effective against Staphylococcus aureus and Enterococcus faecalisN/AN/ASeldes et al. Ref [31]-Palacos R bone cement-Liquid gentamicin and powdered tobramycin- In vitro study/PreclinicalHigh quality score: (4.5/5) (appraisal criteria: comparative logic, mechanical testing, elution methodology, microbiological assay, clinical rationale). Highly influential in vitro study demonstrating that while gentamicin provides potent bactericidal elution, it reduces mechanical propertiesThe addition of liquid gentamicin significantly decreased the ultimate compression strength by 49% and the ultimate tension strength by 46% compared to the controlsBurst release during the initial 24 h, with a mean concentration of 26.4 mcg/mL, and it maintained bactericidal concentrations for at least three weeks, decreasing to 4.15 mcg/mL at three weeks and 0.65 mcg/mL at six weeksBactericidal activity against the Escherichia coli strain tested, indicating effective antibiotic activityN/AN/ALewis and Bhattaram Ref [32]-Low viscosity Cemex O XL and Cemex O Genta LV-Medium-viscosity Endurance TM and Endurance Gentamicin-High-viscosity SmartSet TM HV and SmartSet O GHVIn vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: carrier characterization, elution methodology, analytical precision, biological potency, stability testing). Rigorous evaluation of a bioactive carrier for dual-antibiotic deliveryThe inclusion of gentamicin sulphate powder in the cement's powder does not adversely affect a wide array of in vitro properties of the curing and cured cement, such as strength, modulus, work-to-fracture, and plane-strain fracture toughnessN/AN/AN/AN/AMorrison et al.Ref [33]-PMMA beads were used for the experiment.-gentamicin, silver, and a combination of gentamicin and silverIn vitro study/PreclinicalHigh quality score:(4.5/5) (appraisal criteria: microbiological rigor, biofilm quantification, additive comparison, statistical analysis, methodological depth). Strong methodological focus on biofilm formation. Utilized a modified Calgary Biofilm Device to demonstrate that linezolid and gentamicin significantly inhibit MRSP biofilm on PMMA, while silver-based additives showed variable efficacy, highlighting the challenges of non-antibiotic coatingN/ALow surface area-to-volume ratio of the PMMA beads limits the elution of gentamicin, resulting in a greater percentage of the drug being present in the bulk of the beadEffective at reducing biofilm formation of gentamicin-susceptible MRSP isolates but had no effect on isolates not susceptible to gentamicin.-silver-impregnated PMMA showed no effect on MRSP biofilm formationN/AN/AGasparini et al.Ref [34]-Polymerized cement (Cemex XL; Tecres SpA, Sommacampagna, Italy)-PMMA copolymer powder-tobramycin, vancomycin, teicoplanin, clindamycin, and colistinIn vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: comparative logic, elution monitoring, temporal scope, standardization, microbiological link). Rigorous HPLC-based comparative analysis of dual-antibiotic ALBCsThe addition of antibiotics to the acrylic cement decreases its bending strength compared to standard formulationsBurst release of antibiotics in the first hour, followed by a progressively decreasing elution rateN/AN/AN/ASalih et al. Ref [75]Heraeus Palacos RG cement, Heraeus Copal GC, ammonium acetate bufferGentamicinIn vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: experimental logic, elution methodology, duration of study, clinical simulation, statistical rigor)). A pragmatic in vitro study demonstrating that physical surface modification can increase gentamicin elutionIndentation of cement spacers significantly increased the elution of gentamicin over a period of at least nine weeks, with the total amount of eluted gentamicin being greater for indented discs compared to plain oneIndenting cement spacers with a MacDonald dissector improved the elution of gentamicinAlt et al.Ref [110]-NanoSilver, polymethylmetacrylate bone cement,-gentamicin-loaded bone cement,-plain PMMA bone cementIn vitro study: human osteoblasts and mouse fibroblasts/PreclinicalHigh quality score: (5/5) (appraisal criteria: material characterization, microbiological breadth, cytotoxicity rigor, elution and stability, standardization). Seminal in vitro study on nanosilver-loaded PMMA. Provided comprehensive evidence of broad-spectrum antibacterial activity (including MRSA) and validated biocompatibility with human cell lineN/AN/ANanoSilver bone cement demonstrated high antibacterial activity against multiresistant bacteria, including S. Epidermidis, MRSE, and MRSA, unlike gentamicin-loaded cementNo in vitro cytotoxicityN/ASnir et al.Ref [38]-Linezolid, vancomycin hydrochloride, and gentamicin-commercial PMMA cements: Smart Set GHV and CMW 1.In vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: scientific rationale, control group validity, reproducibility, outcome measurement, dynamic validity). This research demonstrates superior reporting of elution kinetics compared to earlier literature, offering a clearer understanding of the temporal concentration profiles of Linezolid in PMMA. While it remains limited by its static in vitro design—failing to replicate the shear stress and flow rates of human synovial fluid—it provides high-quality data regarding the bactericidal potential of alternative antibioticsThe cement matrix remains unaffected by the admixing of drugs like linezolid, gentamicin, and vancomycinThe elution kinetics of linezolid from PMMA exhibited a typical pattern consisting of a rapid phase followed by a plateau phase, with the combination of linezolid and gentamicin showing a significantly longer plateau phase compared to each antibiotic used aloneLinezolid demonstrated significantly longer GIT against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Staphylococcus epidermidis compared to vancomycin and gentamicinN/AN/AHeffernan et al.Ref [51]-PNDJ hydrogelIn vivo animal model, specifically rabbits and canines/PreclinicalHigh quality score: (8/10) on SYRCLE, (SYRCLE domain: selection bias, performance bias, detection bias, attrition bias, reporting bias, specific safety). Robust in vivo evaluation of a temperature-responsive hydrogelN/AThe drug release is primarily controlled by adjusting the Jeffamine M − 1000 acrylamide repeat unit content, allowing for sustained supra-MIC concentrations of antimicrobials over multiple days in surgical sitesEffectiveness in preventing recurrence of implant-associated Methicillin-Susceptible Staphylococcus aureus (MSSA) and MRSA osteomyelitis in rabbitsWell-tolerated locally and systemically, although mild renal toxicity consistent with the released antimicrobials was identified at high doses in rats, and systemic toxicity was evaluated based on markers of renal and hepatic functionPNDJ hydrogels are compatible with tissue healing at bone-implant interfaces, showing evidence of new bone formation and remodeling in response to load- bearingFoster et al.Ref [52]-PMMA-Antibiotic-loaded hydrogel containing gentamicin and vancomycin-In vivo animal model: Swiss Alpine sheep/Preclinical-In vitro comparative testHigh quality score: (9/10) on SYRCLE. Exceptionally large-animal trial (ovine) evaluating an antibiotic-loaded hydrogel for single-stage MRSA revisionN/ABurst release profile under in vitro conditions, with local gentamicin concentrations being 10-100 times higher in the hydrogel group compared to in vivo PMMA during the first 2-3 days postoperativelyIncreasing concentrations of gentamicin and vancomycin did not significantly increase antibiofilm activity against MRSA biofilmsNo significant differences in renal function tests (creatinine, urea) between the hydrogel and PMMA groups, indicating no evidence of nephrotoxicity or systemic cytotoxicityThe hydrogel showed good biodegradabilityNiska et al. Ref [126]-smart nanofiber coating (PLGA/PEG) to deliver combinatorial antibiotics (vancomycin and rifampin)In vivo animal modeleight-week-old male C57BL6 mice/PreclinicalHigh quality score: (9/10) on SYRCLE. While the study design is highly rigorous, the text does not explicitly detail the security of the randomization sequence before the start of the study, which is a common occurrence in research reports of this timeframeN/AN/AThe combination of vancomycin and rifampin showed enhanced antibiotic activity against S. aureus in the mouse model, effectively reducing bacterial burden and preventing infection-induced changes in bone and joint tissueN/AN/AMecikoglu et al.Ref [54]-PMMA cement,-a Kirschner wire,-Serratiopeptidase enzyme injectionsIn vivo animal model, sixty Sprague-Dawley rats/PreclinicalHigh quality score: (9/10) on SYRCLE. Strong preclinical evidence supporting the use of proteolytic enzymes (Serratiopeptidase) as an adjunct to antibiotic therapyN/AN/ASerratiopeptidase enhances antibiotic activity against Staphylococcus epidermidis strain (ATCC 35984) with a high slime-producing capacity)N/AN/AIrwin et al.Ref [55]-Computerized Numerical Control machined-surgical steel pin with a slotted end.-The biofilm generation media consisted of Difco Tryptic Soy Broth (TSB) at different concentrations for attachment, accumulation, and maturation of biofilmsIn vivo animal model, specifically using male Sprague-Dawley rats/PreclinicalHigh quality score: (10/10) on SYRCLE. A benchmark study for PJI modelling. By utilizing a pre-formed biofilm inoculum, this study provides a more realistic and ‘recalcitrant’ infection environment than traditional planktonic modelsN/AN/A.Both in vitro and in vivo generated biofilms show cefazolin tolerance over 250 times the MICN/AN/AGilchrist et al.Ref [58]-Fusidic acid (FA)-Rifampicin (RIF)-Sodium fusidate (SF)-Poly(D,L-lactic acid-co-glycolic acid) (PLGA)-Tetrahydrofuran (THF)-Dimethylformamide (DMF)-Acetonitrile (ACN)-Methanol (MeOH)-Phosphoric acid-In vitro evaluations using Human Umbilical Vein Endothelial cells (HUVEC)-In vivo animal model female Sprague-Dawley rats/PreclinicalHigh quality score: (4.5/5) – in vitro (appraisal criteria: nanofiber characterization, elution kinetics, combination synergy, cytotoxicity, antibacterial scope); High quality score: (9/10) on SYRCLE – in vivo. It provides a solution to Antibiotic Resistance. By co-loading fusidic acid and rifampicin, the nanofibers prevent the “spontaneous mutation” that often happens when rifampicin is used aloneN/ABiphasic release pattern, characterized by an extensive burst phase over the first 1-2 days, followed by a slow, controlled release over 35 days, with co-loading of RIF and FASF influencing the release rates of the individual drugsComplete eradication of bacteria after 48 h for both strains of MRSA and S. epidermidisN/AN/AMatsuno et al. [53]-Cross-linked hyaluronic acid (HA) gel-GM-in vitro study-in vivo animal model:Retired male NewZealand white rabbits,Male Balb/c mice, 6–8 weeks old/PreclinicalHigh quality score: (4.2/5) – in vitro (appraisal criteria: carrier composition, elution monitoring, antibacterial activity, standardization, cytotoxicity); Moderate to High quality score: (7.5/10) on SYRCLE – in vivo. Many carriers are “foreign bodies” (like PMMA) that can harbour further infection. The study demonstrates that the HA gel does not cause the systemic “toxic spikes” often feared with liquid antibiotics, as the gel acts as a “slow-release” brakeN/AN/ASignificant antibacterial activity against Staphylococcus aureus in both in vitro and in vivo models, effectively suppressing bacterial growthN/AThe bioabsorbable antibacterial carrier does not disturb osseointegration and supports bone ongrowthYan et al.Ref [47]-Continuous wave ultrasound CMW ENDURANCE bone cement,-vancomycin,-powdered PMMA,-liquid monomer-In vivo animal model: 16 New Zealand White female rabbits-The in vitro comparative study/PreclinicalHigh quality score: (4.8/5) – in vitro (appraisal criteria: experimental control, elution monitoring, bioactivity verification, mechanism analysis, temporal data); High quality score: (8.5/10) on SYRCLE – in vivo. The limitations of antibiotic elution from PMMA can be mitigated through external stimuli. The in vitro data confirmed a dose-dependent increase in vancomycin release via ultrasound-mediated cavitation, while the in vivo rabbit model showed a significant reduction in bacterial load and bone destructionN/ACWU significantly enhances vancomycin release, increasing drug elution by 2.57-27.44% compared to controls, with the release following a bi-phasic curve characterized by an initial peak followed by a slower, diffusion-controlled release phaseCWU enhanced the antimicrobial efficacyN/AN/AHasan et al.Ref [48]-PLGA-PEG-PCL (polycaprolactone)-Vancomycin Hydrochloride (V-HCl)-N-Methyl-2-Pyrrolidone (NMP)-Calcium chloride (CaCl2)-PRO OSTEON 500R-MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-TRIzol reagent-SuperScript(tm) VILO(tm) cDNA Synthesis Kit-In vitro study (MG63 osteoblast cells).-In vivo animal model 13 rats implanted with the antibiotic-releasing bone void filling (ABVF) putty and 12 rats in a control groupHigh quality score: (4.7/5) – in vitro (appraisal criteria: drug loading/precision, material properties, biocompatibility, microbiological scope, release mechanism); High quality score: 8/10 on SYRCLE – in vivo. This dual-phase study validates 28-day release kinetics, while the in vivo rat model provided high-certainty evidence that these carriers can simultaneously eradicate osteomyelitis and facilitate bone regenerationThe ABVF putty allowed easy press-fitting and showed an increase in mechanical compliance over time, indicating that the addition of components like PLGA, PEG, and PCL contributed positively to the cement matrix's propertiesSustained vancomycin release over a 6-week period, with an initial burst release of 40% on the first day, followed by a more sustained release due to both erosion of the polymer matrix and diffusion of the drugSustained antimicrobial activity against Staphylococcus aureus for the entire study period of 6 weeksNo nephrotoxic effects, as indicated by serum creatinine levels remaining within normal limits, and non-cytotoxic to host osteoblast cellsThe ABVF putty demonstrated biodegradability in vivo, supported osseointegration, and resulted in a significantly higher bone volume in the treatment group compared to the control groupMukai et al.Ref [44]-CPC (Biopex-R Advance)-PMMA cement (Surgical Simplex P Bone Cement)-Injectable vancomycin hydrochlorideIn vivo animal model using ten-week-old Wistar rats/PreclinicalHigh quality score: (9/10) on SYRCLE. Rigorous in vivo evaluation of calcium phosphate cement (CPC). Utilizing real-time bioluminescence imaging, the study confirmed that CPC provides a superior long-term antibacterial environment compared to traditional carriersN/ACPC/VCM released significantly greater concentrations of VCM over a longer period (24 weeks) compared to PMMA/VCM, releasing 1.4 to 26.1-fold more VCM than PMMA/VCMThe antibacterial activity against Staphylococcus aureus (NBRC 12732) of vancomycin CPC/VCM was logarithmically correlated with VCM concentration. In a 24-week period, CPC/VCM showed significantly larger inhibition zonesN/AN/ALewis et al.Ref [39]DBM and gentamicin-In vivo animal models: athymic nude ratsIn vitro study with culture of rat calvarial osteoblasts/PreclinicalHigh quality score: (4/5) (appraisal criteria: carrier characterization, elution methodology, analytical precision, biological potency, stability testing). Rigorous evaluation of a bioactive carrier for dual-antibiotic deliveryN/ARapid release of 58-78% within the first 48 h, followed by a plateau where clinically relevant concentrations were maintained for up to 13 daysThe gentamicin eluting from the DBM effectively inhibited bacterial colonization, including S. aureus, for up to 12 days at all investigated loading concentrationsN/AGentamicin-loaded DBM showed good biodegradabilityMaurer et al.Ref [114]-Titanium alloy (Ti6Al4V) bolts were used for the experiment.-Copper ions were included in the titanium surface for the coating process-In vivo animal model:36 New Zealand White (NZW) rabbits/PreclinicalHigh quality score: (8/10) on SYRCLE. Rigorous large-animal study evaluating a Cu-TiO2 photocatalytic coating. Demonstrated a significant reduction in bacterial colonization in an acute infection model without systemic copper toxicityN/ACopper ions are released over a duration of 4 weeks, demonstrating an active coating with a maximum peak of copper concentration observed one week after implantation, which is crucial for its antibacterial effectCu-TiO2 coating significantly reduced the infection rate in an animal model simulating acute periprosthetic infection, showing promising antibiotic activity against Staphylococcus aureusSystemic effects of copper, including nephrotoxicity, were monitored by taking weekly creatinine samples, which remained within the normal range throughout the study, indicating no significant nephrotoxic effects were observedN/AUchida et al.Ref [42]-CPC (Biopex-R Advance)-PMMA (Surgical Simplex P Bone Cement),-Injectable VCM hydrochlorideIn vivo animal model:-Wistar rats/PreclinicalHigh quality score: (9/10) on SYRCLE. Rigorous in vivo evaluation of CPC. Utilizing real-time bioluminescence imaging, the study confirmed that CPC provides a superior long-term antibacterial environment compared to traditional carriers- The pore size of CPC impregnated with VCM and GM is smaller than that of CPC impregnated with VCM aloneCPC impregnated with VCM exhibits a sustained release profile, with VCM levels released in vivo being significantly higher than those from PMMA cement, over an extended duration, exceeding the MIC for more than 10 weeks post-implantationN/AN/AN/ALin et al.Ref [35]-PMMA bone cement,-VCM,-treated with US + MB-In vivo animal model:32 healthy adult New Zealand white rabbits were used to evaluate the effectiveness of the treatment.In vitro studyHigh quality score: (4/5) (appraisal criteria: experimental design, novelty/mechanism, microbiological control, standardization, limitation). Innovative in vitro study evaluating the synergy between PMMA and ultrasound-mediated microbubbles. Successfully demonstrated that physical cavitation can significantly enhance vancomycin releaseThe addition of microbubbles and ultrasound treatment significantly enhances the elution rate of vancomycin from the PMMA cement matrixBiphasic elution curve characterized by a transient initial release peak followed by a long-term low releaseSpecimens subjected to US + MB exhibited significantly enhanced antibacterial activity against planktonic Staphylococcus aureus compared to other groupsN/AN/AYang et al.Ref [43]-PMMA cement-Gentamicin and chlorhexidine-Silica nanoparticles-In vivo animal model: modified femoral bone lesion in rats-In vitro: SaoS-2 cellsHigh quality score: (5/5) – in vitro (appraisal criteria: nanomaterial characterization, elution precision, mechanical integrity, anti-biofilm efficacy, cytotoxicity rigor); High quality score: (9.5/10) on SYRCLE. By incorporating halloysite nanotubes into PMMA, the researchers moved beyond the traditional ‘burst-release’ paradigm, achieving a sustained dual-antimicrobial effect- The addition of nanoparticles to the cement matrix did not statistically impact the settling time or the amount of calcium deposited on the surface of the bone cement samplesProlonged release profile, with gentamicin and chlorhexidine being released for over 50 days, with a reduced burst release at the startAntimicrobial inhibition against various bacterial strains, including those resistant to gentamicinN/AN/AXu et al.Ref [106]Vancomycin, meropenem, methyl-methacrylate cement polymer, gentamicin, clindamycin, tobramycin, aztreonam, ampicillin, ceftazidime, linezolid, and ceftriaxoneIn vivo clinical trials-A total of 32 patients-controlled trial conducted on human patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection./RCTHigh quality (low risk of bias via RoB 2- randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, selection of the reported result). A robust clinical RCT demonstrating that closed-suction drainage does not significantly lower the local concentration of antibiotics in the joint space. This study provides high-certainty evidence that surgical drainage can be used safely without compromising the pharmaceutical effectiveness of the spacerN/ABoth vancomycin and meropenem were rapidly released from the cement spacer during the first day, with the release rates gradually decreasing over the subsequent daysAntibacterial activity against MSSA, MRSA, and E. coli during the first five days following spacer implantation.None of the patients presented acute renal failure or side effects related to antibiotic applications, suggesting that the use of vancomycin and meropenem in cement spacers did not result in systemic nephrotoxicityN/AEdelstein et al.Ref [107]-PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement.−3 g of vancomycin and 2.4 g of tobramycin.-Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amountIn vivo human casesA total of 37 patients (20 total knee arthroplasty and 17 total hip arthroplasty) were included in the final cohort for the analysis/Clinical study retrospective cohortHigh quality (moderate risk via ROBINS-I - bias due to confounding, bias in selection of participants, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes, bias in selection of the reported result). Critical safety study using RIFLE criteria to quantify nephrotoxicity. Found a 4.8% incidence of AKI following spacer placement. Identified pre-existing renal insufficiency and high-dose aminoglycosides as primary risk factorsN/AThe rate of antibiotic elution from cement has been found to vary with the type of cement used and the amount, type, and combination of antibiotic usedLocal antibiotic concentrations were achieved well above the MICSubstantial risk of nephrotoxicity associated with the use of high-dose ACSs. Specifically, 27% of patients developed AKI, 5% developed kidney failure. No baseline patient characteristics were significantly associated with the development of AKIN/AVrabec et al.Ref [79]Bone cement mixture: SimplexTM P with Tobramycin; Stryker Howmedica Osteonics containing 1 g of tobramycin with 40 g of bone cementIn vivo human cases: a total of 15 patients: 10 receiving the tobramycin-impregnated bone cement and 5 receiving intravenous tobramycin/Clinical study, prospective cohortHigh quality (ROBINS-I). Critical in vivo clinical analysis of local drug kinetics. Demonstrated that “low-dose” ALBC fails to achieve therapeutic intra-articular concentrations (>4 μg/mL) in the early post-operative period. This study provides high-certainty evidence of the “inefficiency” of treatment in standard cement, justifying the need for high-dose or smart-release carriersThe addition of tobramycin does not adversely affect the cement matrixFavorable elution kinetics during the exothermic polymerization process of the cementTobramycin-impregnated bone achieves supratherapeutic intraarticular concentrations, providing effective local antibiotic activity during the first 48 h postoperatively, while maintaining minimal systemic absorptionAll patients tolerated tobramycin regardless of the administration route, and no evidence of nephrotoxic or allergic complications was observedN/ABertazzoni Minelli et al.Ref [80]-Gentamicin, vancomycinIn vivo human case: patients undergoing two-stage revision surgery for infected arthroplasty/Clinical study (prospective longitudinal)High quality (ROBINS-I). Essential clinical pharmacokinetic study of dual-antibiotic spacers. Confirmed that the combination of GM and VCM maintains synergistic concentrations in synovial fluid well above the MIC for several days, while systemic levels remain safely low. Provides clinical validation for the ‘dual-loading’ strategy used in advanced carriersThe addition of antibiotics to bone cement exceeding a concentration limit of 5-10% leads to a significant decrease in the mechanical resistance of the spacerInitial high release of both antibiotics in wound fluids and maintained persistently high concentrations for at least 24 h after spacer implantationGM and VCM exhibit pronounced antimicrobial activity against multiresistant microorganisms, with effective concentrations achieved in joint fluids after the implantation of antibiotic-loaded spacersThere were no signs of nephrotoxicity or local cytotoxic effects recordedN/ABorick et al.Ref [81]Tobramycin-impregnated PMMA beads and cementIn vivo clinical trialsmale patient with right total knee arthroplasty complicated by prosthetic joint infection/Clinical evidence (Case Report)High quality (CARE/JBI compliant case report). Provides critical evidence of ‘local toxicity’ risks. Demonstrates that while local carriers aim for regional efficacy, the systemic absorption of tobramycin from beads and cement can necessitate emergency explantation to avoid permanent haemodialysis in vulnerable patientsN/ABeads containing tobramycin sustained the highest concentrations throughout their 28-day study, and tobramycin elution can continue at highly therapeutic levels for more than 90 daysNo significant reduction in the rate of infections compared to plain bone cementN/AN/Avan Jiperen et al.Ref [82]-Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate)In vivo clinical trialsconducted on 31 human patients/RCTHigh quality (low risk of bias via RoB 2). Rigorous clinical RCT demonstrating that cement mantle thickness (reservoir volume) does not significantly alter peak local or systemic Gentamicin concentrations. This suggests that surface area and elution kinetics are more influential than total cement volume, providing high-certainty evidence for optimizing spacer and implant designThe composition of Hi-Fatigue Gentamicin Bone Cement includes various components that influence the cement matrix's properties, including its mechanical strength and antibiotic release characteristics.Biphasic elution characteristics, with a high initial burst of local gentamicin concentrations above the MIC followed by a rapid declineEffective against common pathogens found in total hip arthroplasty infections, such as Staphylococci, Enterococci, and Pseudomonas, and it achieves local concentrations above the MIC shortly after surgerySerum gentamicin concentrations never exceeded toxic levels, indicating that local and systemic cytotoxicity, as well as nephrotoxicity, were not observed in the patients involved in the trialN/AMa et al.Ref [115]PMMA spacers from two-stage revision total knee arthroplasty for PJITitanium rods for bacterial incubation and biofilm formationIn vivo clinical trialspatients undergoing two-stage revision total knee arthroplasty for periprosthetic joint infection/Preclinical to Clinical Transition (Observational Cohort)Moderate quality (ROBINS-I).The clinical strength of this study lies in its objective microbiological quantification of bacterial persistence on antibiotic-loaded spacer. While the retrospective observational design introduces inherent limitations regarding potential confounding variables—such as variations in host immune response or initial antibiotic treatment—the clarity of the sampling protocol and the consistency of the findings provide high-quality evidence that persistent biofilm formation remains a significant challengeN/AN/ABiofilm cells exhibit high tolerance to antibiotics. This tolerance is attributed to the presence of bacterial persisters and the protective nature of biofilmsN/AN/AAmmon and StockleyRef [83]Allograft bone obtained from the tissue bank, antibiotic-loaded cement, and systemic antibiotics for prophylactic dosesIn vivo clinical trials57 patients who underwent a two-stage revision for infected hip replacements/Clinical Study (Prospective Longitudinal Cohort)High quality (ROBINS-I). Critical study demonstrating the dual-utility of antibiotic-impregnated allograft. Found an 86% success rate in eradicating infection while simultaneously addressing severe bone lossThe amount of antibiotic added to the cement at the second stage was less than that at the first stage due to concerns about mechanical strength (0.5g of GM and 1g of VCM being added when required)N/AThe use of antibiotic-loaded cement in the two-stage revision procedure is more effective in eliminating infection compared to systemic therapy, (systemic antibiotics may be considered for organisms sensitive only to VCM)N/AN/AMultimer et al.Ref [103]-PMMA cement-GMIn vivo human case:12 patients who underwent a two-stage revision for infected knee arthroplasty/Clinical Study (Prospective Case Series)High quality (moderate risk of bias) (ROBINS-I). Clinical in vivo study quantifying the ‘rapid decay’ of Gentamicin elution from articulating spacers. While initial titers exceeded the MIC for most pathogens, concentrations dropped significantly by 48 hN/AGM levels in synovial fluid remained therapeutic (median 0.46 μg/mL) (standard clinical tests of blood and synovial fluid) at a median of 99 days post-implantation, suggesting a prolonged elution profileGM levels in synovial fluid at the second stage revision were within therapeutic ranges, indicating effective antibiotic activity against susceptible pathogens during the period of implantationLow serum gentamicin levels, <0.24 μg/mL (standard clinical tests of blood and synovial fluid) indicate a low risk of systemic nephrotoxicityN/ACurtis et al.Ref [123]Palacos cement, utilized for both the tobramycin-impregnated beads and the block spacerIn vivo clinical trialsa human case involving an 85-year-old man/Clinical Study (Prospective Case Series)High quality (Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports). This study provides high-quality clinical evidence regarding the risk of systemic nephrotoxicity secondary to the local elution of Tobramycin from antibiotic-loaded bone cementRelease of antibiotics from bone cement occurs in a biphasic manner, with a peak release within the first 24 h followed by a low, continuous release that can last for months to yearsTobramycin-impregnated bone cement allows for local concentrations of antibiotics to exceed the MIC breakpoint of susceptible organismsN/AAminoglycoside-induced nephrotoxicity is especially problematic in patients with underlying renal insufficiency.An 85-year-old man who experienced acute renal failure after its useN/AHsu et al.Ref [104]-vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam,-bone cement-In vivo human case: patients diagnosed with knee periprosthetic joint infection.-In vitro comparative study/Clinical Study (Retrospective Cohort)High quality (moderate risk of bias) (ROBINS-I) By utilizing a synergistic combination of vancomycin and ceftazidime in knee spacers, the researchers achieved a 95.5% infection eradication rateThe efficiency of antibiotic release from bone cement is influenced by the penetration of dissolution fluids into the polymer matrix and the subsequent diffusion of the dissolved drugVancomycin and ceftazidime showed sustained release for up to 60 days, while other antibiotics like aztreonam and imipenem had shorter release durationsBroad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria, including strains such as MSSA, MRSA, S. epidermidis, P. aeruginosa, and E. coli, both in vitro and in vivo.Despite the high concentrations of antibiotics achieved at the site of infection, no toxic systemic effects were observed in any patientN/AHsieh et al.Ref [105]PMMA spacers loaded with a high dose of vancomycin and aztreonamIn vivo clinical trials46 patients who underwent two-stage revision hip arthroplasty for infections/Clinical Study (Prospective Longitudinal Cohort)High quality (moderate risk of bias) (ROBINS-I). This prospective study of 46 hip PJI cases demonstrated that a high-dose vancomycin-aztreonam combination remains bioactive and maintains local concentrations well above the MIC for over 100 days in vivoN/AThe study found that very high levels of vancomycin (1,538,000 μg/mL) and aztreonam (1,003,500 μg/mL) (standard and modified HPLC) were detected in joint fluid on the first day after implantation, with concentrations decreasing significantly over the following days, indicating a rapid initial release followed by a gradual decline, while maintaining therapeutic levels for several monthsThe released antibiotics, vancomycin and aztreonam, were bioactive against the test organisms, demonstrating their effectiveness in controlling infection at the site of the PMMA spacer implantationNo evidence of local or systemic cytotoxicity, nephrotoxicity, or other systemic adverse effects from the use of antibiotics in the PMMA spacers, as indicated by normal serum creatinine and alanine transaminase levels throughout the monitoring periodN/AGriffin et al.Ref [116]-Antibiotic-impregnated PMMA spacerIn vivo clinical trialsHuman patients who underwent two-stage revision arthroplasty for periprosthetic joint infection/Prospective Observational Cohort StudyHigh quality (moderate risk of bias) (ROBINS-I). While the study provides valuable clinical evidence suggesting that biofilm formation may be less prevalent than anticipated on retrieved spacers, the appraisal is tempered by the limited sample size and the challenges inherent in sampling complex spacer geometries for scanning electron microscopyThe admixing of these drugs may influence the elution characteristics.The initial burst release occurs at a high rate and concentrationN/AN/AN/AUeng et al.Ref [84]-PMMA bone cement-Oxacillin-Vancomycin-CefazolinIn vivo human case:30 patients undergoing primary cemented Total-Knee Arthroplasty (TKA)/Clinical trial (RCT)High quality (low risk of bias via RoB 2). A definitive clinical RCT measuring the bioactivity of joint fluid. Demonstrated that while ALBC significantly increases the local antibacterial inhibitory titer compared to plain cement, this activity is short-lived, with a 50% decrease in potency within the first 24 hN/ASustained release for up to 48 h, with oxacillin exhibiting significantly better release efficacy than vancomycin during the sample collection periodAntibacterial activity against MSSA for at least 24 h, longer durations for oxacillin and vancomycin groups. Antibacterial activity against MRSA was only present in the vancomycin groupN/AN/AOe et al.Ref [77]-VCM as an Antibiotic-Loaded Acrylic Cement (ALAC) to prevent infection after Total Hip Arthroplasty (THA) or to treat patients with MRSAIn vivo clinical trials patients underwent THA/Clinical Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). The systemic safety profile of localized high-dose therapy is investigatedThe addition of VCM by means of manually mixing ALAC to antibiotic-loaded acrylic cement affects the mechanical strength and elution characteristics, compared to commercially mixed ALACHigh local concentration when used in ALACN/AIncreased serum creatinine, which indicates nephrotoxicity, was not observed in any patients. Transient arrhythmias post-spacer were noticed in some patientsN/AKlinder et al.Ref [10]Gentamicin, vancomycin, polymethylmethacrylate (PMMA) cement, and antibiotic-impregnated spacersIn vivo human case: patients undergoing two-stage revision. In vitro comparison study/Clinical Study (Prospective Observational Cohort)High quality (moderate risk of bias via ROBINS-I). The fundamental inefficiency of current PMMA carriers is quantified by this clinical analysis. Their study of explanted spacers revealed that over 90% of the antimicrobial payload remains sequestered within the cement matrix at the time of reimplantation, never reaching the site of infectionThe addition of calcium polyphosphate or mesoporous silica nanoparticles, which increase porosity or surface roughness, resulted in improved release kinetics of antibiotics from the cement matrixIn vivo conditions, antibiotics are present at in vitro similar concentrations after an average of 90 days, particularly in the spacer-adjacent soft tissueN/AN/AN/ASudo et al.Ref [66]Antibiotic-impregnated CHA ceramic blocksIn vivo clinical trials Seven patients' treatment for infected hip arthroplasty/Clinical Study (Prospective Case Series)High quality (moderate risk of bias via ROBINS-I). The potential for bioactive ceramics to surpass the limitations of PMMA is demonstrated. By utilizing antibiotic-impregnated calcium hydroxyapatite (CHA) in a two-stage hip revision, the researchers achieved a 100% infection eradication rate. This study provides clinical evidence that osteoconductive materials can serve as highly efficient antibiotic reservoirsN/ASustained release of antibiotics over a long period, with studies showing that gentamicin sulphate in CHA blocks remained effective at 12 weeks, releasing 70% of the antibiotic (5x staphylococci MIC)Effective bacteria eradicationN/AN/AKendoff et al.Ref [65]Gentamicin and vancomycin,-ALBC used in the studyIn vivo clinical trialsHuman patients undergoing one-stage total hip arthroplasty revision/Clinical Study (Prospective Open-Label Trial)High quality (moderate risk of bias via ROBINS-I). By achieving high local titers without reaching systemic toxic thresholds, this study demonstrates that ‘industrial’ level drug loading is both clinically viable and effective. This provides a clear pharmacological foundation for the advanced, controlled-release technologiesThe combination of gentamicin and vancomycin enhances the elution propertiesThe combination of gentamicin and vancomycin reveals a synergism in terms of improved release kinetics when applied in combination, which enhances the anti-infective properties of the bone cementThe combination of gentamicin and vancomycin in antibiotic-loaded bone cement provides sufficient antibiotic protection against common orthopaedic pathogensThe study found no serious adverse events related to the investigated bone cement, and no renal or hepatic events were observedN/AWebb et al.Ref [64]-Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK)-Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany)-In vivo clinical trials-in vivo assessing urinary gentamicin levels in 35 patients who underwent primary total hip arthroplasty/Clinical Pharmacokinetic Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). By measuring in vivo interstitial concentrations, the researchers demonstrated that while PMMA provides high immediate local levels, the diffusion into surrounding tissues is limited and rapidly declines. This spatial and temporal “inefficiency” reinforces the clinical argument for the next-generation carriersN/ABiphasic release pattern, with an initial high release phase followed by a prolonged low-level release, with detectable urinary gentamicin for an average of 43 days and up to 71 days in some cases after primary total hip arthroplastyN/ANephrotoxicity and ototoxicity have not been demonstrated for the incorporated gentamicin into bone cementN/ARegis et al.Ref [63]-PMMA cement-GM, VCMIn vivo clinical trialsHuman patients undergoing two-stage revision of infected total hip arthroplasty/Clinical Study (Prospective Multicenter Cohort)High quality (moderate risk of bias via ROBINS-I). Even when utilizing standardized, preformed commercial spacers, the local antibacterial inhibitory activity was found to decay rapidly within the first 72 h. This high-certainty clinical data reinforces the ‘inefficiency’ argument by showing that therapeutic potency is transientThe addition of VCM to PMMA cement, through manual mixing, allows for high local concentrations of the antibiotic at the implant siteHigh local concentrations were observed in the first few hours after spacer implantation, while serum levels remained below the limit of detection, indicating favorable local release kineticsStrong antimicrobial activity against multiresistant strains, with high drainage fluid bactericidal titers maintained for almost 24 h post-implantationNo signs of nephrotoxicity or local cytotoxic effects were observed in patients after the local and systemic administration of gentamicin and vancomycin, with low systemic exposureN/AMcKenna et al.Ref [62]Cement spacer Palacos R cement-vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively).-Uncemented revision stem (Solution System(r), DePuy Orthopaedics)In vivo clinical trials30 consecutive patients with infected total hip arthroplasties, indicating it is an in vivo human case study/Clinical Study (Prospective Longitudinal Cohort)High quality (moderate risk of bias via ROBINS-I). The potential to improve treatment efficiency by reducing systemic antibiotic burden is clinically demonstrated. A shortened 2-week course of systemic antibiotics—when coupled with high-dose local delivery—yields success rates (87.1%) comparable to traditional 6-to-12 week regimensN/AThe elution achieves higher local tissue concentrations compared to parenteral administration, maintaining effective peri-prosthetic antibiotic levels for up to 4 monthsHigher local tissue concentrations of antibiotics are achieved through elution from ALBC compared to parenteral administration, maintaining effective peri-prosthetic antibiotic levels for up to 4 monthsN/AN/AWhittaker et al.Ref [60]-Palacos R cement-Vancomycin and gentamicin-In vivo clinical trials 43 consecutive patients (44 hips) underwent a two-stage revision procedure/Clinical Study (Prospective Longitudinal Cohort)High quality (moderate risk of bias via ROBINS-I). Their five-year longitudinal analysis demonstrated a 93.5% success rate in treating Gram-positive PJI using high-dose spacers without the need for prolonged systemic antibiotic therapy. This evidence significantly refutes the ‘inefficiency’ argument by showing that local carriers can serve as the primary curative modalityThe addition of 2.0 g of vancomycin and 0.25 g of gentamicin enhances the local delivery of antibiotics while maintaining the structural integrity of the cement matrixN/AVancomycin is effective against all Gram-positive organisms without acquired resistance, particularly against gentamicin-resistant staphylococci.N/AN/AAnagnostakos et al.Ref [59]-Refobacin Palacos and Vanco-cell beads and spacers.-gentamicin-In vivo clinical trials28 human patients undergoing two-stage exchange for infected THA/Clinical Pharmacokinetic Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). The impact of delivery geometry on therapeutic efficacy is evidenced. The in vivo comparison demonstrated that higher surface-area-to-volume ratios (as seen in beads) result in significantly higher local antibiotic titers compared to bulkier spacers. However, both systems exhibited a rapid decline in elution by the end of the first weekManual incorporation of vancomycin into the cement powder influences antibiotic elutionGentamicin and vancomycin released from antibiotic-loaded beads exhibited higher elution characteristics compared to spacers, with peak concentrations reached on day 1, followed by a consistent decay in elution rates over the subsequent daysBoth gentamicin and vancomycin, achieve local concentrations that significantly exceed the minimum inhibitory or bactericidal concentrationsNo renal or hepatic dysfunction was observed in any of the cases studied, indicating no significant nephrotoxicityN/AHsieh et al.Ref. [61]-Liquid gentamicin and vancomycin-bone cement spacersIn vivo human case:42 patients undergoing two-stage revision hip arthroplasty for periprosthetic infection/Prospective Cohort StudyHigh quality (low risk via ROBINS-I – bias) This study provides high-quality longitudinal data on the elution kinetics and systemic safety profile of high-dose Gentamicin-loaded spacers. Its strength lies in the robust monitoring of systemic toxicity, providing a clear clinical rationale for the safety limits observed in two-stage hip revisionThe addition of liquid gentamicin reduces the compressive strength of bone cement by 49% and tensile strength by 46%, indicating that while they enhance antibiotic elution, they compromise the mechanical properties of the cementPrompt release of liquid gentamicin and vancomycin, with joint fluid antibiotic levels remaining well above therapeutic requirements for at least 3 months despite rapid declines during the first few days after implantationBoth gentamicin and vancomycin maintained their bactericidal activities after being eluted from the bone cement spacersNo evidence of nephrotoxicity in patients, as systemic antibiotic concentrations were below detectable levels in the majority, and no patient exhibited renal insufficiency or other systemic adverse effects related to the antibiotics usedN/AJanssen et al.Ref [76]Gentamicin-impregnated StageOne,Select Refobacin Bone Cement R spacers,Refobacin Bone Cement RIn vivo human case studies, (wound drainage fluid samples were collected from patients after implantation of spacers) -in vitro studies were conducted on phosphate-buffered saline/Clinical Pharmacokinetic Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). By utilizing ELISA to compare in vitro elution to actual human drain fluid, the researchers revealed that clinical antibiotic concentrations are significantly lower than laboratory models predict. This discrepancy highlights the physiological barriers to elution in the human joint space and reinforces the critical need for advanced, nano-engineered delivery systemsThe standard mixing method used could have led to variability in PMMA cement porosity and pharmacokinetic release profilesPMMA beads had a significantly higher and prolonged release of gentamicin compared to spacers. The burst release from beads was more than 10 times higher than that from spacers, with beads reaching a plateau phase much later. The release from PMMA beads is divided into two phases: an initial burst release, followed by a sustained release over several days to weeksN/AN/AN/ATable 2Synthetic list of the most relevant aspects of: Study design/sample size/follow-up/level tag related to arthroplasty clinical cases within the reviewed literature.Table 2ReferenceMaterials used for the implant (or specific spacer/blocks/cement model)Study design/sample size/follow-up/level tagHeffernan et al.Ref [51]-Poly (N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M − 1000 acrylamide) (PNDJ) hydrogel•The study design involved in vivo evaluations using animal models, specifically rabbits and canines, to assess the safety and efficacy of the temperature-responsive hydrogel PNDJ for preventing SSIs.•The sample size included multiple animal subjects, although specific numbers are not detailed in the provided contexts.•The follow-up period for assessing outcomes varied, with some evaluations indicating a return to normal values within 14 to 56 days post-treatment.•The evidence level of the study is categorized as animal studies, as it primarily involved testing in rabbits and canines.Foster et al.Ref [52]-PMMA-Antibiotic-loaded hydrogel containing GM and VCM•The study included 13 skeletally mature Swiss Alpine sheep to evaluate a single-stage revision model for Orthopedic Device-Related Infection (ODRI), adapted from a previously described two-stage revision model.•All animals underwent preoperative clinical assessment, including physical examination, blood tests, and radiographic imaging, prior to study inclusion.•Sheep were acclimatized for at least 2 weeks under controlled housing conditions (12 h light/dark cycle) before surgery.•Post-operative follow-up involved daily veterinary monitoring of behavior, limb function, temperature, appetite, and overall health, using a cumulative clinical scoring system to determine humane endpoints (euthanasia if score >7 for 3 days).•Evidence level: Preclinical animal study (controlled in vivo large-animal model).Niska et al.Ref [126]Vancomycin and rifampin•The study utilized a preclinical mouse model to evaluate the efficacy of vancomycin single-agent therapy compared to combination therapy with vancomycin and rifampin against Staphylococcus aureus prosthetic joint infection.•The sample size for the experiments was at least 8 mice per group.•The study involved a follow-up period of 6 weeks, with assessments conducted on postoperative days 0, 3, 7, 14, 21, 28, 35, 42, and 49.•The evidence level of the study is classified as animal research.Irwin et al.Ref [55]-Computerized Numerical Control machined-surgical steel pin with a slotted end.-The biofilm generation media consisted of Difco TSB at different concentrations for attachment, accumulation, and maturation of biofilms•The study design involved a rat model of PJI using biofilm inocula in male Sprague-Dawley rats.•The sample size and follow-up details are not explicitly provided in the context.•The study can be classified as an animal study, specifically using a cohort design, as it involved multiple groups of rats receiving different treatments.Gilchrist et al.Ref [58]-Fusidic acid-Rifampicin-Sodium fusidate-Poly(D,L-lactic acid-co-glycolic acid-Tetrahydrofuran-Dimethylformamide-Acetonitrile-Methanol-Phosphoric acid•The study was conducted in vivo using 13 female Sprague-Dawley rats (195–225 g) to evaluate the antibacterial efficacy of antibiotic-loaded nanofibers in preventing MRSA colonization on titanium implants.•Each rat received two subcutaneous implants—one titanium disk with antibiotic-loaded nanofibers (test) and one with blank PLGA nanofibers (control)—implanted in separate dorsal pockets.•Immediately after implantation, ∼108 CFU of MRSA (Newman strain) was inoculated onto the titanium surface to induce localized infection.•Animals were monitored for 7 days post-implantation before being sacrificed for microbiological (CFU count) and histopathological evaluation of implant sites.•Evidence level: Preclinical animal study (controlled experimental design, in vivo rat model).Matsuno et al.Ref [53]-Cross-linked Hyaluronic Acid (HAc) gel-gentamicin•The study design involved both in vitro and animal models to evaluate the antibacterial activity of the GM-containing HAc gel.•The sample size included a total of 45 mice for the durability study of the antibacterial activity, with five mice examined at each time point (0, 1, 2, 7, and 14 days).•In the rabbit osteomyelitis model, five rabbits were used in each of the four experimental groups, totalling 20 rabbits.•The study can be classified as an animal study, specifically using mouse and rabbit models to assess the effectiveness of the antibacterial carrier.Yan et al.Ref [47]-Continuous wave ultrasound CMW ENDURANCE bone cement,-vancomycin,-powdered PMMA,-liquid monomer•The study involved a sample size of sixteen New Zealand White female rabbits.•The rabbits were divided into two groups: one group received CWU treatment, while the control group did not.•The follow-up period lasted for 30 days after the implantation of ALBC.•The study design can be classified as an animal study.Hasan et al.Ref [48]-PLGA-PEG (-PCL-Vancomycin hydrochloride (V-HCl)-N-Methyl-2-pyrrolidone (NMP)-CaCl2 (calcium chloride)-PRO OSTEON 500R3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid (MTT)-TRIzol reagent-SuperScript VILO cDNA Synthesis Kit•The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens.•A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin•The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis.•The study design can be classified as an animal study with a cohort design, as it involved multiple time points for follow-up and comparison between two different materials.Mukai et al.Ref [44]-CPC (Biopex-R Advance)-PMMA cement (Surgical Simplex P Bone Cement)-Injectable vancomycin hydrochloride•The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens.•A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin.•The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis.•The study design can be classified as an animal study with a cohort design.Lewis et al.Ref [39]DBM and gentamicin.•The study design involved in vitro and in vivo assays to evaluate the effects of gentamicin loading on the osteoinductive properties of human demineralized bone matrix.•The in vivo component utilized an ectopic pouch model in athymic nude rats to analyse the osteoinductivity of DBM samples.•The sample size for the in vivo study involved six samples implanted per animal, with animals being euthanized 28 days post-implantation.•The evidence level for the study includes both in vitro and animal studies.Uchida et al.Ref [42]-CPC (Biopex-R Advance)-PMMA (Surgical Simplex P Bone Cement),-Injectable VCM hydrochloride.•The study design involved both in vitro and in vivo experiments to evaluate the release profile of vancomycin from calcium phosphate cement and polymethylmethacrylate cement.•For in vivo experiments, test specimens were implanted between the fascia and muscle of rats, and residual vancomycin was extracted from the removed specimens to determine the amount released into rat tissues.•The sample size for the in vivo study is not explicitly mentioned in the provided contexts.•The evidence level includes in vitro studies and animal studies (rat model).Lin et al.Ref [35]-PMMA) bone cement,-VAN,-treated with microbubbles and ultrasound•The study involved both in vitro and in vivo evaluations, indicating a mixed study design.•The sample size for the in vivo study consisted of 32 rabbits, with 64 tibiae divided into four groups for treatment.•The evidence level for the in vitro part is classified as in vitro, while the in vivo part is classified as animal study.Yang et al.Ref [43]-PMMA cement-Gentamicin and chlorhexidine-Silica nanoparticles were•The study involved the development of a nanocomposite bone cement and its evaluation in an in vivo model of an infected bone defect, indicating an animal study design.•The sample size for the in vivo experiments is not explicitly mentioned in the provided contexts (Winstar rats).•Follow-up was performed after 14 and 28 days by CT of Winstar rat femur bone•The evidence level of the study is categorized as an animal research due to the use of an infected bone lesion model for testing.Xu et al.Ref [106]Vancomycin, meropenem, methyl-methacrylate cement polymer, gentamicin, clindamycin, tobramycin, aztreonam, ampicillin, ceftazidime, linezolid, and ceftriaxone•The study design is a prospective, randomized, controlled trial.•The sample size consisted of 32 patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection.•The follow-up period involved collecting drainage samples every 24 h for the first five days following spacer implantation.•The evidence level is classified as clinical, specifically a randomized controlled trial.Edelstein et al.Ref [107]-PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement.−3 g of vancomycin and 2.4 g of tobramycin.-Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amount.•The study design is a prospective cohort study.•The sample size included a total of 37 patients, with 20 undergoing total knee arthroplasty and 17 undergoing total hip arthroplasty.•Follow-up was conducted over a period of 8 weeks, with serum creatinine and glomerular filtration rate data collected at baseline and weekly intervals.•The evidence level is classified as clinical, specifically a cohort study.Vrabec et al.Ref [79]Bone cement mixture: SimplexTM P with Tobramycin; Stryker Howmedica Osteonics containing 1 g of tobramycin with 40 g of bone cement.•The study design involved a clinical cohort study, evaluating patients undergoing primary TKA over a 6-month period.•The study enrolled 15 patients undergoing primary TKA by one of two surgeons (GV, JP) who met the inclusion criteria; Follow-up was conducted for one year, during which no complications or infections were reported.•The evidence level is classified as clinical, specifically a cohort study.Bertazzoni Minelli et al.Ref [80]-Gentamicin, vancomycin•The study involved a sample size of 12 patients (8 male and 4 female) undergoing two-stage revision surgery with antibiotic-loaded spacers.•The follow-up included the collection of serum and joint fluid samples at 1, 4, and 24 h after spacer implantation.•The study design is classified as a clinical case series.Van Jiperen et al.Ref [82]-Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate)•The study design is a randomized, non-blinded, comparative, and prospective clinical investigation.•The sample size consisted of 31 participants, with 16 allocated to the thin cement mantle group and 15 to the thick cement mantle group.•The evidence level is classified as a clinical randomized controlled trial.Ma et al.Ref [115]PMMA spacers from two-stage revision total knee arthroplasty for periprosthetic joint infection (PJI)Titanium rods for bacterial incubation and biofilm formation•The study design is a prospective, multicentre analytic cohort study of patients undergoing explant of antibiotic PMMA spacers for TKA PJI.•The study included patients who underwent a two-stage exchange for TKA PJI with an antibiotic cement spacer.•Inclusion criteria required that antibiotic spacers did not culture any organisms after removal and that there was no evidence of infection recurrence for at least 1 year following the two-stage exchange.•The sample size involved 13 antibiotic PMMA spacers collected for analysis.•The evidence level is classified as a clinical cohort study.Ammon and StockleyRef [83]Allograft bone obtained from the tissue bank, antibiotic-loaded cement, and systemic antibiotics for prophylactic doses•The study involved a sample size of 57 patients who underwent a two-stage revision for infection in hip replacements.•The follow-up period for these patients was a minimum of two years from the second stage, with a mean follow-up of 4.5 years.•The study design can be classified as a clinical case series.Mutimer et al.Ref [103]-PMMA cement-gentamicin•The study involved a clinical design, specifically a case series, as it assessed the levels of gentamicin in patients undergoing a two-stage revision total knee arthroplasty.•The sample size consisted of twelve patients who received a gentamicin-loaded articulating spacer.•Follow-up was conducted at the second stage of the procedure, which occurred at a median of 99 days following the spacer insertion.•The study aimed to measure the gentamicin levels in synovial fluid and blood samples collected during the second-stage revision.Hsu et al.Ref [104]-Vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam,-bone cement•The study design involved a clinical case series with a sample size of 8 patients (4 women and 4 men between 51 and 79 years of age) diagnosed with chronic knee periprosthetic joint infection.•The antibiotic concentrations in the joint fluid were measured daily for 7 days.•The evidence level is classified as clinical, specifically a case seriesHsieh et al.Ref [105]PMMA spacers loaded with a high dose of vancomycin and aztreonam•The study design involved a clinical case series with a sample size of 46 patients who underwent two-stage revision hip arthroplasty for infections.•The average follow-up period after the first-stage surgery was 107 days.•The study was conducted according to a prospective protocol, and all patients provided informed consent.•The evidence level of the study is classified as clinical.Griffin et al.Ref [116]-Antibiotic-impregnated PMMA spacer•The study design is a prospective case series.•The sample size consists of six patients from whom antibiotic-impregnated cement spacers were removed for analysis.•The follow-up involved the analysis of the spacers at the time of second-stage revision arthroplasty.•The evidence level is classified as clinical, specifically a case seriesUeng et al.Ref [84]-PMMA bone cement-Oxacillin-Vancomycin-Cefazolin•The study involved a sample size of 30 patients who were scheduled for primary cemented total-knee arthroplasty.•The follow-up period included the collection of joint fluid samples at 8, 16, 24, 32, 40, and 48 h after prosthesis implantation.•The study design is classified as a clinical cohort study, as it compares the antibacterial activities of joint fluids from patients receiving different types of bone cement (with or without antibiotic loading)Oe et al.Ref [77]Vancomycin as an antibiotic-loaded acrylic cement to prevent infection after THA or to treat patients with MRSA•The study design involved a clinical cohort study with a sample size of 27 hips treated with antibiotic-loaded acrylic cement including, vancomycin, at the institution.•Patients were classified into two groups: a low-dose group (21 hips) and a high-dose group (6 hips), based on the type of THA performed.•Follow-up assessments of serum concentrations of VCM and creatinine were conducted at multiple postoperative time points: days 1, 4, 7, 14, and 28, as well as at 3 and 6 months.•The evidence level of the study is classified as clinical, specifically a cohort study.Klinder et al.Ref [10]Gentamicin, vancomycin, polymethylmethacrylate (PMMA) cement, and antibiotic-impregnated spacers.•The study design included patients from two prospective, multicenter trials investigating cement spacer treatment of implant-associated infections after total hip and knee joint replacement.•The sample size consisted of 18 patients (10 hip and 8 knee patients) who were due for two-stage treatment after a periprosthetic joint infection.•The follow-up involved taking control samples, including joint fluid and a punch biopsy of the soft tissue around the spacer, after a 4-to-6-week systemic antibiotics therapy and an antibiotics-free interval of 2 weeks.•The evidence level is classified as clinical, as it involves a prospective clinical trial.Sudo et al.Ref [66]-Antibiotic-impregnated CHA ceramic blocks.•The study design is a retrospective case series involving seven consecutive patients.•The sample size consists of 7 patients, with an average age of 65 years.•The follow-up duration averaged 5.0 years, with a range of 2.3 to 6.1 years.•The evidence level is classified as clinical, specifically a case seriesKendoff et al.Ref [65]Gentamicin and vancomycin,-ALBC used in the study.•Prospective open-label clinical case series including 20 patients (7 women, 13 men; mean age 62.5 years) undergoing one-stage revision for infected hip prostheses with vancomycin-susceptible bacteria.•Patients received Copal® G + V PMMA bone cement containing gentamicin (0.5 g) and vancomycin (2.0 g) per 43 g powder; postoperative systemic antibiotics were continued for about 13 days.•Pharmacokinetic monitoring of gentamicin and vancomycin was performed via serial plasma, urine, and wound exudate samples up to 10 days post-surgery using LC-MS-MS.•Follow-up: daily assessments until day 10 and a final evaluation at 7 months to assess antibiotic release and infection outcomes.•Evidence level: Clinical study – Prospective case series (non-randomized, single-center)Webb et al.Ref [64]-Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK)-Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany)•The study design involved a clinical cohort study with a sample size of 35 patients who underwent primary total hip arthroplasty•Patients were followed up for a minimum of 12 weeks post-operatively, with urinary samples collected for analysis.•The study aimed to investigate the in vivo elution kinetics of gentamicin from bone cement.•The evidence level of the study is classified as clinicalRegis et al.Ref [63]PMMA cement -Gentamicin, vancomycin•The study involved a sample size of 7 patients who received preformed spacers for two-stage revision of a THA due to infection.•The follow-up included monthly clinical evaluations, laboratory tests, and radiographic examinations.•The study design is classified as a clinical case series.McKenna et al.Ref [62]Cement spacer Palacos R cement-vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively) advice.-Uncemented revision stem (Solution System(r), DePuy Orthopaedics)•The study design is a retrospective case series involving 30 consecutive patients with 31 infected total hip arthroplasties treated by a single surgeon over a 4-year period.•The sample size consists of 30 patients, with data recorded for 28 of them.•The mean follow-up duration for the patients was 35 months, with a minimum follow-up of 24 months.•The evidence level is classified as a clinical case series.Whittaker et al.Ref [60]-Palacos R cement-Vancomycin and gentamicin•The study involved a clinical design, specifically a case series, as it reported on the experience of multiple surgeons treating patients with chronic peri-prosthetic infection.•The sample size consisted of 43 consecutive patients (44 hips) who underwent the two-stage revision procedure.•The median follow-up period for the patients was 49 months, ranging from 25 to 83 months.Anagnostakos et al.Ref [59]-Refobacin Palacos and Vanco-cell beads and spacers.-gentamicin•The study involved a clinical design with a sample size of 28 patients, consisting of 17 hip spacers and 11 chains.•The follow-up period for the study included daily measurements of antibiotic elution from the drainage fluid for up to 13 days for beads and 7 days for spacers.•The evidence level of the study is classified as clinical, specifically a case series, as it evaluates the elution of antibiotics in patients undergoing two-stage exchange for infected total hip arthroplastyJanssen et al.Ref [76]Gentamicin-impregnated StageOne,Select Refobacin Bone Cement R spacers,Refobacin Bone Cement R•The study design involved both in vitro and in vivo experiments to assess the pharmacokinetic release profile of antibiotics from PMMA spacers and beads.•The in vitro component measured gentamicin concentrations from PMMA spacers and beads submerged in phosphate-buffered saline using ELISA.•The in vivo component collected wound drainage fluid samples from patients after implantation of a spacer over a maximum period of 14 days.•The sample size for the in vitro experiments included multiple time points for gentamicin concentration measurement, while the clinical samples were collected from patients with different types of spacers.•The evidence level for the in vitro part of the study is classified as in vitro, while the in vivo part is classified as clinical (case series). Table 1Synthetic list of the most relevant aspects of arthroplasty implants in reviewed literature: 1 -Materials used for the implant (or specific spacer, blocks cement commercial model); 2 - Type of study: in vitro, in vivo animal model, in vivo human case; 3 – Quality assessment/Risk of bias; 4 -Effects on cement matrix by additional components, treatments and admixing of drugs; 5 - Drug release, kinetic and elution characteristics; 6 - Antibiotic activity; 7 - Local and systemic cytotoxicity, nephrotoxicity; 8 - Biodegradability – Osseointegration – Bone volume analysis. Unavailable aspects for specific reference are indicated with N/A.Table 1ReferenceMaterials used for the implant (or specific spacer/blocks/cement model)Type of study: in vitro, in vivo animal model, in vivo human caseQuality Assessment/Risk of BiasEffects on the cement matrix from additional components, treatments, and drug admixturesDrug release, kinetic, and elution characteristicsAntibiotic activityLocal and systemic cytotoxicity, nephrotoxicityBiodegradability – Osseointegration - Bone volume analysisAlt et al.Ref [36]PMMA-cement loaded with 1% nanoparticulate silverIn vitro study/PreclinicalModerate quality score (3.4/5) (appraisal criteria:scientific rationale and setup, control group validity, reproducibility, outcome measurement, dynamic validity) – It provides a robust experimental design with appropriate positive and negative controls for evaluating the antimicrobial efficacy of silver nanoparticles in PMMA, it is limited by the absence of blinding in outcome assessment and the use of static in vitro testing conditionsN/AN/AComplete inhibition of bacterial growth against gentamicin-resistant MRSE and MRSA strains, while both unloaded and gentamicin-loaded cements showed no antibacterial activityNo signs of cytotoxicity in three different in vitro tests, indicating a lack of local and systemic cytotoxic effects; however, further in vivo cytotoxicity studies are necessary to confirm these initial findingsN/AHasandoost et al.Ref [29]Glass Polyalkenoate Cement (GPC), calcium sulphate (CaSO4), and PMMAIn vitro study/PreclinicalHigh quality score (4/5) (appraisal criteria: experimental design, material characterization, biological control, mechanical validation, antibacterial scope)- Excellent adherence to ISO 10993-5 standards for cytotoxicity and ISO 9917-1 for mechanical integrity. High certainty regarding the osteoconductivity and biocompatibilityCaSO4 enhances the release of ions such as Ca2+ and Zn2+, while also promoting the formation of pores near the surfaceIncreased release of ions such as Ca2+ and Zn2+ over a maturation period of 30 days in deionized waterN/AN/AN/ATaddei and AffatatoRef [78]-Vancogenx-space knee,-gentamicin sulphate, vancomycin hydrochloride, barium sulphate, benzoyl peroxide, N, N-dimethyl-para-toluidine, and traces of hydroquinoneIn vitro study/PreclinicalHigh quality score (4/5) (appraisal criteria: methodological innovation, comparative rigor, material aging, statistical analysis, standardization). Exceptional molecular characterization using Raman spectroscopy. Provided critical insights into the antibiotic's effect on PMMA polymerization and wear resistance, identifying that vancomycin-loaded spacers maintain better molecular stability during clinical useThe addition of vancomycin hydrochloride to the cement matrix appears to influence the polymerization degree of PMMARelease of vancomycin hydrochloride is minimal, with over 90% of the loaded antibiotics remaining trapped in the PMMA matrixN/AN/AN/AAnagnostakos et al.Ref [30]-Palacos R cement, -antibiotic powders such as gentamicin, vancomycin, teicoplanin, and SynercidIn vitro study/PreclinicalHigh quality score: (4.5/5) – in vitro (appraisal criteria: analytical precision, drug synergy, microbiological link, temporal scope, fluid simulation). Rigorous analytical study characterizing dual-antibiotic elution (GM/VCM) from PMMAAddition of a glycopeptide, such as vancomycin, enhances the release of gentamicin from the cement matrix, suggesting that the ratio of incorporated antibiotics may influence their elutionGentamicin showed superior elution characteristics compared to vancomycin, with a higher percentage of gentamicin released over time, particularly from gentamicin-vancomycin or gentamicin-teicoplanin-loaded spacersGentamicin + vancomycin showed the best antimicrobial activity against Staphylococcus epidermidis and MRSA, while gentamicin + teicoplanin was most effective against Staphylococcus aureus and Enterococcus faecalisN/AN/ASeldes et al. Ref [31]-Palacos R bone cement-Liquid gentamicin and powdered tobramycin- In vitro study/PreclinicalHigh quality score: (4.5/5) (appraisal criteria: comparative logic, mechanical testing, elution methodology, microbiological assay, clinical rationale). Highly influential in vitro study demonstrating that while gentamicin provides potent bactericidal elution, it reduces mechanical propertiesThe addition of liquid gentamicin significantly decreased the ultimate compression strength by 49% and the ultimate tension strength by 46% compared to the controlsBurst release during the initial 24 h, with a mean concentration of 26.4 mcg/mL, and it maintained bactericidal concentrations for at least three weeks, decreasing to 4.15 mcg/mL at three weeks and 0.65 mcg/mL at six weeksBactericidal activity against the Escherichia coli strain tested, indicating effective antibiotic activityN/AN/ALewis and Bhattaram Ref [32]-Low viscosity Cemex O XL and Cemex O Genta LV-Medium-viscosity Endurance TM and Endurance Gentamicin-High-viscosity SmartSet TM HV and SmartSet O GHVIn vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: carrier characterization, elution methodology, analytical precision, biological potency, stability testing). Rigorous evaluation of a bioactive carrier for dual-antibiotic deliveryThe inclusion of gentamicin sulphate powder in the cement's powder does not adversely affect a wide array of in vitro properties of the curing and cured cement, such as strength, modulus, work-to-fracture, and plane-strain fracture toughnessN/AN/AN/AN/AMorrison et al.Ref [33]-PMMA beads were used for the experiment.-gentamicin, silver, and a combination of gentamicin and silverIn vitro study/PreclinicalHigh quality score:(4.5/5) (appraisal criteria: microbiological rigor, biofilm quantification, additive comparison, statistical analysis, methodological depth). Strong methodological focus on biofilm formation. Utilized a modified Calgary Biofilm Device to demonstrate that linezolid and gentamicin significantly inhibit MRSP biofilm on PMMA, while silver-based additives showed variable efficacy, highlighting the challenges of non-antibiotic coatingN/ALow surface area-to-volume ratio of the PMMA beads limits the elution of gentamicin, resulting in a greater percentage of the drug being present in the bulk of the beadEffective at reducing biofilm formation of gentamicin-susceptible MRSP isolates but had no effect on isolates not susceptible to gentamicin.-silver-impregnated PMMA showed no effect on MRSP biofilm formationN/AN/AGasparini et al.Ref [34]-Polymerized cement (Cemex XL; Tecres SpA, Sommacampagna, Italy)-PMMA copolymer powder-tobramycin, vancomycin, teicoplanin, clindamycin, and colistinIn vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: comparative logic, elution monitoring, temporal scope, standardization, microbiological link). Rigorous HPLC-based comparative analysis of dual-antibiotic ALBCsThe addition of antibiotics to the acrylic cement decreases its bending strength compared to standard formulationsBurst release of antibiotics in the first hour, followed by a progressively decreasing elution rateN/AN/AN/ASalih et al. Ref [75]Heraeus Palacos RG cement, Heraeus Copal GC, ammonium acetate bufferGentamicinIn vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: experimental logic, elution methodology, duration of study, clinical simulation, statistical rigor)). A pragmatic in vitro study demonstrating that physical surface modification can increase gentamicin elutionIndentation of cement spacers significantly increased the elution of gentamicin over a period of at least nine weeks, with the total amount of eluted gentamicin being greater for indented discs compared to plain oneIndenting cement spacers with a MacDonald dissector improved the elution of gentamicinAlt et al.Ref [110]-NanoSilver, polymethylmetacrylate bone cement,-gentamicin-loaded bone cement,-plain PMMA bone cementIn vitro study: human osteoblasts and mouse fibroblasts/PreclinicalHigh quality score: (5/5) (appraisal criteria: material characterization, microbiological breadth, cytotoxicity rigor, elution and stability, standardization). Seminal in vitro study on nanosilver-loaded PMMA. Provided comprehensive evidence of broad-spectrum antibacterial activity (including MRSA) and validated biocompatibility with human cell lineN/AN/ANanoSilver bone cement demonstrated high antibacterial activity against multiresistant bacteria, including S. Epidermidis, MRSE, and MRSA, unlike gentamicin-loaded cementNo in vitro cytotoxicityN/ASnir et al.Ref [38]-Linezolid, vancomycin hydrochloride, and gentamicin-commercial PMMA cements: Smart Set GHV and CMW 1.In vitro study/PreclinicalHigh quality score: (4/5) (appraisal criteria: scientific rationale, control group validity, reproducibility, outcome measurement, dynamic validity). This research demonstrates superior reporting of elution kinetics compared to earlier literature, offering a clearer understanding of the temporal concentration profiles of Linezolid in PMMA. While it remains limited by its static in vitro design—failing to replicate the shear stress and flow rates of human synovial fluid—it provides high-quality data regarding the bactericidal potential of alternative antibioticsThe cement matrix remains unaffected by the admixing of drugs like linezolid, gentamicin, and vancomycinThe elution kinetics of linezolid from PMMA exhibited a typical pattern consisting of a rapid phase followed by a plateau phase, with the combination of linezolid and gentamicin showing a significantly longer plateau phase compared to each antibiotic used aloneLinezolid demonstrated significantly longer GIT against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Staphylococcus epidermidis compared to vancomycin and gentamicinN/AN/AHeffernan et al.Ref [51]-PNDJ hydrogelIn vivo animal model, specifically rabbits and canines/PreclinicalHigh quality score: (8/10) on SYRCLE, (SYRCLE domain: selection bias, performance bias, detection bias, attrition bias, reporting bias, specific safety). Robust in vivo evaluation of a temperature-responsive hydrogelN/AThe drug release is primarily controlled by adjusting the Jeffamine M − 1000 acrylamide repeat unit content, allowing for sustained supra-MIC concentrations of antimicrobials over multiple days in surgical sitesEffectiveness in preventing recurrence of implant-associated Methicillin-Susceptible Staphylococcus aureus (MSSA) and MRSA osteomyelitis in rabbitsWell-tolerated locally and systemically, although mild renal toxicity consistent with the released antimicrobials was identified at high doses in rats, and systemic toxicity was evaluated based on markers of renal and hepatic functionPNDJ hydrogels are compatible with tissue healing at bone-implant interfaces, showing evidence of new bone formation and remodeling in response to load- bearingFoster et al.Ref [52]-PMMA-Antibiotic-loaded hydrogel containing gentamicin and vancomycin-In vivo animal model: Swiss Alpine sheep/Preclinical-In vitro comparative testHigh quality score: (9/10) on SYRCLE. Exceptionally large-animal trial (ovine) evaluating an antibiotic-loaded hydrogel for single-stage MRSA revisionN/ABurst release profile under in vitro conditions, with local gentamicin concentrations being 10-100 times higher in the hydrogel group compared to in vivo PMMA during the first 2-3 days postoperativelyIncreasing concentrations of gentamicin and vancomycin did not significantly increase antibiofilm activity against MRSA biofilmsNo significant differences in renal function tests (creatinine, urea) between the hydrogel and PMMA groups, indicating no evidence of nephrotoxicity or systemic cytotoxicityThe hydrogel showed good biodegradabilityNiska et al. Ref [126]-smart nanofiber coating (PLGA/PEG) to deliver combinatorial antibiotics (vancomycin and rifampin)In vivo animal modeleight-week-old male C57BL6 mice/PreclinicalHigh quality score: (9/10) on SYRCLE. While the study design is highly rigorous, the text does not explicitly detail the security of the randomization sequence before the start of the study, which is a common occurrence in research reports of this timeframeN/AN/AThe combination of vancomycin and rifampin showed enhanced antibiotic activity against S. aureus in the mouse model, effectively reducing bacterial burden and preventing infection-induced changes in bone and joint tissueN/AN/AMecikoglu et al.Ref [54]-PMMA cement,-a Kirschner wire,-Serratiopeptidase enzyme injectionsIn vivo animal model, sixty Sprague-Dawley rats/PreclinicalHigh quality score: (9/10) on SYRCLE. Strong preclinical evidence supporting the use of proteolytic enzymes (Serratiopeptidase) as an adjunct to antibiotic therapyN/AN/ASerratiopeptidase enhances antibiotic activity against Staphylococcus epidermidis strain (ATCC 35984) with a high slime-producing capacity)N/AN/AIrwin et al.Ref [55]-Computerized Numerical Control machined-surgical steel pin with a slotted end.-The biofilm generation media consisted of Difco Tryptic Soy Broth (TSB) at different concentrations for attachment, accumulation, and maturation of biofilmsIn vivo animal model, specifically using male Sprague-Dawley rats/PreclinicalHigh quality score: (10/10) on SYRCLE. A benchmark study for PJI modelling. By utilizing a pre-formed biofilm inoculum, this study provides a more realistic and ‘recalcitrant’ infection environment than traditional planktonic modelsN/AN/A.Both in vitro and in vivo generated biofilms show cefazolin tolerance over 250 times the MICN/AN/AGilchrist et al.Ref [58]-Fusidic acid (FA)-Rifampicin (RIF)-Sodium fusidate (SF)-Poly(D,L-lactic acid-co-glycolic acid) (PLGA)-Tetrahydrofuran (THF)-Dimethylformamide (DMF)-Acetonitrile (ACN)-Methanol (MeOH)-Phosphoric acid-In vitro evaluations using Human Umbilical Vein Endothelial cells (HUVEC)-In vivo animal model female Sprague-Dawley rats/PreclinicalHigh quality score: (4.5/5) – in vitro (appraisal criteria: nanofiber characterization, elution kinetics, combination synergy, cytotoxicity, antibacterial scope); High quality score: (9/10) on SYRCLE – in vivo. It provides a solution to Antibiotic Resistance. By co-loading fusidic acid and rifampicin, the nanofibers prevent the “spontaneous mutation” that often happens when rifampicin is used aloneN/ABiphasic release pattern, characterized by an extensive burst phase over the first 1-2 days, followed by a slow, controlled release over 35 days, with co-loading of RIF and FASF influencing the release rates of the individual drugsComplete eradication of bacteria after 48 h for both strains of MRSA and S. epidermidisN/AN/AMatsuno et al. [53]-Cross-linked hyaluronic acid (HA) gel-GM-in vitro study-in vivo animal model:Retired male NewZealand white rabbits,Male Balb/c mice, 6–8 weeks old/PreclinicalHigh quality score: (4.2/5) – in vitro (appraisal criteria: carrier composition, elution monitoring, antibacterial activity, standardization, cytotoxicity); Moderate to High quality score: (7.5/10) on SYRCLE – in vivo. Many carriers are “foreign bodies” (like PMMA) that can harbour further infection. The study demonstrates that the HA gel does not cause the systemic “toxic spikes” often feared with liquid antibiotics, as the gel acts as a “slow-release” brakeN/AN/ASignificant antibacterial activity against Staphylococcus aureus in both in vitro and in vivo models, effectively suppressing bacterial growthN/AThe bioabsorbable antibacterial carrier does not disturb osseointegration and supports bone ongrowthYan et al.Ref [47]-Continuous wave ultrasound CMW ENDURANCE bone cement,-vancomycin,-powdered PMMA,-liquid monomer-In vivo animal model: 16 New Zealand White female rabbits-The in vitro comparative study/PreclinicalHigh quality score: (4.8/5) – in vitro (appraisal criteria: experimental control, elution monitoring, bioactivity verification, mechanism analysis, temporal data); High quality score: (8.5/10) on SYRCLE – in vivo. The limitations of antibiotic elution from PMMA can be mitigated through external stimuli. The in vitro data confirmed a dose-dependent increase in vancomycin release via ultrasound-mediated cavitation, while the in vivo rabbit model showed a significant reduction in bacterial load and bone destructionN/ACWU significantly enhances vancomycin release, increasing drug elution by 2.57-27.44% compared to controls, with the release following a bi-phasic curve characterized by an initial peak followed by a slower, diffusion-controlled release phaseCWU enhanced the antimicrobial efficacyN/AN/AHasan et al.Ref [48]-PLGA-PEG-PCL (polycaprolactone)-Vancomycin Hydrochloride (V-HCl)-N-Methyl-2-Pyrrolidone (NMP)-Calcium chloride (CaCl2)-PRO OSTEON 500R-MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-TRIzol reagent-SuperScript(tm) VILO(tm) cDNA Synthesis Kit-In vitro study (MG63 osteoblast cells).-In vivo animal model 13 rats implanted with the antibiotic-releasing bone void filling (ABVF) putty and 12 rats in a control groupHigh quality score: (4.7/5) – in vitro (appraisal criteria: drug loading/precision, material properties, biocompatibility, microbiological scope, release mechanism); High quality score: 8/10 on SYRCLE – in vivo. This dual-phase study validates 28-day release kinetics, while the in vivo rat model provided high-certainty evidence that these carriers can simultaneously eradicate osteomyelitis and facilitate bone regenerationThe ABVF putty allowed easy press-fitting and showed an increase in mechanical compliance over time, indicating that the addition of components like PLGA, PEG, and PCL contributed positively to the cement matrix's propertiesSustained vancomycin release over a 6-week period, with an initial burst release of 40% on the first day, followed by a more sustained release due to both erosion of the polymer matrix and diffusion of the drugSustained antimicrobial activity against Staphylococcus aureus for the entire study period of 6 weeksNo nephrotoxic effects, as indicated by serum creatinine levels remaining within normal limits, and non-cytotoxic to host osteoblast cellsThe ABVF putty demonstrated biodegradability in vivo, supported osseointegration, and resulted in a significantly higher bone volume in the treatment group compared to the control groupMukai et al.Ref [44]-CPC (Biopex-R Advance)-PMMA cement (Surgical Simplex P Bone Cement)-Injectable vancomycin hydrochlorideIn vivo animal model using ten-week-old Wistar rats/PreclinicalHigh quality score: (9/10) on SYRCLE. Rigorous in vivo evaluation of calcium phosphate cement (CPC). Utilizing real-time bioluminescence imaging, the study confirmed that CPC provides a superior long-term antibacterial environment compared to traditional carriersN/ACPC/VCM released significantly greater concentrations of VCM over a longer period (24 weeks) compared to PMMA/VCM, releasing 1.4 to 26.1-fold more VCM than PMMA/VCMThe antibacterial activity against Staphylococcus aureus (NBRC 12732) of vancomycin CPC/VCM was logarithmically correlated with VCM concentration. In a 24-week period, CPC/VCM showed significantly larger inhibition zonesN/AN/ALewis et al.Ref [39]DBM and gentamicin-In vivo animal models: athymic nude ratsIn vitro study with culture of rat calvarial osteoblasts/PreclinicalHigh quality score: (4/5) (appraisal criteria: carrier characterization, elution methodology, analytical precision, biological potency, stability testing). Rigorous evaluation of a bioactive carrier for dual-antibiotic deliveryN/ARapid release of 58-78% within the first 48 h, followed by a plateau where clinically relevant concentrations were maintained for up to 13 daysThe gentamicin eluting from the DBM effectively inhibited bacterial colonization, including S. aureus, for up to 12 days at all investigated loading concentrationsN/AGentamicin-loaded DBM showed good biodegradabilityMaurer et al.Ref [114]-Titanium alloy (Ti6Al4V) bolts were used for the experiment.-Copper ions were included in the titanium surface for the coating process-In vivo animal model:36 New Zealand White (NZW) rabbits/PreclinicalHigh quality score: (8/10) on SYRCLE. Rigorous large-animal study evaluating a Cu-TiO2 photocatalytic coating. Demonstrated a significant reduction in bacterial colonization in an acute infection model without systemic copper toxicityN/ACopper ions are released over a duration of 4 weeks, demonstrating an active coating with a maximum peak of copper concentration observed one week after implantation, which is crucial for its antibacterial effectCu-TiO2 coating significantly reduced the infection rate in an animal model simulating acute periprosthetic infection, showing promising antibiotic activity against Staphylococcus aureusSystemic effects of copper, including nephrotoxicity, were monitored by taking weekly creatinine samples, which remained within the normal range throughout the study, indicating no significant nephrotoxic effects were observedN/AUchida et al.Ref [42]-CPC (Biopex-R Advance)-PMMA (Surgical Simplex P Bone Cement),-Injectable VCM hydrochlorideIn vivo animal model:-Wistar rats/PreclinicalHigh quality score: (9/10) on SYRCLE. Rigorous in vivo evaluation of CPC. Utilizing real-time bioluminescence imaging, the study confirmed that CPC provides a superior long-term antibacterial environment compared to traditional carriers- The pore size of CPC impregnated with VCM and GM is smaller than that of CPC impregnated with VCM aloneCPC impregnated with VCM exhibits a sustained release profile, with VCM levels released in vivo being significantly higher than those from PMMA cement, over an extended duration, exceeding the MIC for more than 10 weeks post-implantationN/AN/AN/ALin et al.Ref [35]-PMMA bone cement,-VCM,-treated with US + MB-In vivo animal model:32 healthy adult New Zealand white rabbits were used to evaluate the effectiveness of the treatment.In vitro studyHigh quality score: (4/5) (appraisal criteria: experimental design, novelty/mechanism, microbiological control, standardization, limitation). Innovative in vitro study evaluating the synergy between PMMA and ultrasound-mediated microbubbles. Successfully demonstrated that physical cavitation can significantly enhance vancomycin releaseThe addition of microbubbles and ultrasound treatment significantly enhances the elution rate of vancomycin from the PMMA cement matrixBiphasic elution curve characterized by a transient initial release peak followed by a long-term low releaseSpecimens subjected to US + MB exhibited significantly enhanced antibacterial activity against planktonic Staphylococcus aureus compared to other groupsN/AN/AYang et al.Ref [43]-PMMA cement-Gentamicin and chlorhexidine-Silica nanoparticles-In vivo animal model: modified femoral bone lesion in rats-In vitro: SaoS-2 cellsHigh quality score: (5/5) – in vitro (appraisal criteria: nanomaterial characterization, elution precision, mechanical integrity, anti-biofilm efficacy, cytotoxicity rigor); High quality score: (9.5/10) on SYRCLE. By incorporating halloysite nanotubes into PMMA, the researchers moved beyond the traditional ‘burst-release’ paradigm, achieving a sustained dual-antimicrobial effect- The addition of nanoparticles to the cement matrix did not statistically impact the settling time or the amount of calcium deposited on the surface of the bone cement samplesProlonged release profile, with gentamicin and chlorhexidine being released for over 50 days, with a reduced burst release at the startAntimicrobial inhibition against various bacterial strains, including those resistant to gentamicinN/AN/AXu et al.Ref [106]Vancomycin, meropenem, methyl-methacrylate cement polymer, gentamicin, clindamycin, tobramycin, aztreonam, ampicillin, ceftazidime, linezolid, and ceftriaxoneIn vivo clinical trials-A total of 32 patients-controlled trial conducted on human patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection./RCTHigh quality (low risk of bias via RoB 2- randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, selection of the reported result). A robust clinical RCT demonstrating that closed-suction drainage does not significantly lower the local concentration of antibiotics in the joint space. This study provides high-certainty evidence that surgical drainage can be used safely without compromising the pharmaceutical effectiveness of the spacerN/ABoth vancomycin and meropenem were rapidly released from the cement spacer during the first day, with the release rates gradually decreasing over the subsequent daysAntibacterial activity against MSSA, MRSA, and E. coli during the first five days following spacer implantation.None of the patients presented acute renal failure or side effects related to antibiotic applications, suggesting that the use of vancomycin and meropenem in cement spacers did not result in systemic nephrotoxicityN/AEdelstein et al.Ref [107]-PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement.−3 g of vancomycin and 2.4 g of tobramycin.-Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amountIn vivo human casesA total of 37 patients (20 total knee arthroplasty and 17 total hip arthroplasty) were included in the final cohort for the analysis/Clinical study retrospective cohortHigh quality (moderate risk via ROBINS-I - bias due to confounding, bias in selection of participants, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes, bias in selection of the reported result). Critical safety study using RIFLE criteria to quantify nephrotoxicity. Found a 4.8% incidence of AKI following spacer placement. Identified pre-existing renal insufficiency and high-dose aminoglycosides as primary risk factorsN/AThe rate of antibiotic elution from cement has been found to vary with the type of cement used and the amount, type, and combination of antibiotic usedLocal antibiotic concentrations were achieved well above the MICSubstantial risk of nephrotoxicity associated with the use of high-dose ACSs. Specifically, 27% of patients developed AKI, 5% developed kidney failure. No baseline patient characteristics were significantly associated with the development of AKIN/AVrabec et al.Ref [79]Bone cement mixture: SimplexTM P with Tobramycin; Stryker Howmedica Osteonics containing 1 g of tobramycin with 40 g of bone cementIn vivo human cases: a total of 15 patients: 10 receiving the tobramycin-impregnated bone cement and 5 receiving intravenous tobramycin/Clinical study, prospective cohortHigh quality (ROBINS-I). Critical in vivo clinical analysis of local drug kinetics. Demonstrated that “low-dose” ALBC fails to achieve therapeutic intra-articular concentrations (>4 μg/mL) in the early post-operative period. This study provides high-certainty evidence of the “inefficiency” of treatment in standard cement, justifying the need for high-dose or smart-release carriersThe addition of tobramycin does not adversely affect the cement matrixFavorable elution kinetics during the exothermic polymerization process of the cementTobramycin-impregnated bone achieves supratherapeutic intraarticular concentrations, providing effective local antibiotic activity during the first 48 h postoperatively, while maintaining minimal systemic absorptionAll patients tolerated tobramycin regardless of the administration route, and no evidence of nephrotoxic or allergic complications was observedN/ABertazzoni Minelli et al.Ref [80]-Gentamicin, vancomycinIn vivo human case: patients undergoing two-stage revision surgery for infected arthroplasty/Clinical study (prospective longitudinal)High quality (ROBINS-I). Essential clinical pharmacokinetic study of dual-antibiotic spacers. Confirmed that the combination of GM and VCM maintains synergistic concentrations in synovial fluid well above the MIC for several days, while systemic levels remain safely low. Provides clinical validation for the ‘dual-loading’ strategy used in advanced carriersThe addition of antibiotics to bone cement exceeding a concentration limit of 5-10% leads to a significant decrease in the mechanical resistance of the spacerInitial high release of both antibiotics in wound fluids and maintained persistently high concentrations for at least 24 h after spacer implantationGM and VCM exhibit pronounced antimicrobial activity against multiresistant microorganisms, with effective concentrations achieved in joint fluids after the implantation of antibiotic-loaded spacersThere were no signs of nephrotoxicity or local cytotoxic effects recordedN/ABorick et al.Ref [81]Tobramycin-impregnated PMMA beads and cementIn vivo clinical trialsmale patient with right total knee arthroplasty complicated by prosthetic joint infection/Clinical evidence (Case Report)High quality (CARE/JBI compliant case report). Provides critical evidence of ‘local toxicity’ risks. Demonstrates that while local carriers aim for regional efficacy, the systemic absorption of tobramycin from beads and cement can necessitate emergency explantation to avoid permanent haemodialysis in vulnerable patientsN/ABeads containing tobramycin sustained the highest concentrations throughout their 28-day study, and tobramycin elution can continue at highly therapeutic levels for more than 90 daysNo significant reduction in the rate of infections compared to plain bone cementN/AN/Avan Jiperen et al.Ref [82]-Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate)In vivo clinical trialsconducted on 31 human patients/RCTHigh quality (low risk of bias via RoB 2). Rigorous clinical RCT demonstrating that cement mantle thickness (reservoir volume) does not significantly alter peak local or systemic Gentamicin concentrations. This suggests that surface area and elution kinetics are more influential than total cement volume, providing high-certainty evidence for optimizing spacer and implant designThe composition of Hi-Fatigue Gentamicin Bone Cement includes various components that influence the cement matrix's properties, including its mechanical strength and antibiotic release characteristics.Biphasic elution characteristics, with a high initial burst of local gentamicin concentrations above the MIC followed by a rapid declineEffective against common pathogens found in total hip arthroplasty infections, such as Staphylococci, Enterococci, and Pseudomonas, and it achieves local concentrations above the MIC shortly after surgerySerum gentamicin concentrations never exceeded toxic levels, indicating that local and systemic cytotoxicity, as well as nephrotoxicity, were not observed in the patients involved in the trialN/AMa et al.Ref [115]PMMA spacers from two-stage revision total knee arthroplasty for PJITitanium rods for bacterial incubation and biofilm formationIn vivo clinical trialspatients undergoing two-stage revision total knee arthroplasty for periprosthetic joint infection/Preclinical to Clinical Transition (Observational Cohort)Moderate quality (ROBINS-I).The clinical strength of this study lies in its objective microbiological quantification of bacterial persistence on antibiotic-loaded spacer. While the retrospective observational design introduces inherent limitations regarding potential confounding variables—such as variations in host immune response or initial antibiotic treatment—the clarity of the sampling protocol and the consistency of the findings provide high-quality evidence that persistent biofilm formation remains a significant challengeN/AN/ABiofilm cells exhibit high tolerance to antibiotics. This tolerance is attributed to the presence of bacterial persisters and the protective nature of biofilmsN/AN/AAmmon and StockleyRef [83]Allograft bone obtained from the tissue bank, antibiotic-loaded cement, and systemic antibiotics for prophylactic dosesIn vivo clinical trials57 patients who underwent a two-stage revision for infected hip replacements/Clinical Study (Prospective Longitudinal Cohort)High quality (ROBINS-I). Critical study demonstrating the dual-utility of antibiotic-impregnated allograft. Found an 86% success rate in eradicating infection while simultaneously addressing severe bone lossThe amount of antibiotic added to the cement at the second stage was less than that at the first stage due to concerns about mechanical strength (0.5g of GM and 1g of VCM being added when required)N/AThe use of antibiotic-loaded cement in the two-stage revision procedure is more effective in eliminating infection compared to systemic therapy, (systemic antibiotics may be considered for organisms sensitive only to VCM)N/AN/AMultimer et al.Ref [103]-PMMA cement-GMIn vivo human case:12 patients who underwent a two-stage revision for infected knee arthroplasty/Clinical Study (Prospective Case Series)High quality (moderate risk of bias) (ROBINS-I). Clinical in vivo study quantifying the ‘rapid decay’ of Gentamicin elution from articulating spacers. While initial titers exceeded the MIC for most pathogens, concentrations dropped significantly by 48 hN/AGM levels in synovial fluid remained therapeutic (median 0.46 μg/mL) (standard clinical tests of blood and synovial fluid) at a median of 99 days post-implantation, suggesting a prolonged elution profileGM levels in synovial fluid at the second stage revision were within therapeutic ranges, indicating effective antibiotic activity against susceptible pathogens during the period of implantationLow serum gentamicin levels, <0.24 μg/mL (standard clinical tests of blood and synovial fluid) indicate a low risk of systemic nephrotoxicityN/ACurtis et al.Ref [123]Palacos cement, utilized for both the tobramycin-impregnated beads and the block spacerIn vivo clinical trialsa human case involving an 85-year-old man/Clinical Study (Prospective Case Series)High quality (Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports). This study provides high-quality clinical evidence regarding the risk of systemic nephrotoxicity secondary to the local elution of Tobramycin from antibiotic-loaded bone cementRelease of antibiotics from bone cement occurs in a biphasic manner, with a peak release within the first 24 h followed by a low, continuous release that can last for months to yearsTobramycin-impregnated bone cement allows for local concentrations of antibiotics to exceed the MIC breakpoint of susceptible organismsN/AAminoglycoside-induced nephrotoxicity is especially problematic in patients with underlying renal insufficiency.An 85-year-old man who experienced acute renal failure after its useN/AHsu et al.Ref [104]-vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam,-bone cement-In vivo human case: patients diagnosed with knee periprosthetic joint infection.-In vitro comparative study/Clinical Study (Retrospective Cohort)High quality (moderate risk of bias) (ROBINS-I) By utilizing a synergistic combination of vancomycin and ceftazidime in knee spacers, the researchers achieved a 95.5% infection eradication rateThe efficiency of antibiotic release from bone cement is influenced by the penetration of dissolution fluids into the polymer matrix and the subsequent diffusion of the dissolved drugVancomycin and ceftazidime showed sustained release for up to 60 days, while other antibiotics like aztreonam and imipenem had shorter release durationsBroad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria, including strains such as MSSA, MRSA, S. epidermidis, P. aeruginosa, and E. coli, both in vitro and in vivo.Despite the high concentrations of antibiotics achieved at the site of infection, no toxic systemic effects were observed in any patientN/AHsieh et al.Ref [105]PMMA spacers loaded with a high dose of vancomycin and aztreonamIn vivo clinical trials46 patients who underwent two-stage revision hip arthroplasty for infections/Clinical Study (Prospective Longitudinal Cohort)High quality (moderate risk of bias) (ROBINS-I). This prospective study of 46 hip PJI cases demonstrated that a high-dose vancomycin-aztreonam combination remains bioactive and maintains local concentrations well above the MIC for over 100 days in vivoN/AThe study found that very high levels of vancomycin (1,538,000 μg/mL) and aztreonam (1,003,500 μg/mL) (standard and modified HPLC) were detected in joint fluid on the first day after implantation, with concentrations decreasing significantly over the following days, indicating a rapid initial release followed by a gradual decline, while maintaining therapeutic levels for several monthsThe released antibiotics, vancomycin and aztreonam, were bioactive against the test organisms, demonstrating their effectiveness in controlling infection at the site of the PMMA spacer implantationNo evidence of local or systemic cytotoxicity, nephrotoxicity, or other systemic adverse effects from the use of antibiotics in the PMMA spacers, as indicated by normal serum creatinine and alanine transaminase levels throughout the monitoring periodN/AGriffin et al.Ref [116]-Antibiotic-impregnated PMMA spacerIn vivo clinical trialsHuman patients who underwent two-stage revision arthroplasty for periprosthetic joint infection/Prospective Observational Cohort StudyHigh quality (moderate risk of bias) (ROBINS-I). While the study provides valuable clinical evidence suggesting that biofilm formation may be less prevalent than anticipated on retrieved spacers, the appraisal is tempered by the limited sample size and the challenges inherent in sampling complex spacer geometries for scanning electron microscopyThe admixing of these drugs may influence the elution characteristics.The initial burst release occurs at a high rate and concentrationN/AN/AN/AUeng et al.Ref [84]-PMMA bone cement-Oxacillin-Vancomycin-CefazolinIn vivo human case:30 patients undergoing primary cemented Total-Knee Arthroplasty (TKA)/Clinical trial (RCT)High quality (low risk of bias via RoB 2). A definitive clinical RCT measuring the bioactivity of joint fluid. Demonstrated that while ALBC significantly increases the local antibacterial inhibitory titer compared to plain cement, this activity is short-lived, with a 50% decrease in potency within the first 24 hN/ASustained release for up to 48 h, with oxacillin exhibiting significantly better release efficacy than vancomycin during the sample collection periodAntibacterial activity against MSSA for at least 24 h, longer durations for oxacillin and vancomycin groups. Antibacterial activity against MRSA was only present in the vancomycin groupN/AN/AOe et al.Ref [77]-VCM as an Antibiotic-Loaded Acrylic Cement (ALAC) to prevent infection after Total Hip Arthroplasty (THA) or to treat patients with MRSAIn vivo clinical trials patients underwent THA/Clinical Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). The systemic safety profile of localized high-dose therapy is investigatedThe addition of VCM by means of manually mixing ALAC to antibiotic-loaded acrylic cement affects the mechanical strength and elution characteristics, compared to commercially mixed ALACHigh local concentration when used in ALACN/AIncreased serum creatinine, which indicates nephrotoxicity, was not observed in any patients. Transient arrhythmias post-spacer were noticed in some patientsN/AKlinder et al.Ref [10]Gentamicin, vancomycin, polymethylmethacrylate (PMMA) cement, and antibiotic-impregnated spacersIn vivo human case: patients undergoing two-stage revision. In vitro comparison study/Clinical Study (Prospective Observational Cohort)High quality (moderate risk of bias via ROBINS-I). The fundamental inefficiency of current PMMA carriers is quantified by this clinical analysis. Their study of explanted spacers revealed that over 90% of the antimicrobial payload remains sequestered within the cement matrix at the time of reimplantation, never reaching the site of infectionThe addition of calcium polyphosphate or mesoporous silica nanoparticles, which increase porosity or surface roughness, resulted in improved release kinetics of antibiotics from the cement matrixIn vivo conditions, antibiotics are present at in vitro similar concentrations after an average of 90 days, particularly in the spacer-adjacent soft tissueN/AN/AN/ASudo et al.Ref [66]Antibiotic-impregnated CHA ceramic blocksIn vivo clinical trials Seven patients' treatment for infected hip arthroplasty/Clinical Study (Prospective Case Series)High quality (moderate risk of bias via ROBINS-I). The potential for bioactive ceramics to surpass the limitations of PMMA is demonstrated. By utilizing antibiotic-impregnated calcium hydroxyapatite (CHA) in a two-stage hip revision, the researchers achieved a 100% infection eradication rate. This study provides clinical evidence that osteoconductive materials can serve as highly efficient antibiotic reservoirsN/ASustained release of antibiotics over a long period, with studies showing that gentamicin sulphate in CHA blocks remained effective at 12 weeks, releasing 70% of the antibiotic (5x staphylococci MIC)Effective bacteria eradicationN/AN/AKendoff et al.Ref [65]Gentamicin and vancomycin,-ALBC used in the studyIn vivo clinical trialsHuman patients undergoing one-stage total hip arthroplasty revision/Clinical Study (Prospective Open-Label Trial)High quality (moderate risk of bias via ROBINS-I). By achieving high local titers without reaching systemic toxic thresholds, this study demonstrates that ‘industrial’ level drug loading is both clinically viable and effective. This provides a clear pharmacological foundation for the advanced, controlled-release technologiesThe combination of gentamicin and vancomycin enhances the elution propertiesThe combination of gentamicin and vancomycin reveals a synergism in terms of improved release kinetics when applied in combination, which enhances the anti-infective properties of the bone cementThe combination of gentamicin and vancomycin in antibiotic-loaded bone cement provides sufficient antibiotic protection against common orthopaedic pathogensThe study found no serious adverse events related to the investigated bone cement, and no renal or hepatic events were observedN/AWebb et al.Ref [64]-Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK)-Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany)-In vivo clinical trials-in vivo assessing urinary gentamicin levels in 35 patients who underwent primary total hip arthroplasty/Clinical Pharmacokinetic Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). By measuring in vivo interstitial concentrations, the researchers demonstrated that while PMMA provides high immediate local levels, the diffusion into surrounding tissues is limited and rapidly declines. This spatial and temporal “inefficiency” reinforces the clinical argument for the next-generation carriersN/ABiphasic release pattern, with an initial high release phase followed by a prolonged low-level release, with detectable urinary gentamicin for an average of 43 days and up to 71 days in some cases after primary total hip arthroplastyN/ANephrotoxicity and ototoxicity have not been demonstrated for the incorporated gentamicin into bone cementN/ARegis et al.Ref [63]-PMMA cement-GM, VCMIn vivo clinical trialsHuman patients undergoing two-stage revision of infected total hip arthroplasty/Clinical Study (Prospective Multicenter Cohort)High quality (moderate risk of bias via ROBINS-I). Even when utilizing standardized, preformed commercial spacers, the local antibacterial inhibitory activity was found to decay rapidly within the first 72 h. This high-certainty clinical data reinforces the ‘inefficiency’ argument by showing that therapeutic potency is transientThe addition of VCM to PMMA cement, through manual mixing, allows for high local concentrations of the antibiotic at the implant siteHigh local concentrations were observed in the first few hours after spacer implantation, while serum levels remained below the limit of detection, indicating favorable local release kineticsStrong antimicrobial activity against multiresistant strains, with high drainage fluid bactericidal titers maintained for almost 24 h post-implantationNo signs of nephrotoxicity or local cytotoxic effects were observed in patients after the local and systemic administration of gentamicin and vancomycin, with low systemic exposureN/AMcKenna et al.Ref [62]Cement spacer Palacos R cement-vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively).-Uncemented revision stem (Solution System(r), DePuy Orthopaedics)In vivo clinical trials30 consecutive patients with infected total hip arthroplasties, indicating it is an in vivo human case study/Clinical Study (Prospective Longitudinal Cohort)High quality (moderate risk of bias via ROBINS-I). The potential to improve treatment efficiency by reducing systemic antibiotic burden is clinically demonstrated. A shortened 2-week course of systemic antibiotics—when coupled with high-dose local delivery—yields success rates (87.1%) comparable to traditional 6-to-12 week regimensN/AThe elution achieves higher local tissue concentrations compared to parenteral administration, maintaining effective peri-prosthetic antibiotic levels for up to 4 monthsHigher local tissue concentrations of antibiotics are achieved through elution from ALBC compared to parenteral administration, maintaining effective peri-prosthetic antibiotic levels for up to 4 monthsN/AN/AWhittaker et al.Ref [60]-Palacos R cement-Vancomycin and gentamicin-In vivo clinical trials 43 consecutive patients (44 hips) underwent a two-stage revision procedure/Clinical Study (Prospective Longitudinal Cohort)High quality (moderate risk of bias via ROBINS-I). Their five-year longitudinal analysis demonstrated a 93.5% success rate in treating Gram-positive PJI using high-dose spacers without the need for prolonged systemic antibiotic therapy. This evidence significantly refutes the ‘inefficiency’ argument by showing that local carriers can serve as the primary curative modalityThe addition of 2.0 g of vancomycin and 0.25 g of gentamicin enhances the local delivery of antibiotics while maintaining the structural integrity of the cement matrixN/AVancomycin is effective against all Gram-positive organisms without acquired resistance, particularly against gentamicin-resistant staphylococci.N/AN/AAnagnostakos et al.Ref [59]-Refobacin Palacos and Vanco-cell beads and spacers.-gentamicin-In vivo clinical trials28 human patients undergoing two-stage exchange for infected THA/Clinical Pharmacokinetic Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). The impact of delivery geometry on therapeutic efficacy is evidenced. The in vivo comparison demonstrated that higher surface-area-to-volume ratios (as seen in beads) result in significantly higher local antibiotic titers compared to bulkier spacers. However, both systems exhibited a rapid decline in elution by the end of the first weekManual incorporation of vancomycin into the cement powder influences antibiotic elutionGentamicin and vancomycin released from antibiotic-loaded beads exhibited higher elution characteristics compared to spacers, with peak concentrations reached on day 1, followed by a consistent decay in elution rates over the subsequent daysBoth gentamicin and vancomycin, achieve local concentrations that significantly exceed the minimum inhibitory or bactericidal concentrationsNo renal or hepatic dysfunction was observed in any of the cases studied, indicating no significant nephrotoxicityN/AHsieh et al.Ref. [61]-Liquid gentamicin and vancomycin-bone cement spacersIn vivo human case:42 patients undergoing two-stage revision hip arthroplasty for periprosthetic infection/Prospective Cohort StudyHigh quality (low risk via ROBINS-I – bias) This study provides high-quality longitudinal data on the elution kinetics and systemic safety profile of high-dose Gentamicin-loaded spacers. Its strength lies in the robust monitoring of systemic toxicity, providing a clear clinical rationale for the safety limits observed in two-stage hip revisionThe addition of liquid gentamicin reduces the compressive strength of bone cement by 49% and tensile strength by 46%, indicating that while they enhance antibiotic elution, they compromise the mechanical properties of the cementPrompt release of liquid gentamicin and vancomycin, with joint fluid antibiotic levels remaining well above therapeutic requirements for at least 3 months despite rapid declines during the first few days after implantationBoth gentamicin and vancomycin maintained their bactericidal activities after being eluted from the bone cement spacersNo evidence of nephrotoxicity in patients, as systemic antibiotic concentrations were below detectable levels in the majority, and no patient exhibited renal insufficiency or other systemic adverse effects related to the antibiotics usedN/AJanssen et al.Ref [76]Gentamicin-impregnated StageOne,Select Refobacin Bone Cement R spacers,Refobacin Bone Cement RIn vivo human case studies, (wound drainage fluid samples were collected from patients after implantation of spacers) -in vitro studies were conducted on phosphate-buffered saline/Clinical Pharmacokinetic Study (Prospective Cohort)High quality (moderate risk of bias via ROBINS-I). By utilizing ELISA to compare in vitro elution to actual human drain fluid, the researchers revealed that clinical antibiotic concentrations are significantly lower than laboratory models predict. This discrepancy highlights the physiological barriers to elution in the human joint space and reinforces the critical need for advanced, nano-engineered delivery systemsThe standard mixing method used could have led to variability in PMMA cement porosity and pharmacokinetic release profilesPMMA beads had a significantly higher and prolonged release of gentamicin compared to spacers. The burst release from beads was more than 10 times higher than that from spacers, with beads reaching a plateau phase much later. The release from PMMA beads is divided into two phases: an initial burst release, followed by a sustained release over several days to weeksN/AN/AN/A Synthetic list of the most relevant aspects of arthroplasty implants in reviewed literature: 1 -Materials used for the implant (or specific spacer, blocks cement commercial model); 2 - Type of study: in vitro, in vivo animal model, in vivo human case; 3 – Quality assessment/Risk of bias; 4 -Effects on cement matrix by additional components, treatments and admixing of drugs; 5 - Drug release, kinetic and elution characteristics; 6 - Antibiotic activity; 7 - Local and systemic cytotoxicity, nephrotoxicity; 8 - Biodegradability – Osseointegration – Bone volume analysis. Unavailable aspects for specific reference are indicated with N/A. -Vancogenx-space knee, Vancogenx-space knee, -gentamicin sulphate, vancomycin hydrochloride, barium sulphate, benzoyl peroxide, N, N-dimethyl-para-toluidine, and traces of hydroquinone gentamicin sulphate, vancomycin hydrochloride, barium sulphate, benzoyl peroxide, N, N-dimethyl-para-toluidine, and traces of hydroquinone -Palacos R cement, -antibiotic powders such as gentamicin, vancomycin, teicoplanin, and Synercid Palacos R cement, -antibiotic powders such as gentamicin, vancomycin, teicoplanin, and Synercid -Palacos R bone cement Palacos R bone cement -Liquid gentamicin and powdered tobramycin Liquid gentamicin and powdered tobramycin -Low viscosity Cemex O XL and Cemex O Genta LV Low viscosity Cemex O XL and Cemex O Genta LV -Medium-viscosity Endurance TM and Endurance Gentamicin Medium-viscosity Endurance TM and Endurance Gentamicin -High-viscosity SmartSet TM HV and SmartSet O GHV High-viscosity SmartSet TM HV and SmartSet O GHV -PMMA beads were used for the experiment. PMMA beads were used for the experiment. -gentamicin, silver, and a combination of gentamicin and silver gentamicin, silver, and a combination of gentamicin and silver -silver-impregnated PMMA showed no effect on MRSP biofilm formation silver-impregnated PMMA showed no effect on MRSP biofilm formation -Polymerized cement (Cemex XL; Tecres SpA, Sommacampagna, Italy) Polymerized cement (Cemex XL; Tecres SpA, Sommacampagna, Italy) -PMMA copolymer powder PMMA copolymer powder -tobramycin, vancomycin, teicoplanin, clindamycin, and colistin tobramycin, vancomycin, teicoplanin, clindamycin, and colistin -NanoSilver, polymethylmetacrylate bone cement, NanoSilver, polymethylmetacrylate bone cement, -gentamicin-loaded bone cement, gentamicin-loaded bone cement, -plain PMMA bone cement plain PMMA bone cement -Linezolid, vancomycin hydrochloride, and gentamicin Linezolid, vancomycin hydrochloride, and gentamicin -commercial PMMA cements: Smart Set GHV and CMW 1. commercial PMMA cements: Smart Set GHV and CMW 1. -PNDJ hydrogel PNDJ hydrogel -PMMA PMMA -Antibiotic-loaded hydrogel containing gentamicin and vancomycin Antibiotic-loaded hydrogel containing gentamicin and vancomycin -In vivo animal model: Swiss Alpine sheep/Preclinical In vivo animal model: Swiss Alpine sheep/Preclinical -In vitro comparative test In vitro comparative test -smart nanofiber coating (PLGA/PEG) to deliver combinatorial antibiotics (vancomycin and rifampin) smart nanofiber coating (PLGA/PEG) to deliver combinatorial antibiotics (vancomycin and rifampin) -PMMA cement, PMMA cement, -a Kirschner wire, a Kirschner wire, -Serratiopeptidase enzyme injections Serratiopeptidase enzyme injections -Computerized Numerical Control machined-surgical steel pin with a slotted end. Computerized Numerical Control machined-surgical steel pin with a slotted end. -The biofilm generation media consisted of Difco Tryptic Soy Broth (TSB) at different concentrations for attachment, accumulation, and maturation of biofilms The biofilm generation media consisted of Difco Tryptic Soy Broth (TSB) at different concentrations for attachment, accumulation, and maturation of biofilms -Fusidic acid (FA) Fusidic acid (FA) -Rifampicin (RIF) Rifampicin (RIF) -Sodium fusidate (SF) Sodium fusidate (SF) -Poly(D,L-lactic acid-co-glycolic acid) (PLGA) Poly(D,L-lactic acid-co-glycolic acid) (PLGA) -Tetrahydrofuran (THF) Tetrahydrofuran (THF) -Dimethylformamide (DMF) Dimethylformamide (DMF) -Acetonitrile (ACN) Acetonitrile (ACN) -Methanol (MeOH) Methanol (MeOH) -Phosphoric acid Phosphoric acid -In vitro evaluations using Human Umbilical Vein Endothelial cells (HUVEC) In vitro evaluations using Human Umbilical Vein Endothelial cells (HUVEC) -In vivo animal model female Sprague-Dawley rats/Preclinical In vivo animal model female Sprague-Dawley rats/Preclinical -Cross-linked hyaluronic acid (HA) gel Cross-linked hyaluronic acid (HA) gel -GM GM -in vitro study in vitro study -in vivo animal model: in vivo animal model: -Continuous wave ultrasound CMW ENDURANCE bone cement, Continuous wave ultrasound CMW ENDURANCE bone cement, -vancomycin, vancomycin, -powdered PMMA, powdered PMMA, -liquid monomer liquid monomer -In vivo animal model: 16 New Zealand White female rabbits In vivo animal model: 16 New Zealand White female rabbits -The in vitro comparative study/Preclinical The in vitro comparative study/Preclinical -PLGA PLGA -PEG PEG -PCL (polycaprolactone) PCL (polycaprolactone) -Vancomycin Hydrochloride (V-HCl) Vancomycin Hydrochloride (V-HCl) -N-Methyl-2-Pyrrolidone (NMP) N-Methyl-2-Pyrrolidone (NMP) -Calcium chloride (CaCl2) Calcium chloride (CaCl2) -PRO OSTEON 500R PRO OSTEON 500R -MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) -TRIzol reagent TRIzol reagent -SuperScript(tm) VILO(tm) cDNA Synthesis Kit SuperScript(tm) VILO(tm) cDNA Synthesis Kit -In vitro study (MG63 osteoblast cells). In vitro study (MG63 osteoblast cells). -In vivo animal model 13 rats implanted with the antibiotic-releasing bone void filling (ABVF) putty and 12 rats in a control group In vivo animal model 13 rats implanted with the antibiotic-releasing bone void filling (ABVF) putty and 12 rats in a control group -CPC (Biopex-R Advance) CPC (Biopex-R Advance) -PMMA cement (Surgical Simplex P Bone Cement) PMMA cement (Surgical Simplex P Bone Cement) -Injectable vancomycin hydrochloride Injectable vancomycin hydrochloride -In vivo animal models: athymic nude rats In vivo animal models: athymic nude rats -Titanium alloy (Ti6Al4V) bolts were used for the experiment. Titanium alloy (Ti6Al4V) bolts were used for the experiment. -Copper ions were included in the titanium surface for the coating process Copper ions were included in the titanium surface for the coating process -In vivo animal model: In vivo animal model: -CPC (Biopex-R Advance) CPC (Biopex-R Advance) -PMMA (Surgical Simplex P Bone Cement), PMMA (Surgical Simplex P Bone Cement), -Injectable VCM hydrochloride Injectable VCM hydrochloride -Wistar rats/Preclinical Wistar rats/Preclinical -PMMA bone cement, PMMA bone cement, -VCM, VCM, -treated with US + MB treated with US + MB -In vivo animal model: In vivo animal model: -PMMA cement PMMA cement -Gentamicin and chlorhexidine Gentamicin and chlorhexidine -Silica nanoparticles Silica nanoparticles -In vivo animal model: modified femoral bone lesion in rats In vivo animal model: modified femoral bone lesion in rats -In vitro: SaoS-2 cells In vitro: SaoS-2 cells -A total of 32 patients A total of 32 patients -controlled trial conducted on human patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection./RCT controlled trial conducted on human patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection./RCT -PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement. PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement. −3 g of vancomycin and 2.4 g of tobramycin. 3 g of vancomycin and 2.4 g of tobramycin. -Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amount Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amount -Gentamicin, vancomycin Gentamicin, vancomycin -Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate) Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate) -PMMA cement PMMA cement -GM GM -vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam, vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam, -bone cement bone cement -In vivo human case: patients diagnosed with knee periprosthetic joint infection. In vivo human case: patients diagnosed with knee periprosthetic joint infection. -In vitro comparative study/Clinical Study (Retrospective Cohort) In vitro comparative study/Clinical Study (Retrospective Cohort) -Antibiotic-impregnated PMMA spacer Antibiotic-impregnated PMMA spacer -PMMA bone cement PMMA bone cement -Oxacillin Oxacillin -Vancomycin Vancomycin -Cefazolin Cefazolin -VCM as an Antibiotic-Loaded Acrylic Cement (ALAC) to prevent infection after Total Hip Arthroplasty (THA) or to treat patients with MRSA VCM as an Antibiotic-Loaded Acrylic Cement (ALAC) to prevent infection after Total Hip Arthroplasty (THA) or to treat patients with MRSA Gentamicin and vancomycin, Gentamicin and vancomycin, -ALBC used in the study ALBC used in the study -Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK) Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK) -Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany) Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany) -In vivo clinical trials In vivo clinical trials -in vivo assessing urinary gentamicin levels in 35 patients who underwent primary total hip arthroplasty/Clinical Pharmacokinetic Study (Prospective Cohort) in vivo assessing urinary gentamicin levels in 35 patients who underwent primary total hip arthroplasty/Clinical Pharmacokinetic Study (Prospective Cohort) -PMMA cement PMMA cement -GM, VCM GM, VCM -vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively). vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively). -Uncemented revision stem (Solution System(r), DePuy Orthopaedics) Uncemented revision stem (Solution System(r), DePuy Orthopaedics) -Palacos R cement Palacos R cement -Vancomycin and gentamicin Vancomycin and gentamicin -In vivo clinical trials 43 consecutive patients (44 hips) underwent a two-stage revision procedure/Clinical Study (Prospective Longitudinal Cohort) In vivo clinical trials 43 consecutive patients (44 hips) underwent a two-stage revision procedure/Clinical Study (Prospective Longitudinal Cohort) -Refobacin Palacos and Vanco-cell beads and spacers. Refobacin Palacos and Vanco-cell beads and spacers. -gentamicin gentamicin -In vivo clinical trials28 human patients undergoing two-stage exchange for infected THA/Clinical Pharmacokinetic Study (Prospective Cohort) In vivo clinical trials28 human patients undergoing two-stage exchange for infected THA/Clinical Pharmacokinetic Study (Prospective Cohort) -Liquid gentamicin and vancomycin Liquid gentamicin and vancomycin -bone cement spacers bone cement spacers -in vitro studies were conducted on phosphate-buffered saline/Clinical Pharmacokinetic Study (Prospective Cohort) in vitro studies were conducted on phosphate-buffered saline/Clinical Pharmacokinetic Study (Prospective Cohort) Table 2Synthetic list of the most relevant aspects of: Study design/sample size/follow-up/level tag related to arthroplasty clinical cases within the reviewed literature.Table 2ReferenceMaterials used for the implant (or specific spacer/blocks/cement model)Study design/sample size/follow-up/level tagHeffernan et al.Ref [51]-Poly (N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M − 1000 acrylamide) (PNDJ) hydrogel•The study design involved in vivo evaluations using animal models, specifically rabbits and canines, to assess the safety and efficacy of the temperature-responsive hydrogel PNDJ for preventing SSIs.•The sample size included multiple animal subjects, although specific numbers are not detailed in the provided contexts.•The follow-up period for assessing outcomes varied, with some evaluations indicating a return to normal values within 14 to 56 days post-treatment.•The evidence level of the study is categorized as animal studies, as it primarily involved testing in rabbits and canines.Foster et al.Ref [52]-PMMA-Antibiotic-loaded hydrogel containing GM and VCM•The study included 13 skeletally mature Swiss Alpine sheep to evaluate a single-stage revision model for Orthopedic Device-Related Infection (ODRI), adapted from a previously described two-stage revision model.•All animals underwent preoperative clinical assessment, including physical examination, blood tests, and radiographic imaging, prior to study inclusion.•Sheep were acclimatized for at least 2 weeks under controlled housing conditions (12 h light/dark cycle) before surgery.•Post-operative follow-up involved daily veterinary monitoring of behavior, limb function, temperature, appetite, and overall health, using a cumulative clinical scoring system to determine humane endpoints (euthanasia if score >7 for 3 days).•Evidence level: Preclinical animal study (controlled in vivo large-animal model).Niska et al.Ref [126]Vancomycin and rifampin•The study utilized a preclinical mouse model to evaluate the efficacy of vancomycin single-agent therapy compared to combination therapy with vancomycin and rifampin against Staphylococcus aureus prosthetic joint infection.•The sample size for the experiments was at least 8 mice per group.•The study involved a follow-up period of 6 weeks, with assessments conducted on postoperative days 0, 3, 7, 14, 21, 28, 35, 42, and 49.•The evidence level of the study is classified as animal research.Irwin et al.Ref [55]-Computerized Numerical Control machined-surgical steel pin with a slotted end.-The biofilm generation media consisted of Difco TSB at different concentrations for attachment, accumulation, and maturation of biofilms•The study design involved a rat model of PJI using biofilm inocula in male Sprague-Dawley rats.•The sample size and follow-up details are not explicitly provided in the context.•The study can be classified as an animal study, specifically using a cohort design, as it involved multiple groups of rats receiving different treatments.Gilchrist et al.Ref [58]-Fusidic acid-Rifampicin-Sodium fusidate-Poly(D,L-lactic acid-co-glycolic acid-Tetrahydrofuran-Dimethylformamide-Acetonitrile-Methanol-Phosphoric acid•The study was conducted in vivo using 13 female Sprague-Dawley rats (195–225 g) to evaluate the antibacterial efficacy of antibiotic-loaded nanofibers in preventing MRSA colonization on titanium implants.•Each rat received two subcutaneous implants—one titanium disk with antibiotic-loaded nanofibers (test) and one with blank PLGA nanofibers (control)—implanted in separate dorsal pockets.•Immediately after implantation, ∼108 CFU of MRSA (Newman strain) was inoculated onto the titanium surface to induce localized infection.•Animals were monitored for 7 days post-implantation before being sacrificed for microbiological (CFU count) and histopathological evaluation of implant sites.•Evidence level: Preclinical animal study (controlled experimental design, in vivo rat model).Matsuno et al.Ref [53]-Cross-linked Hyaluronic Acid (HAc) gel-gentamicin•The study design involved both in vitro and animal models to evaluate the antibacterial activity of the GM-containing HAc gel.•The sample size included a total of 45 mice for the durability study of the antibacterial activity, with five mice examined at each time point (0, 1, 2, 7, and 14 days).•In the rabbit osteomyelitis model, five rabbits were used in each of the four experimental groups, totalling 20 rabbits.•The study can be classified as an animal study, specifically using mouse and rabbit models to assess the effectiveness of the antibacterial carrier.Yan et al.Ref [47]-Continuous wave ultrasound CMW ENDURANCE bone cement,-vancomycin,-powdered PMMA,-liquid monomer•The study involved a sample size of sixteen New Zealand White female rabbits.•The rabbits were divided into two groups: one group received CWU treatment, while the control group did not.•The follow-up period lasted for 30 days after the implantation of ALBC.•The study design can be classified as an animal study.Hasan et al.Ref [48]-PLGA-PEG (-PCL-Vancomycin hydrochloride (V-HCl)-N-Methyl-2-pyrrolidone (NMP)-CaCl2 (calcium chloride)-PRO OSTEON 500R3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid (MTT)-TRIzol reagent-SuperScript VILO cDNA Synthesis Kit•The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens.•A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin•The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis.•The study design can be classified as an animal study with a cohort design, as it involved multiple time points for follow-up and comparison between two different materials.Mukai et al.Ref [44]-CPC (Biopex-R Advance)-PMMA cement (Surgical Simplex P Bone Cement)-Injectable vancomycin hydrochloride•The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens.•A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin.•The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis.•The study design can be classified as an animal study with a cohort design.Lewis et al.Ref [39]DBM and gentamicin.•The study design involved in vitro and in vivo assays to evaluate the effects of gentamicin loading on the osteoinductive properties of human demineralized bone matrix.•The in vivo component utilized an ectopic pouch model in athymic nude rats to analyse the osteoinductivity of DBM samples.•The sample size for the in vivo study involved six samples implanted per animal, with animals being euthanized 28 days post-implantation.•The evidence level for the study includes both in vitro and animal studies.Uchida et al.Ref [42]-CPC (Biopex-R Advance)-PMMA (Surgical Simplex P Bone Cement),-Injectable VCM hydrochloride.•The study design involved both in vitro and in vivo experiments to evaluate the release profile of vancomycin from calcium phosphate cement and polymethylmethacrylate cement.•For in vivo experiments, test specimens were implanted between the fascia and muscle of rats, and residual vancomycin was extracted from the removed specimens to determine the amount released into rat tissues.•The sample size for the in vivo study is not explicitly mentioned in the provided contexts.•The evidence level includes in vitro studies and animal studies (rat model).Lin et al.Ref [35]-PMMA) bone cement,-VAN,-treated with microbubbles and ultrasound•The study involved both in vitro and in vivo evaluations, indicating a mixed study design.•The sample size for the in vivo study consisted of 32 rabbits, with 64 tibiae divided into four groups for treatment.•The evidence level for the in vitro part is classified as in vitro, while the in vivo part is classified as animal study.Yang et al.Ref [43]-PMMA cement-Gentamicin and chlorhexidine-Silica nanoparticles were•The study involved the development of a nanocomposite bone cement and its evaluation in an in vivo model of an infected bone defect, indicating an animal study design.•The sample size for the in vivo experiments is not explicitly mentioned in the provided contexts (Winstar rats).•Follow-up was performed after 14 and 28 days by CT of Winstar rat femur bone•The evidence level of the study is categorized as an animal research due to the use of an infected bone lesion model for testing.Xu et al.Ref [106]Vancomycin, meropenem, methyl-methacrylate cement polymer, gentamicin, clindamycin, tobramycin, aztreonam, ampicillin, ceftazidime, linezolid, and ceftriaxone•The study design is a prospective, randomized, controlled trial.•The sample size consisted of 32 patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection.•The follow-up period involved collecting drainage samples every 24 h for the first five days following spacer implantation.•The evidence level is classified as clinical, specifically a randomized controlled trial.Edelstein et al.Ref [107]-PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement.−3 g of vancomycin and 2.4 g of tobramycin.-Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amount.•The study design is a prospective cohort study.•The sample size included a total of 37 patients, with 20 undergoing total knee arthroplasty and 17 undergoing total hip arthroplasty.•Follow-up was conducted over a period of 8 weeks, with serum creatinine and glomerular filtration rate data collected at baseline and weekly intervals.•The evidence level is classified as clinical, specifically a cohort study.Vrabec et al.Ref [79]Bone cement mixture: SimplexTM P with Tobramycin; Stryker Howmedica Osteonics containing 1 g of tobramycin with 40 g of bone cement.•The study design involved a clinical cohort study, evaluating patients undergoing primary TKA over a 6-month period.•The study enrolled 15 patients undergoing primary TKA by one of two surgeons (GV, JP) who met the inclusion criteria; Follow-up was conducted for one year, during which no complications or infections were reported.•The evidence level is classified as clinical, specifically a cohort study.Bertazzoni Minelli et al.Ref [80]-Gentamicin, vancomycin•The study involved a sample size of 12 patients (8 male and 4 female) undergoing two-stage revision surgery with antibiotic-loaded spacers.•The follow-up included the collection of serum and joint fluid samples at 1, 4, and 24 h after spacer implantation.•The study design is classified as a clinical case series.Van Jiperen et al.Ref [82]-Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate)•The study design is a randomized, non-blinded, comparative, and prospective clinical investigation.•The sample size consisted of 31 participants, with 16 allocated to the thin cement mantle group and 15 to the thick cement mantle group.•The evidence level is classified as a clinical randomized controlled trial.Ma et al.Ref [115]PMMA spacers from two-stage revision total knee arthroplasty for periprosthetic joint infection (PJI)Titanium rods for bacterial incubation and biofilm formation•The study design is a prospective, multicentre analytic cohort study of patients undergoing explant of antibiotic PMMA spacers for TKA PJI.•The study included patients who underwent a two-stage exchange for TKA PJI with an antibiotic cement spacer.•Inclusion criteria required that antibiotic spacers did not culture any organisms after removal and that there was no evidence of infection recurrence for at least 1 year following the two-stage exchange.•The sample size involved 13 antibiotic PMMA spacers collected for analysis.•The evidence level is classified as a clinical cohort study.Ammon and StockleyRef [83]Allograft bone obtained from the tissue bank, antibiotic-loaded cement, and systemic antibiotics for prophylactic doses•The study involved a sample size of 57 patients who underwent a two-stage revision for infection in hip replacements.•The follow-up period for these patients was a minimum of two years from the second stage, with a mean follow-up of 4.5 years.•The study design can be classified as a clinical case series.Mutimer et al.Ref [103]-PMMA cement-gentamicin•The study involved a clinical design, specifically a case series, as it assessed the levels of gentamicin in patients undergoing a two-stage revision total knee arthroplasty.•The sample size consisted of twelve patients who received a gentamicin-loaded articulating spacer.•Follow-up was conducted at the second stage of the procedure, which occurred at a median of 99 days following the spacer insertion.•The study aimed to measure the gentamicin levels in synovial fluid and blood samples collected during the second-stage revision.Hsu et al.Ref [104]-Vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam,-bone cement•The study design involved a clinical case series with a sample size of 8 patients (4 women and 4 men between 51 and 79 years of age) diagnosed with chronic knee periprosthetic joint infection.•The antibiotic concentrations in the joint fluid were measured daily for 7 days.•The evidence level is classified as clinical, specifically a case seriesHsieh et al.Ref [105]PMMA spacers loaded with a high dose of vancomycin and aztreonam•The study design involved a clinical case series with a sample size of 46 patients who underwent two-stage revision hip arthroplasty for infections.•The average follow-up period after the first-stage surgery was 107 days.•The study was conducted according to a prospective protocol, and all patients provided informed consent.•The evidence level of the study is classified as clinical.Griffin et al.Ref [116]-Antibiotic-impregnated PMMA spacer•The study design is a prospective case series.•The sample size consists of six patients from whom antibiotic-impregnated cement spacers were removed for analysis.•The follow-up involved the analysis of the spacers at the time of second-stage revision arthroplasty.•The evidence level is classified as clinical, specifically a case seriesUeng et al.Ref [84]-PMMA bone cement-Oxacillin-Vancomycin-Cefazolin•The study involved a sample size of 30 patients who were scheduled for primary cemented total-knee arthroplasty.•The follow-up period included the collection of joint fluid samples at 8, 16, 24, 32, 40, and 48 h after prosthesis implantation.•The study design is classified as a clinical cohort study, as it compares the antibacterial activities of joint fluids from patients receiving different types of bone cement (with or without antibiotic loading)Oe et al.Ref [77]Vancomycin as an antibiotic-loaded acrylic cement to prevent infection after THA or to treat patients with MRSA•The study design involved a clinical cohort study with a sample size of 27 hips treated with antibiotic-loaded acrylic cement including, vancomycin, at the institution.•Patients were classified into two groups: a low-dose group (21 hips) and a high-dose group (6 hips), based on the type of THA performed.•Follow-up assessments of serum concentrations of VCM and creatinine were conducted at multiple postoperative time points: days 1, 4, 7, 14, and 28, as well as at 3 and 6 months.•The evidence level of the study is classified as clinical, specifically a cohort study.Klinder et al.Ref [10]Gentamicin, vancomycin, polymethylmethacrylate (PMMA) cement, and antibiotic-impregnated spacers.•The study design included patients from two prospective, multicenter trials investigating cement spacer treatment of implant-associated infections after total hip and knee joint replacement.•The sample size consisted of 18 patients (10 hip and 8 knee patients) who were due for two-stage treatment after a periprosthetic joint infection.•The follow-up involved taking control samples, including joint fluid and a punch biopsy of the soft tissue around the spacer, after a 4-to-6-week systemic antibiotics therapy and an antibiotics-free interval of 2 weeks.•The evidence level is classified as clinical, as it involves a prospective clinical trial.Sudo et al.Ref [66]-Antibiotic-impregnated CHA ceramic blocks.•The study design is a retrospective case series involving seven consecutive patients.•The sample size consists of 7 patients, with an average age of 65 years.•The follow-up duration averaged 5.0 years, with a range of 2.3 to 6.1 years.•The evidence level is classified as clinical, specifically a case seriesKendoff et al.Ref [65]Gentamicin and vancomycin,-ALBC used in the study.•Prospective open-label clinical case series including 20 patients (7 women, 13 men; mean age 62.5 years) undergoing one-stage revision for infected hip prostheses with vancomycin-susceptible bacteria.•Patients received Copal® G + V PMMA bone cement containing gentamicin (0.5 g) and vancomycin (2.0 g) per 43 g powder; postoperative systemic antibiotics were continued for about 13 days.•Pharmacokinetic monitoring of gentamicin and vancomycin was performed via serial plasma, urine, and wound exudate samples up to 10 days post-surgery using LC-MS-MS.•Follow-up: daily assessments until day 10 and a final evaluation at 7 months to assess antibiotic release and infection outcomes.•Evidence level: Clinical study – Prospective case series (non-randomized, single-center)Webb et al.Ref [64]-Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK)-Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany)•The study design involved a clinical cohort study with a sample size of 35 patients who underwent primary total hip arthroplasty•Patients were followed up for a minimum of 12 weeks post-operatively, with urinary samples collected for analysis.•The study aimed to investigate the in vivo elution kinetics of gentamicin from bone cement.•The evidence level of the study is classified as clinicalRegis et al.Ref [63]PMMA cement -Gentamicin, vancomycin•The study involved a sample size of 7 patients who received preformed spacers for two-stage revision of a THA due to infection.•The follow-up included monthly clinical evaluations, laboratory tests, and radiographic examinations.•The study design is classified as a clinical case series.McKenna et al.Ref [62]Cement spacer Palacos R cement-vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively) advice.-Uncemented revision stem (Solution System(r), DePuy Orthopaedics)•The study design is a retrospective case series involving 30 consecutive patients with 31 infected total hip arthroplasties treated by a single surgeon over a 4-year period.•The sample size consists of 30 patients, with data recorded for 28 of them.•The mean follow-up duration for the patients was 35 months, with a minimum follow-up of 24 months.•The evidence level is classified as a clinical case series.Whittaker et al.Ref [60]-Palacos R cement-Vancomycin and gentamicin•The study involved a clinical design, specifically a case series, as it reported on the experience of multiple surgeons treating patients with chronic peri-prosthetic infection.•The sample size consisted of 43 consecutive patients (44 hips) who underwent the two-stage revision procedure.•The median follow-up period for the patients was 49 months, ranging from 25 to 83 months.Anagnostakos et al.Ref [59]-Refobacin Palacos and Vanco-cell beads and spacers.-gentamicin•The study involved a clinical design with a sample size of 28 patients, consisting of 17 hip spacers and 11 chains.•The follow-up period for the study included daily measurements of antibiotic elution from the drainage fluid for up to 13 days for beads and 7 days for spacers.•The evidence level of the study is classified as clinical, specifically a case series, as it evaluates the elution of antibiotics in patients undergoing two-stage exchange for infected total hip arthroplastyJanssen et al.Ref [76]Gentamicin-impregnated StageOne,Select Refobacin Bone Cement R spacers,Refobacin Bone Cement R•The study design involved both in vitro and in vivo experiments to assess the pharmacokinetic release profile of antibiotics from PMMA spacers and beads.•The in vitro component measured gentamicin concentrations from PMMA spacers and beads submerged in phosphate-buffered saline using ELISA.•The in vivo component collected wound drainage fluid samples from patients after implantation of a spacer over a maximum period of 14 days.•The sample size for the in vitro experiments included multiple time points for gentamicin concentration measurement, while the clinical samples were collected from patients with different types of spacers.•The evidence level for the in vitro part of the study is classified as in vitro, while the in vivo part is classified as clinical (case series). Synthetic list of the most relevant aspects of: Study design/sample size/follow-up/level tag related to arthroplasty clinical cases within the reviewed literature. -Poly (N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M − 1000 acrylamide) (PNDJ) hydrogel Poly (N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M − 1000 acrylamide) (PNDJ) hydrogel •The study design involved in vivo evaluations using animal models, specifically rabbits and canines, to assess the safety and efficacy of the temperature-responsive hydrogel PNDJ for preventing SSIs. The study design involved in vivo evaluations using animal models, specifically rabbits and canines, to assess the safety and efficacy of the temperature-responsive hydrogel PNDJ for preventing SSIs. •The sample size included multiple animal subjects, although specific numbers are not detailed in the provided contexts. The sample size included multiple animal subjects, although specific numbers are not detailed in the provided contexts. •The follow-up period for assessing outcomes varied, with some evaluations indicating a return to normal values within 14 to 56 days post-treatment. The follow-up period for assessing outcomes varied, with some evaluations indicating a return to normal values within 14 to 56 days post-treatment. •The evidence level of the study is categorized as animal studies, as it primarily involved testing in rabbits and canines. The evidence level of the study is categorized as animal studies, as it primarily involved testing in rabbits and canines. -PMMA PMMA -Antibiotic-loaded hydrogel containing GM and VCM Antibiotic-loaded hydrogel containing GM and VCM •The study included 13 skeletally mature Swiss Alpine sheep to evaluate a single-stage revision model for Orthopedic Device-Related Infection (ODRI), adapted from a previously described two-stage revision model. The study included 13 skeletally mature Swiss Alpine sheep to evaluate a single-stage revision model for Orthopedic Device-Related Infection (ODRI), adapted from a previously described two-stage revision model. •All animals underwent preoperative clinical assessment, including physical examination, blood tests, and radiographic imaging, prior to study inclusion. All animals underwent preoperative clinical assessment, including physical examination, blood tests, and radiographic imaging, prior to study inclusion. •Sheep were acclimatized for at least 2 weeks under controlled housing conditions (12 h light/dark cycle) before surgery. Sheep were acclimatized for at least 2 weeks under controlled housing conditions (12 h light/dark cycle) before surgery. •Post-operative follow-up involved daily veterinary monitoring of behavior, limb function, temperature, appetite, and overall health, using a cumulative clinical scoring system to determine humane endpoints (euthanasia if score >7 for 3 days). Post-operative follow-up involved daily veterinary monitoring of behavior, limb function, temperature, appetite, and overall health, using a cumulative clinical scoring system to determine humane endpoints (euthanasia if score >7 for 3 days). •Evidence level: Preclinical animal study (controlled in vivo large-animal model). Evidence level: Preclinical animal study (controlled in vivo large-animal model). •The study utilized a preclinical mouse model to evaluate the efficacy of vancomycin single-agent therapy compared to combination therapy with vancomycin and rifampin against Staphylococcus aureus prosthetic joint infection. The study utilized a preclinical mouse model to evaluate the efficacy of vancomycin single-agent therapy compared to combination therapy with vancomycin and rifampin against Staphylococcus aureus prosthetic joint infection. •The sample size for the experiments was at least 8 mice per group. The sample size for the experiments was at least 8 mice per group. •The study involved a follow-up period of 6 weeks, with assessments conducted on postoperative days 0, 3, 7, 14, 21, 28, 35, 42, and 49. The study involved a follow-up period of 6 weeks, with assessments conducted on postoperative days 0, 3, 7, 14, 21, 28, 35, 42, and 49. •The evidence level of the study is classified as animal research. The evidence level of the study is classified as animal research. -Computerized Numerical Control machined-surgical steel pin with a slotted end. Computerized Numerical Control machined-surgical steel pin with a slotted end. -The biofilm generation media consisted of Difco TSB at different concentrations for attachment, accumulation, and maturation of biofilms The biofilm generation media consisted of Difco TSB at different concentrations for attachment, accumulation, and maturation of biofilms •The study design involved a rat model of PJI using biofilm inocula in male Sprague-Dawley rats. The study design involved a rat model of PJI using biofilm inocula in male Sprague-Dawley rats. •The sample size and follow-up details are not explicitly provided in the context. The sample size and follow-up details are not explicitly provided in the context. •The study can be classified as an animal study, specifically using a cohort design, as it involved multiple groups of rats receiving different treatments. The study can be classified as an animal study, specifically using a cohort design, as it involved multiple groups of rats receiving different treatments. -Fusidic acid Fusidic acid -Rifampicin Rifampicin -Sodium fusidate Sodium fusidate -Poly(D,L-lactic acid-co-glycolic acid Poly(D,L-lactic acid-co-glycolic acid -Tetrahydrofuran Tetrahydrofuran -Dimethylformamide Dimethylformamide -Acetonitrile Acetonitrile -Methanol Methanol -Phosphoric acid Phosphoric acid •The study was conducted in vivo using 13 female Sprague-Dawley rats (195–225 g) to evaluate the antibacterial efficacy of antibiotic-loaded nanofibers in preventing MRSA colonization on titanium implants. The study was conducted in vivo using 13 female Sprague-Dawley rats (195–225 g) to evaluate the antibacterial efficacy of antibiotic-loaded nanofibers in preventing MRSA colonization on titanium implants. •Each rat received two subcutaneous implants—one titanium disk with antibiotic-loaded nanofibers (test) and one with blank PLGA nanofibers (control)—implanted in separate dorsal pockets. Each rat received two subcutaneous implants—one titanium disk with antibiotic-loaded nanofibers (test) and one with blank PLGA nanofibers (control)—implanted in separate dorsal pockets. •Immediately after implantation, ∼108 CFU of MRSA (Newman strain) was inoculated onto the titanium surface to induce localized infection. Immediately after implantation, ∼108 CFU of MRSA (Newman strain) was inoculated onto the titanium surface to induce localized infection. •Animals were monitored for 7 days post-implantation before being sacrificed for microbiological (CFU count) and histopathological evaluation of implant sites. Animals were monitored for 7 days post-implantation before being sacrificed for microbiological (CFU count) and histopathological evaluation of implant sites. •Evidence level: Preclinical animal study (controlled experimental design, in vivo rat model). Evidence level: Preclinical animal study (controlled experimental design, in vivo rat model). -Cross-linked Hyaluronic Acid (HAc) gel Cross-linked Hyaluronic Acid (HAc) gel -gentamicin gentamicin •The study design involved both in vitro and animal models to evaluate the antibacterial activity of the GM-containing HAc gel. The study design involved both in vitro and animal models to evaluate the antibacterial activity of the GM-containing HAc gel. •The sample size included a total of 45 mice for the durability study of the antibacterial activity, with five mice examined at each time point (0, 1, 2, 7, and 14 days). The sample size included a total of 45 mice for the durability study of the antibacterial activity, with five mice examined at each time point (0, 1, 2, 7, and 14 days). •In the rabbit osteomyelitis model, five rabbits were used in each of the four experimental groups, totalling 20 rabbits. In the rabbit osteomyelitis model, five rabbits were used in each of the four experimental groups, totalling 20 rabbits. •The study can be classified as an animal study, specifically using mouse and rabbit models to assess the effectiveness of the antibacterial carrier. The study can be classified as an animal study, specifically using mouse and rabbit models to assess the effectiveness of the antibacterial carrier. -Continuous wave ultrasound CMW ENDURANCE bone cement, Continuous wave ultrasound CMW ENDURANCE bone cement, -vancomycin, vancomycin, -powdered PMMA, powdered PMMA, -liquid monomer liquid monomer •The study involved a sample size of sixteen New Zealand White female rabbits. The study involved a sample size of sixteen New Zealand White female rabbits. •The rabbits were divided into two groups: one group received CWU treatment, while the control group did not. The rabbits were divided into two groups: one group received CWU treatment, while the control group did not. •The follow-up period lasted for 30 days after the implantation of ALBC. The follow-up period lasted for 30 days after the implantation of ALBC. •The study design can be classified as an animal study. The study design can be classified as an animal study. -PLGA PLGA -PEG ( PEG ( -PCL PCL -Vancomycin hydrochloride (V-HCl) Vancomycin hydrochloride (V-HCl) -N-Methyl-2-pyrrolidone (NMP) N-Methyl-2-pyrrolidone (NMP) -CaCl2 (calcium chloride) CaCl2 (calcium chloride) -PRO OSTEON 500R PRO OSTEON 500R 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid (MTT) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid (MTT) -TRIzol reagent TRIzol reagent -SuperScript VILO cDNA Synthesis Kit SuperScript VILO cDNA Synthesis Kit •The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens. The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens. •A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin •The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis. The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis. •The study design can be classified as an animal study with a cohort design, as it involved multiple time points for follow-up and comparison between two different materials. The study design can be classified as an animal study with a cohort design, as it involved multiple time points for follow-up and comparison between two different materials. -CPC (Biopex-R Advance) CPC (Biopex-R Advance) -PMMA cement (Surgical Simplex P Bone Cement) PMMA cement (Surgical Simplex P Bone Cement) -Injectable vancomycin hydrochloride Injectable vancomycin hydrochloride •The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens. The study involved an animal model, specifically using ten-week-old Wistar rats for the implantation of test specimens. •A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin. A total of 40 rats were implanted with calcium phosphate cement impregnated with vancomycin and polymethylmethacrylate impregnated with vancomycin. •The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis. The follow-up period for the study was 24 weeks, during which the test specimens were removed at weeks 4, 8, 12, and 24 for analysis. •The study design can be classified as an animal study with a cohort design. The study design can be classified as an animal study with a cohort design. •The study design involved in vitro and in vivo assays to evaluate the effects of gentamicin loading on the osteoinductive properties of human demineralized bone matrix. The study design involved in vitro and in vivo assays to evaluate the effects of gentamicin loading on the osteoinductive properties of human demineralized bone matrix. •The in vivo component utilized an ectopic pouch model in athymic nude rats to analyse the osteoinductivity of DBM samples. The in vivo component utilized an ectopic pouch model in athymic nude rats to analyse the osteoinductivity of DBM samples. •The sample size for the in vivo study involved six samples implanted per animal, with animals being euthanized 28 days post-implantation. The sample size for the in vivo study involved six samples implanted per animal, with animals being euthanized 28 days post-implantation. •The evidence level for the study includes both in vitro and animal studies. The evidence level for the study includes both in vitro and animal studies. -CPC (Biopex-R Advance) CPC (Biopex-R Advance) -PMMA (Surgical Simplex P Bone Cement), PMMA (Surgical Simplex P Bone Cement), -Injectable VCM hydrochloride. Injectable VCM hydrochloride. •The study design involved both in vitro and in vivo experiments to evaluate the release profile of vancomycin from calcium phosphate cement and polymethylmethacrylate cement. The study design involved both in vitro and in vivo experiments to evaluate the release profile of vancomycin from calcium phosphate cement and polymethylmethacrylate cement. •For in vivo experiments, test specimens were implanted between the fascia and muscle of rats, and residual vancomycin was extracted from the removed specimens to determine the amount released into rat tissues. For in vivo experiments, test specimens were implanted between the fascia and muscle of rats, and residual vancomycin was extracted from the removed specimens to determine the amount released into rat tissues. •The sample size for the in vivo study is not explicitly mentioned in the provided contexts. The sample size for the in vivo study is not explicitly mentioned in the provided contexts. •The evidence level includes in vitro studies and animal studies (rat model). The evidence level includes in vitro studies and animal studies (rat model). -PMMA) bone cement, PMMA) bone cement, -VAN, VAN, -treated with microbubbles and ultrasound treated with microbubbles and ultrasound •The study involved both in vitro and in vivo evaluations, indicating a mixed study design. The study involved both in vitro and in vivo evaluations, indicating a mixed study design. •The sample size for the in vivo study consisted of 32 rabbits, with 64 tibiae divided into four groups for treatment. The sample size for the in vivo study consisted of 32 rabbits, with 64 tibiae divided into four groups for treatment. •The evidence level for the in vitro part is classified as in vitro, while the in vivo part is classified as animal study. The evidence level for the in vitro part is classified as in vitro, while the in vivo part is classified as animal study. -PMMA cement PMMA cement -Gentamicin and chlorhexidine Gentamicin and chlorhexidine -Silica nanoparticles were Silica nanoparticles were •The study involved the development of a nanocomposite bone cement and its evaluation in an in vivo model of an infected bone defect, indicating an animal study design. The study involved the development of a nanocomposite bone cement and its evaluation in an in vivo model of an infected bone defect, indicating an animal study design. •The sample size for the in vivo experiments is not explicitly mentioned in the provided contexts (Winstar rats). The sample size for the in vivo experiments is not explicitly mentioned in the provided contexts (Winstar rats). •Follow-up was performed after 14 and 28 days by CT of Winstar rat femur bone Follow-up was performed after 14 and 28 days by CT of Winstar rat femur bone •The evidence level of the study is categorized as an animal research due to the use of an infected bone lesion model for testing. The evidence level of the study is categorized as an animal research due to the use of an infected bone lesion model for testing. •The study design is a prospective, randomized, controlled trial. The study design is a prospective, randomized, controlled trial. •The sample size consisted of 32 patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection. The sample size consisted of 32 patients undergoing two-stage exchange arthroplasty for periprosthetic hip infection. •The follow-up period involved collecting drainage samples every 24 h for the first five days following spacer implantation. The follow-up period involved collecting drainage samples every 24 h for the first five days following spacer implantation. •The evidence level is classified as clinical, specifically a randomized controlled trial. The evidence level is classified as clinical, specifically a randomized controlled trial. -PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement. PALACOS R Bone Cement, Palacos RthG Bone Cement, Cobalt HV Bone Cement. −3 g of vancomycin and 2.4 g of tobramycin. 3 g of vancomycin and 2.4 g of tobramycin. -Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amount. Cement spacers were made with 2 to 4 packs of antibiotic cement based on patient size and bone loss amount. •The study design is a prospective cohort study. The study design is a prospective cohort study. •The sample size included a total of 37 patients, with 20 undergoing total knee arthroplasty and 17 undergoing total hip arthroplasty. The sample size included a total of 37 patients, with 20 undergoing total knee arthroplasty and 17 undergoing total hip arthroplasty. •Follow-up was conducted over a period of 8 weeks, with serum creatinine and glomerular filtration rate data collected at baseline and weekly intervals. Follow-up was conducted over a period of 8 weeks, with serum creatinine and glomerular filtration rate data collected at baseline and weekly intervals. •The evidence level is classified as clinical, specifically a cohort study. The evidence level is classified as clinical, specifically a cohort study. •The study design involved a clinical cohort study, evaluating patients undergoing primary TKA over a 6-month period. The study design involved a clinical cohort study, evaluating patients undergoing primary TKA over a 6-month period. •The study enrolled 15 patients undergoing primary TKA by one of two surgeons (GV, JP) who met the inclusion criteria; Follow-up was conducted for one year, during which no complications or infections were reported. The study enrolled 15 patients undergoing primary TKA by one of two surgeons (GV, JP) who met the inclusion criteria; Follow-up was conducted for one year, during which no complications or infections were reported. •The evidence level is classified as clinical, specifically a cohort study. The evidence level is classified as clinical, specifically a cohort study. -Gentamicin, vancomycin Gentamicin, vancomycin •The study involved a sample size of 12 patients (8 male and 4 female) undergoing two-stage revision surgery with antibiotic-loaded spacers. The study involved a sample size of 12 patients (8 male and 4 female) undergoing two-stage revision surgery with antibiotic-loaded spacers. •The follow-up included the collection of serum and joint fluid samples at 1, 4, and 24 h after spacer implantation. The follow-up included the collection of serum and joint fluid samples at 1, 4, and 24 h after spacer implantation. •The study design is classified as a clinical case series. The study design is classified as a clinical case series. -Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate) Hi-Fatigue Gentamicin Bone Cement (Components: Poly(methylacrylat-methylmethacrylate), Poly(methylmethacrylate-Styrene), Zirconium dioxide, Benzoyl peroxide, and Gentamicin sulphate) •The study design is a randomized, non-blinded, comparative, and prospective clinical investigation. The study design is a randomized, non-blinded, comparative, and prospective clinical investigation. •The sample size consisted of 31 participants, with 16 allocated to the thin cement mantle group and 15 to the thick cement mantle group. The sample size consisted of 31 participants, with 16 allocated to the thin cement mantle group and 15 to the thick cement mantle group. •The evidence level is classified as a clinical randomized controlled trial. The evidence level is classified as a clinical randomized controlled trial. •The study design is a prospective, multicentre analytic cohort study of patients undergoing explant of antibiotic PMMA spacers for TKA PJI. The study design is a prospective, multicentre analytic cohort study of patients undergoing explant of antibiotic PMMA spacers for TKA PJI. •The study included patients who underwent a two-stage exchange for TKA PJI with an antibiotic cement spacer. The study included patients who underwent a two-stage exchange for TKA PJI with an antibiotic cement spacer. •Inclusion criteria required that antibiotic spacers did not culture any organisms after removal and that there was no evidence of infection recurrence for at least 1 year following the two-stage exchange. Inclusion criteria required that antibiotic spacers did not culture any organisms after removal and that there was no evidence of infection recurrence for at least 1 year following the two-stage exchange. •The sample size involved 13 antibiotic PMMA spacers collected for analysis. The sample size involved 13 antibiotic PMMA spacers collected for analysis. •The evidence level is classified as a clinical cohort study. The evidence level is classified as a clinical cohort study. •The study involved a sample size of 57 patients who underwent a two-stage revision for infection in hip replacements. The study involved a sample size of 57 patients who underwent a two-stage revision for infection in hip replacements. •The follow-up period for these patients was a minimum of two years from the second stage, with a mean follow-up of 4.5 years. The follow-up period for these patients was a minimum of two years from the second stage, with a mean follow-up of 4.5 years. •The study design can be classified as a clinical case series. The study design can be classified as a clinical case series. -PMMA cement PMMA cement -gentamicin gentamicin •The study involved a clinical design, specifically a case series, as it assessed the levels of gentamicin in patients undergoing a two-stage revision total knee arthroplasty. The study involved a clinical design, specifically a case series, as it assessed the levels of gentamicin in patients undergoing a two-stage revision total knee arthroplasty. •The sample size consisted of twelve patients who received a gentamicin-loaded articulating spacer. The sample size consisted of twelve patients who received a gentamicin-loaded articulating spacer. •Follow-up was conducted at the second stage of the procedure, which occurred at a median of 99 days following the spacer insertion. Follow-up was conducted at the second stage of the procedure, which occurred at a median of 99 days following the spacer insertion. •The study aimed to measure the gentamicin levels in synovial fluid and blood samples collected during the second-stage revision. The study aimed to measure the gentamicin levels in synovial fluid and blood samples collected during the second-stage revision. -Vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam, Vancomycin, teicoplanin, ceftazidime, imipenem, and aztreonam, -bone cement bone cement •The study design involved a clinical case series with a sample size of 8 patients (4 women and 4 men between 51 and 79 years of age) diagnosed with chronic knee periprosthetic joint infection. The study design involved a clinical case series with a sample size of 8 patients (4 women and 4 men between 51 and 79 years of age) diagnosed with chronic knee periprosthetic joint infection. •The antibiotic concentrations in the joint fluid were measured daily for 7 days. The antibiotic concentrations in the joint fluid were measured daily for 7 days. •The evidence level is classified as clinical, specifically a case series The evidence level is classified as clinical, specifically a case series •The study design involved a clinical case series with a sample size of 46 patients who underwent two-stage revision hip arthroplasty for infections. The study design involved a clinical case series with a sample size of 46 patients who underwent two-stage revision hip arthroplasty for infections. •The average follow-up period after the first-stage surgery was 107 days. The average follow-up period after the first-stage surgery was 107 days. •The study was conducted according to a prospective protocol, and all patients provided informed consent. The study was conducted according to a prospective protocol, and all patients provided informed consent. •The evidence level of the study is classified as clinical. The evidence level of the study is classified as clinical. -Antibiotic-impregnated PMMA spacer Antibiotic-impregnated PMMA spacer •The study design is a prospective case series. The study design is a prospective case series. •The sample size consists of six patients from whom antibiotic-impregnated cement spacers were removed for analysis. The sample size consists of six patients from whom antibiotic-impregnated cement spacers were removed for analysis. •The follow-up involved the analysis of the spacers at the time of second-stage revision arthroplasty. The follow-up involved the analysis of the spacers at the time of second-stage revision arthroplasty. •The evidence level is classified as clinical, specifically a case series The evidence level is classified as clinical, specifically a case series -PMMA bone cement PMMA bone cement -Oxacillin Oxacillin -Vancomycin Vancomycin -Cefazolin Cefazolin •The study involved a sample size of 30 patients who were scheduled for primary cemented total-knee arthroplasty. The study involved a sample size of 30 patients who were scheduled for primary cemented total-knee arthroplasty. •The follow-up period included the collection of joint fluid samples at 8, 16, 24, 32, 40, and 48 h after prosthesis implantation. The follow-up period included the collection of joint fluid samples at 8, 16, 24, 32, 40, and 48 h after prosthesis implantation. •The study design is classified as a clinical cohort study, as it compares the antibacterial activities of joint fluids from patients receiving different types of bone cement (with or without antibiotic loading) The study design is classified as a clinical cohort study, as it compares the antibacterial activities of joint fluids from patients receiving different types of bone cement (with or without antibiotic loading) •The study design involved a clinical cohort study with a sample size of 27 hips treated with antibiotic-loaded acrylic cement including, vancomycin, at the institution. The study design involved a clinical cohort study with a sample size of 27 hips treated with antibiotic-loaded acrylic cement including, vancomycin, at the institution. •Patients were classified into two groups: a low-dose group (21 hips) and a high-dose group (6 hips), based on the type of THA performed. Patients were classified into two groups: a low-dose group (21 hips) and a high-dose group (6 hips), based on the type of THA performed. •Follow-up assessments of serum concentrations of VCM and creatinine were conducted at multiple postoperative time points: days 1, 4, 7, 14, and 28, as well as at 3 and 6 months. Follow-up assessments of serum concentrations of VCM and creatinine were conducted at multiple postoperative time points: days 1, 4, 7, 14, and 28, as well as at 3 and 6 months. •The evidence level of the study is classified as clinical, specifically a cohort study. The evidence level of the study is classified as clinical, specifically a cohort study. •The study design included patients from two prospective, multicenter trials investigating cement spacer treatment of implant-associated infections after total hip and knee joint replacement. The study design included patients from two prospective, multicenter trials investigating cement spacer treatment of implant-associated infections after total hip and knee joint replacement. •The sample size consisted of 18 patients (10 hip and 8 knee patients) who were due for two-stage treatment after a periprosthetic joint infection. The sample size consisted of 18 patients (10 hip and 8 knee patients) who were due for two-stage treatment after a periprosthetic joint infection. •The follow-up involved taking control samples, including joint fluid and a punch biopsy of the soft tissue around the spacer, after a 4-to-6-week systemic antibiotics therapy and an antibiotics-free interval of 2 weeks. The follow-up involved taking control samples, including joint fluid and a punch biopsy of the soft tissue around the spacer, after a 4-to-6-week systemic antibiotics therapy and an antibiotics-free interval of 2 weeks. •The evidence level is classified as clinical, as it involves a prospective clinical trial. The evidence level is classified as clinical, as it involves a prospective clinical trial. -Antibiotic-impregnated CHA ceramic blocks. Antibiotic-impregnated CHA ceramic blocks. •The study design is a retrospective case series involving seven consecutive patients. The study design is a retrospective case series involving seven consecutive patients. •The sample size consists of 7 patients, with an average age of 65 years. The sample size consists of 7 patients, with an average age of 65 years. •The follow-up duration averaged 5.0 years, with a range of 2.3 to 6.1 years. The follow-up duration averaged 5.0 years, with a range of 2.3 to 6.1 years. •The evidence level is classified as clinical, specifically a case series •The evidence level is classified as clinical, specifically a case series -ALBC used in the study. -ALBC used in the study. •Prospective open-label clinical case series including 20 patients (7 women, 13 men; mean age 62.5 years) undergoing one-stage revision for infected hip prostheses with vancomycin-susceptible bacteria. •Prospective open-label clinical case series including 20 patients (7 women, 13 men; mean age 62.5 years) undergoing one-stage revision for infected hip prostheses with vancomycin-susceptible bacteria. •Patients received Copal® G + V PMMA bone cement containing gentamicin (0.5 g) and vancomycin (2.0 g) per 43 g powder; postoperative systemic antibiotics were continued for about 13 days. Patients received Copal® G + V PMMA bone cement containing gentamicin (0.5 g) and vancomycin (2.0 g) per 43 g powder; postoperative systemic antibiotics were continued for about 13 days. •Pharmacokinetic monitoring of gentamicin and vancomycin was performed via serial plasma, urine, and wound exudate samples up to 10 days post-surgery using LC-MS-MS. Pharmacokinetic monitoring of gentamicin and vancomycin was performed via serial plasma, urine, and wound exudate samples up to 10 days post-surgery using LC-MS-MS. •Follow-up: daily assessments until day 10 and a final evaluation at 7 months to assess antibiotic release and infection outcomes. Follow-up: daily assessments until day 10 and a final evaluation at 7 months to assess antibiotic release and infection outcomes. •Evidence level: Clinical study – Prospective case series (non-randomized, single-center) Evidence level: Clinical study – Prospective case series (non-randomized, single-center) -Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK) Palacos(r) R-40 with Gentamicin Cement (Schering-Plough, UK) -Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany) Refobacin(r)-Palacos(r) Cement (Biomet Merck, Merck Biomaterials GmbH, Darmstadt, Germany) •The study design involved a clinical cohort study with a sample size of 35 patients who underwent primary total hip arthroplasty The study design involved a clinical cohort study with a sample size of 35 patients who underwent primary total hip arthroplasty •Patients were followed up for a minimum of 12 weeks post-operatively, with urinary samples collected for analysis. Patients were followed up for a minimum of 12 weeks post-operatively, with urinary samples collected for analysis. •The study aimed to investigate the in vivo elution kinetics of gentamicin from bone cement. The study aimed to investigate the in vivo elution kinetics of gentamicin from bone cement. •The evidence level of the study is classified as clinical The evidence level of the study is classified as clinical -Gentamicin, vancomycin Gentamicin, vancomycin •The study involved a sample size of 7 patients who received preformed spacers for two-stage revision of a THA due to infection. The study involved a sample size of 7 patients who received preformed spacers for two-stage revision of a THA due to infection. •The follow-up included monthly clinical evaluations, laboratory tests, and radiographic examinations. The follow-up included monthly clinical evaluations, laboratory tests, and radiographic examinations. •The study design is classified as a clinical case series. The study design is classified as a clinical case series. Cement spacer Palacos R cement Cement spacer Palacos R cement -vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively) advice. vancomycin, rifampicin, linezolid, and gentamycin (administered post-operatively) advice. -Uncemented revision stem (Solution System(r), DePuy Orthopaedics) Uncemented revision stem (Solution System(r), DePuy Orthopaedics) •The study design is a retrospective case series involving 30 consecutive patients with 31 infected total hip arthroplasties treated by a single surgeon over a 4-year period. The study design is a retrospective case series involving 30 consecutive patients with 31 infected total hip arthroplasties treated by a single surgeon over a 4-year period. •The sample size consists of 30 patients, with data recorded for 28 of them. The sample size consists of 30 patients, with data recorded for 28 of them. •The mean follow-up duration for the patients was 35 months, with a minimum follow-up of 24 months. The mean follow-up duration for the patients was 35 months, with a minimum follow-up of 24 months. •The evidence level is classified as a clinical case series. The evidence level is classified as a clinical case series. -Palacos R cement Palacos R cement -Vancomycin and gentamicin Vancomycin and gentamicin •The study involved a clinical design, specifically a case series, as it reported on the experience of multiple surgeons treating patients with chronic peri-prosthetic infection. The study involved a clinical design, specifically a case series, as it reported on the experience of multiple surgeons treating patients with chronic peri-prosthetic infection. •The sample size consisted of 43 consecutive patients (44 hips) who underwent the two-stage revision procedure. The sample size consisted of 43 consecutive patients (44 hips) who underwent the two-stage revision procedure. •The median follow-up period for the patients was 49 months, ranging from 25 to 83 months. The median follow-up period for the patients was 49 months, ranging from 25 to 83 months. -Refobacin Palacos and Vanco-cell beads and spacers. Refobacin Palacos and Vanco-cell beads and spacers. -gentamicin gentamicin •The study involved a clinical design with a sample size of 28 patients, consisting of 17 hip spacers and 11 chains. The study involved a clinical design with a sample size of 28 patients, consisting of 17 hip spacers and 11 chains. •The follow-up period for the study included daily measurements of antibiotic elution from the drainage fluid for up to 13 days for beads and 7 days for spacers. The follow-up period for the study included daily measurements of antibiotic elution from the drainage fluid for up to 13 days for beads and 7 days for spacers. •The evidence level of the study is classified as clinical, specifically a case series, as it evaluates the elution of antibiotics in patients undergoing two-stage exchange for infected total hip arthroplasty The evidence level of the study is classified as clinical, specifically a case series, as it evaluates the elution of antibiotics in patients undergoing two-stage exchange for infected total hip arthroplasty •The study design involved both in vitro and in vivo experiments to assess the pharmacokinetic release profile of antibiotics from PMMA spacers and beads. The study design involved both in vitro and in vivo experiments to assess the pharmacokinetic release profile of antibiotics from PMMA spacers and beads. •The in vitro component measured gentamicin concentrations from PMMA spacers and beads submerged in phosphate-buffered saline using ELISA. The in vitro component measured gentamicin concentrations from PMMA spacers and beads submerged in phosphate-buffered saline using ELISA. •The in vivo component collected wound drainage fluid samples from patients after implantation of a spacer over a maximum period of 14 days. The in vivo component collected wound drainage fluid samples from patients after implantation of a spacer over a maximum period of 14 days. •The sample size for the in vitro experiments included multiple time points for gentamicin concentration measurement, while the clinical samples were collected from patients with different types of spacers. The sample size for the in vitro experiments included multiple time points for gentamicin concentration measurement, while the clinical samples were collected from patients with different types of spacers. •The evidence level for the in vitro part of the study is classified as in vitro, while the in vivo part is classified as clinical (case series). The evidence level for the in vitro part of the study is classified as in vitro, while the in vivo part is classified as clinical (case series). Another aspect that is worth mentioning is the search strategy. We chose to search the Web of Science (WoS) Core Collection, as mentioned in the Abstract section, since this database is a high-impact collection for orthopaedics and biomaterials literature, but we admit that the exclusion of PubMed or Scopus is a limitation of our investigation. However, studies included in WoS are usually also available in the other two databases mentioned above. We will address this limitation in a future study. The searched time window was set between 1st of January 2023, and 31st of December 2025, with the last search in October 2025. The search strategy combined controlled keywords and free-text terms related to (i) PJI and arthroplasty, (ii) local delivery and biomaterial carriers, and (iii) antibiotics/antibiofilm agents. Our full search string for preparing the paper was: TS = ((“periprosthetic joint infection” OR “prosthetic joint infection” OR PJI OR “joint implant infection∗") AND (arthroplast∗ OR “total joint arthroplast∗" OR TJA OR “total hip arthroplast∗" OR THA OR “total knee arthroplast∗" OR TKA) AND (local OR locoregional OR “drug deliver∗" OR elution OR release OR “antibiotic-loaded” OR impregnated) AND (cement OR PMMA OR “bone cement” OR spacer∗ OR bead∗ OR hydrogel∗ OR “calcium sulphate” OR hydroxyapatite OR “calcium phosphate” OR bioglass OR DBM OR “demineralized bone matrix” OR coating∗ OR nanoparticle∗ OR nanomaterial∗ OR peptide∗ OR “antimicrobial peptide∗" OR AMP∗ OR bacteriophage∗) AND (antibiotic∗ OR gentamicin OR vancomycin OR tobramycin OR meropenem OR rifampicin OR daptomycin OR linezolid OR teicoplanin)) Regarding screening workflow and conflict resolution, two independent reviewers screened 300 records by importing them into RAYYAN software (2026 RAYYAN version, Cambridge, MA, USA). After removing duplicates and screening titles/abstracts, 138 studies met the full-text eligibility criteria (14 in vitro, 25 animal, 99 clinical). Any disagreements were resolved via a third-party (an experienced senior reviewer). Studies were included if they: (1) investigated local antibacterial strategies intended for prevention or treatment of PJI or implant-associated infection in arthroplasty-relevant contexts; (2) reported material/carrying platform details (e.g., PMMA cement/spacer, beads, resorbable ceramics, hydrogels, coatings, nanomaterials, peptides); and (3) provided outcomes relevant to antibacterial activity, release kinetics, biofilm endpoints, biocompatibility/cytotoxicity, or clinically relevant endpoints (infection control, recurrence, complications). In vitro, animal, and clinical studies were eligible. Studies were excluded if they: (1) addressed non-implant infections without relevance to arthroplasty/PJI; (2) focused exclusively on systemic antibiotic therapy without a local delivery component; (3) were editorials, conference-only abstracts lacking sufficient methodological detail, or non-English full texts; or (4) lacked extractable outcomes. Final data from the 138 included studies were extracted into a standardized extraction sheet. Extracted variables included: study design (in vitro/animal/clinical), quality appraisal strategy computation, model details (species, defect site, infection model), sample size, pathogen(s), antibacterials (drug type(s), dose/loading, combinations), carrier/material platform (composition, porosity/surface modifications, manufacturing), release testing methods (media, time points, quantification), antibacterial endpoints (Minimum Inhibitory Concentration (MIC)/MBEC-related outcomes, Colony-Forming Unit (CFU) reduction, biofilm biomass/viability), host-response endpoints (cytotoxicity, inflammatory markers/macrophage polarization when available), and—for clinical studies—population, intervention, follow-up duration, infection-control outcomes, reoperation/recurrence, and safety events (including renal function). Regarding the quality and Risk of Bias (RoB) this aspect was assessed separately as it follows: (i) clinical studies: Risk of Bias tool for Randomized Trials, 2019 (RoB 2) version or Risk of Bias in Non-Randomized Studies of Interventions for non-randomized/observational studies, 2025 (ROBINS-I)-V2 version, as appropriate; (ii) animal studies: Systematic Review Centre for Laboratory Animal Experimental (SYRCLE) - risk-of-bias domains (randomization, allocation concealment, blinding, incomplete outcome data, selective reporting); (iii) in vitro studies: an adapted methodological quality checklist capturing replication, control groups, standardized inoculum/biofilm methods, validated quantification, and reporting completeness [28]. Overall certainty of evidence was graded qualitatively as Higher/Moderate/Lower by outcome domain, driven by study design, consistency, directness to PJI clinical conditions, and risk of bias. Due to heterogeneity in materials, elution protocols, biofilm models, and clinical endpoints, a meta-analysis was not pursued. Evidence was synthesized narratively using a clinical-pathway framework (cement/spacer-based strategies; resorbable carriers; coatings/nanomaterials; emerging antibiofilm agents), and each section concludes with a concise comparative interpretation highlighting (a) what the evidence supports, (b) key limitations/bias risks, and (c) remaining unmet needs. The PRISMA 2020 aligned workflow and reporting elements are presented in Table S1 and Fig. S1 (supplementary file). The objective was to map and critically synthesize evidence on local antibacterial strategies for periprosthetic joint infection (PJI), spanning antibiotic-loaded cements/spacers, resorbable carriers, coatings/nanomaterials, and emerging antibiofilm agents, across in vitro, animal, and clinical study designs. (supplementary document S1). To this aim, the literature research was conducted by enquiring the WoS database portal using the following keywords: arthroplasty, stage, total, knee, hip, implant, infection, antibacterial, antimicrobial, cement, spacer, blocks, and in vivo. Logical operators such as OR, AND, and NOT have been applied in several combinations to refine research in order to return, as an outcome, the papers that mostly cover the in vivo human cases or in vivo animal models. Along with in vivo studies, some in vitro results have been considered to be included in this review due to interesting aspects and proposed strategies that emerged during the meta-analysis of these papers. In order to give a logical rationale to this review, the present work it has been organized according to a three-section hierarchical structure:1)Section I: Before Implantation2)Section II: After Implantation3)Section III: Implantation follow-up and after explantation 1)Section I: Before Implantation Section I: Before Implantation 2)Section II: After Implantation Section II: After Implantation 3)Section III: Implantation follow-up and after explantation Section III: Implantation follow-up and after explantation Each of these main sections contains different thematic chapters, while each chapter is organized into 3 paragraphs, in which in vitro, in vivo animal models, and in vivo clinical trials are addressed separately. A graphic representation of the chapter's structure of the present work is depicted in Fig. 1.Fig. 1Schematic representation of the chapter structure of the review.Fig. 1 Schematic representation of the chapter structure of the review. A comprehensive table (Table 1) was inserted at the end of this paper. This table reports a synthesis of all the major covered aspects: 1 - Materials used for the implant or commercial model of spacer, blocks cement, etc.; 2 - Type of study: in vitro, in vivo animal model, and in vivo human case; 3 - Quality assessment/Risk of bias; 4 - Effects on cement matrix by additional components, treatments and admixing of drugs; 5 - Drug release, kinetic and elution characteristics; 6 - Antibiotic activity; 7 - Local and systemic cytotoxicity and nephrotoxicity; - Biodegradability - Osseointegration – Bone volume analysis. The table includes all the reviewed works. Table 1 has two main purposes: 1) allowing the audience to a quick and specific finding of the most important achievements of the investigated literature and 2) reporting the methodological aspect of the investigated studies, such as the materials used as antibiotic-loaded matrix/carrier (cements, specific commercial spacers, hydrogels, etc.), and antibacterial agents (mostly commercial antibiotics). Specific quantities or concentrations were also noticed when mentioned in the analysed literature. Other reported methodology aspects (Table 2) are the study design/sample size/follow-up/level tag and the type of study: in vitro, in vivo animal model, in vivo human case, where cell lines, specific animal models, or aspects concerning the enrolled patients for human case studies, such as age, sex, study design, follow-up, and level tag, were detailed according to the information provided in the reviewed papers. The decision to detail these methodological aspects in the tables permitted the authors to adopt a more agile writing style, allowing, when appropriate, the grouping of similar results and the highlighting of similarities or differences among the reported papers. Finally, it also allowed the chapters and paragraphs presented in this systematic review to be structured. Section I: Before Implantation. Selection of cement, spacers, and antibiotic agents In vitro One of the most common choices for arthroplasty implants is represented by using typical acrylic PMMA bone cement either admixed with a single antibiotic or a combination of two or more antibiotics. Even though the commercial formulation of acrylic PMMA cement represents the most common matrix to be used as implant/spacer materials, several studies have explored modifications of this classical formula. For example, one study reported a cement prepared by the addition of calcium sulphate (CaSO4) to the Modified Glass Polyalkenoate Cements (mGPCs), which was expected to influence various properties of the matrix [29], [28]. Common antibiotics usually selected for this purpose include gentamicin (GM), vancomycin (VCM), teicoplanin, synercid, linezolid, polymyxins, meropenem, rifampicin (RIF), tigecycline, ceftriaxone sodium, amikacin, colistin sulphate, clindamycin, streptomycin, and tobramycin sulphate [[30], [31], [32], [33], [34]]. The use of single antibiotics represents just a minor strategy in local drug delivery. More complex strategies, such as mechanically treated cement or the dual or multiple antibiotic-releasing systems, have been widely adopted over the last two decades. Lin et al. [35] proposed the use of Ultrasound (US) or Microbubbles-Mediated Ultrasound (US + MB) during the admixing procedure with antibiotics, aiming to improve the elution and antibacterial performance of the cement. One in vitro study by Alt et al. [36] utilized PMMA cement loaded with 1% Silver (Ag) nanoparticles as an antibacterial agent. Dual or multiple antibiotic-releasing is the broadly applied protocol in the frame of local delivery. Combinations of antibiotics have been increasingly favoured, with popular pairings including vancomycin-rifampicin [37], linezolid-vancomycin, linezolid-gentamicin [38], and gentamicin-vancomycin or gentamicin-teicoplanin [30]. A study performed by Morrison et al. [33] further investigated the synergistic effects of gentamicin combined with silver-embedded PMMA beads to combat biofilm formation. Biologically derived matrices such as Demineralized Bone Matrix (DBM) are not primarily fixation/spacer materials; rather, they are used clinically as bone void fillers/scaffolds for defect repair. DBM has nevertheless been explored as a local antibiotic carrier (e.g., gentamicin-loaded DBM) to couple defect management with infection control [39]. In vivo animal models The investigated literature focused on animal model arthroplasty and revealed that various materials and tools are used as implantable devices that are able to provide antibacterial properties. The different solutions can be grouped into four types:(i)Antibiotic-Loaded Bone Cements: often used in the form of spacers or blocks, ALBCs have been extensively studied and applied in both clinical and experimental settings to deliver localized antibiotics directly to the surgical site. This method is particularly effective for temporary implantation during two-stage revision surgeries for infected joint replacements, helping to reduce bacterial colonization and biofilm formation [35,[40], [41], [42], [43], [44], [45], [46], [47]].(ii)Antibiotic-Releasing Bone Void Filling (ABVF) putties: these types of materials are designed to fill bone defects while simultaneously releasing antibiotics over time, ensuring sustained antibacterial action during the healing process. ABVF putties are commonly used in cases where bone infections or voids are a concern, providing structural support along with infection control [37,48,49].(iii)Gel and hydrogel-based materials: these versatile biomaterials offer the advantage of being easily mouldable and adaptable to complex anatomical sites. Gels and hydrogels can be loaded with antibiotics, allowing for controlled and localized drug release, which is particularly useful for preventing bacterial contamination in wounds and implanted devices. Additionally, they can be used as implant coatings or directly applied to tissues [[50], [51], [52], [53]].(iv)Metal devices coated or filled with antibacterial materials: metal implants, such as titanium alloys, cobalt-chromium alloys, and stainless steel, can be engineered to have antibacterial properties by either coating them with antibiotic-releasing layers or incorporating antimicrobial agents directly into the metal structure. This approach not only maintains the mechanical strength and durability of the metal but also provides long-term protection against bacterial colonization and biofilm formation, which are significant risks in joint replacement surgeries [[54], [55], [56], [57], [58]]. (i)Antibiotic-Loaded Bone Cements: often used in the form of spacers or blocks, ALBCs have been extensively studied and applied in both clinical and experimental settings to deliver localized antibiotics directly to the surgical site. This method is particularly effective for temporary implantation during two-stage revision surgeries for infected joint replacements, helping to reduce bacterial colonization and biofilm formation [35,[40], [41], [42], [43], [44], [45], [46], [47]]. Antibiotic-Loaded Bone Cements: often used in the form of spacers or blocks, ALBCs have been extensively studied and applied in both clinical and experimental settings to deliver localized antibiotics directly to the surgical site. This method is particularly effective for temporary implantation during two-stage revision surgeries for infected joint replacements, helping to reduce bacterial colonization and biofilm formation [35,[40], [41], [42], [43], [44], [45], [46], [47]]. (ii)Antibiotic-Releasing Bone Void Filling (ABVF) putties: these types of materials are designed to fill bone defects while simultaneously releasing antibiotics over time, ensuring sustained antibacterial action during the healing process. ABVF putties are commonly used in cases where bone infections or voids are a concern, providing structural support along with infection control [37,48,49]. Antibiotic-Releasing Bone Void Filling (ABVF) putties: these types of materials are designed to fill bone defects while simultaneously releasing antibiotics over time, ensuring sustained antibacterial action during the healing process. ABVF putties are commonly used in cases where bone infections or voids are a concern, providing structural support along with infection control [37,48,49]. (iii)Gel and hydrogel-based materials: these versatile biomaterials offer the advantage of being easily mouldable and adaptable to complex anatomical sites. Gels and hydrogels can be loaded with antibiotics, allowing for controlled and localized drug release, which is particularly useful for preventing bacterial contamination in wounds and implanted devices. Additionally, they can be used as implant coatings or directly applied to tissues [[50], [51], [52], [53]]. Gel and hydrogel-based materials: these versatile biomaterials offer the advantage of being easily mouldable and adaptable to complex anatomical sites. Gels and hydrogels can be loaded with antibiotics, allowing for controlled and localized drug release, which is particularly useful for preventing bacterial contamination in wounds and implanted devices. Additionally, they can be used as implant coatings or directly applied to tissues [[50], [51], [52], [53]]. (iv)Metal devices coated or filled with antibacterial materials: metal implants, such as titanium alloys, cobalt-chromium alloys, and stainless steel, can be engineered to have antibacterial properties by either coating them with antibiotic-releasing layers or incorporating antimicrobial agents directly into the metal structure. This approach not only maintains the mechanical strength and durability of the metal but also provides long-term protection against bacterial colonization and biofilm formation, which are significant risks in joint replacement surgeries [[54], [55], [56], [57], [58]]. Metal devices coated or filled with antibacterial materials: metal implants, such as titanium alloys, cobalt-chromium alloys, and stainless steel, can be engineered to have antibacterial properties by either coating them with antibiotic-releasing layers or incorporating antimicrobial agents directly into the metal structure. This approach not only maintains the mechanical strength and durability of the metal but also provides long-term protection against bacterial colonization and biofilm formation, which are significant risks in joint replacement surgeries [[54], [55], [56], [57], [58]]. In vivo clinical trials Several studies have explored various materials and techniques for developing antibiotic-eluting spacers and cements, primarily focusing on PMMA as the base material due to its common use in orthopaedics. Studies [[59], [60], [61], [62], [63]] utilized PMMA as the primary phase, incorporating different antibiotic agents and preparation methods to enhance its antibacterial properties. For example [59,60,63], integrated both vancomycin and gentamicin into PMMA-based spacers or beads, while [61,63] employed similar antibiotic combinations but allowed for adjusted delivery behaviour. Several investigations focused on specific formulations of PMMA-based bone cement. Studies [60,[62], [63], [64]] utilized Palacos R cement, a type of PMMA, often pre-mixed with gentamicin, with additional antibiotics such as vancomycin and tobramycin added in some cases to increase antimicrobial efficacy. Kendoff et al. [65] explored a slightly different approach by using a commercially manufactured antibiotic-loaded bone cement, Copal® GV, pre-mixed with gentamicin and vancomycin, offering a standardized, ready-to-use alternative. In contrast, the study of Sudo et al. [66] deviated from the traditional use of PMMA, employing Antibiotic-impregnated Calcium Hydroxyapatite (CHA) ceramic blocks as a novel strategy. This approach aims to overcome some of the limitations associated with PMMA, such as low antibiotic release rates and the risk of bacterial colonization on the cement surface. It is important to define that there are currently no clinical indications for the use of resorbable Hydroxyapatite (HA) spacers for PJI and, they are not part of established one-stage or two-stage revision protocols. Although resorbable HA spacers were evaluated in trials with antibiotic-loaded HA composites for early osteomyelitis, in chronic PJI management and revision surgery, resorbable HA spacers in PJI surgery have not gained any traction or semblance of clinical application. The only local delivery systems for antibiotic therapy are deemed PMMA (non-resorbable) antibiotic-loaded cement spacers or bioabsorbable delivery systems such as calcium sulphate (CaS) due to predictable elution profiles and clinical availability [[67], [68], [69]]. Contemporary clinical trials in two-stage revision for chronic knee PJI suggest that using either calcium sulphate beads or PMMA spacers yields control rates greater than 80–95%. Resorbable implants based on HA have not been included in these protocols [70]. In vivo clinical trials, patient preparation through antiseptic procedures Preoperative decolonization of the patient's mouth, nose, and skin is an important measures to minimize the occurrence of Surgical Site Infections (SSIs) and is particularly important in orthopaedic, implant and prosthetic surgeries. Staphylococcus aureus, especially methicillin-resistant strains, colonizes the nares and oropharynx and acts as a significant factor for endogenous infection. Current recommendations for this patient population endorse interventions like nasal mupirocin and chlorhexidine gluconate (CHG) bathing, which have been validated to reduce bacterial colonization and SSI rates [71]. Bennis et al. [72] suggested in a recent multicentre survey that these practices are indeed widespread across institutions but still noted heterogeneity within practices, and also observed the need for standardization. Other reviews also emphasized that preoperative antiseptic skin preparation and oropharyngeal hygiene are cost-effective means of combating microbial load within potential surgical entry sites [73]. In conjunction with these steps, these efforts represent an important part of multimodal SSI prevention. A schematic representation of the most common TJA is reported in Fig. 2.Fig. 2Schematic representation of the most common Total Joint Arthroplasty (TJA).Fig. 2 Schematic representation of the most common Total Joint Arthroplasty (TJA). Effects of additional components, treatments, and admixing of drugs on the cement matrix In vitro Commercial products such as PMMA bone cement brands, including Charnley, Mentore, and Waugh (CMW) Endurance (DePuy, Leeds, UK) [35], Cemex XL-Tecres SpA [34], [7], Zimmer LV, Palacos R, and Simplex P [32], are standardized and possess well-known characteristics. Therefore, investigations of the pristine cements or spacers are limited to only a few analysed cases. In these studies, authors primarily explored the influence of additional components, unconventional treatments, or modifications induced by the introduction of antibiotics on the cement matrix. Hasandoost et al. [29] reported that the addition of calcium sulphate (CaSO4) to the mGPCs reduced the setting time and increased the release of therapeutic ions such as calcium (Ca2+) and zinc (Zn2+) over 30 days of maturation period in deionized water. The compressive strength of mGPCs with 5% and 15% CaSO4 increased to over 30 MPa after 30 days of maturation, closely matching the predictions made by using the Rule of Mixtures (RM). Surface topography analysed by Scanning Electron Microscopy (SEM) revealed the presence of micro-cracks and random pore distribution, with small and large pores throughout the specimens. Furthermore, Fourier Transform Infrared (FTIR) analysis indicated no cross-linking between CaSO4 and mGPC after 30 days, suggesting that CaSO4 remained a distinct phase within the cement. In another study, Seldes et al. [31] observed that the addition of liquid gentamicin to Palacos R bone cement significantly reduced its mechanical properties, with the mean compression modulus dropping by 41%, and the mean tensile modulus decreased by 35% compared to the control specimens and those containing powdered tobramycin. Moreover, the ultimate compression strength of the cement with liquid gentamicin decreased by 49%, and the ultimate tension strength decreased by 46% compared to the control specimens. Lewis and Bhattaram [32] investigated the effect of the addition of gentamycin on various commercial acrylic cements. The study concluded that the addition of gentamicin sulphate did not degrade the properties of the cement, including strength, modulus, work-to-fracture, plane-strain fracture toughness, Weibull mean fatigue life, activation energy, frequency factor for polymerization, and the diffusion coefficient for phosphate-buffered saline absorption. Snir et al. [38] found that the mechanical strength of PMMA beads impregnated with linezolid, vancomycin, or gentamicin, either alone or in combination, was not compromised, maintaining compliance with International Standard 5833 [74]. Morrison et al. [33] assessed the potential decrease in bending strength of the cement when loaded with antibiotics, providing valuable insights into the balance between antibiotic loading and mechanical performance in bone cement formulations. Salih et al. [75] reported that indenting the cement spacers increased the surface area, potentially exposing cracks and pits within the spacer, which could enhance antibiotic elution. However, this did not adversely affect the spacer's function in staged revision procedures. Moreover, the presence of clindamycin did not inhibit gentamicin elution, suggesting that the matrix's integrity was maintained. In vivo animal models Though the regulatory requirements for in vivo animal models are more restrictive compared to in vitro experiments, there is still room for some experimentation and novel solutions for local antibiotic delivery. Several authors proposed some modifications to traditional in vivo antibacterial strategies. Inceoglu et al. [40] compared two types of cement: one obtained by directly mixing VCM into a PMMA matrix and another micro-composite obtained by embedding vancomycin‐loaded mesoporous silica into PMMA. Mechanical strength testing revealed that the micro-composite cement had lower bending strength but a similar elastic modulus compared to the antibiotic-containing standard cement. Despite lower ultimate strength, the micro composite remained several-fold stronger than trabecular bone (≈4–6 MPa) and retained sufficient mechanical integrity even after most of the drug had been released to safely fulfil its dual delivery/support function. Moreover, after 4 weeks of in vitro solution immersion, porosity measurements revealed that the micro-composite implants exhibited a 57% increase in porosity and significantly larger pore diameters compared to plain drug-loaded Simplex cement, contributing to the enhanced drug release kinetics. Yang et al. [43] explored a similar solution, where a cement micro composite was prepared using functionalized silica nanoparticles coated with sodium alginate/chlorhexidine or gentamicin/sodium alginate/Poly(Beta-Amino Ester) (PBAE) layers. These nanoparticles were subsequently admixed with Cemex bone cement. Mechanical tests indicated that the incorporation of silica nanoparticles did not negatively impact the mechanical properties of bone cement, such as compression tests, four-point bending tests, and fracture toughness tests. Uchida et al. [42] prepared two disc-shaped spacers using PMMA and CPC, and both were loaded with vancomycin. SEM images and mercury porosimetry analysis revealed that CPC/VCM had a significantly larger pore size compared to PMMA/VCM (0.22 μm vs 0.011 μm), which likely contributed to its higher release profile. Quaternised Chitosan-Loaded PMMA (PMMAeH) bone cement was developed by Tan et al. [45]. The obtained results demonstrated that the mechanical properties of PMMAeH were significantly reduced compared to both pure PMMA and gentamicin-loaded PMMA, particularly in terms of compressive strength. After 4 weeks of immersion in Phosphate-Buffered Saline (PBS), the bending strength of PMMAeH decreased from 44.7 MPa to 30.7 MPa, with a final value of approximately ± 5.83 MPa. Biodegradable Porous pPlyurethane (PUR) scaffolds for local delivery of vancomycin were proposed by Li et al. [46]. Confocal microscopy demonstrated that antibiotic loading did not compromise the stability of the scaffold and its pore morphology, with 7 wt% of antibiotic content in the PUR matrix. Jones et al. [49] investigated different formulations of biodegradable ABVF in a pilot study involving rat implantation. SEM images revealed that the formulation containing the highest amount of biopolymers (15% of Poly(Lactic-co-Glycolic Acid) (PLGA)) exhibited extensive degradation observed after 90 days in phosphate-buffered saline, indicating a significant resorption rate compared to the other proposed formulations. An interesting biodegradable localized drug delivery system using electrospun PLGA nanofibers co-loaded with Fusidic Acid (FA) was reported by Gilchrist et al. [58]. This matrix successfully encapsulated rifampicin with efficiencies ranging from 75% to 100% without affecting the surface morphology of the nanofibers, as confirmed by SEM and X-ray diffraction patterns. In vivo clinical trials The incorporation of antibiotics into bone cement significantly influences both its mechanical properties and drug release profiles. Several reports [59,[76], [77], [78]] highlight that manual mixing of antibiotics, such as vancomycin, can introduce variability in drug distribution, often leading to reduced mechanical strength due to increased porosity and irregular incorporation. In contrast, other works [62,79,80] report that when antibiotics, such as tobramycin, are used in lower concentrations (no more than 5-10% of the cement's weight), the cement's structural integrity remains largely intact. Borick et al. [81] noted that the inclusion of tobramycin can affect the cement matrix by increasing porosity and permeability, leading to higher drug release rates. This is particularly observed with generic tobramycin, which has less compact particles compared to other formulations. A different approach was explored by Sudo et al. [66], where hydroxyapatite (HA) ceramic blocks were utilized to prevent thermal degradation of antibiotics during polymerization, thus maintaining their potency. Enhancements to cement composition were also addressed by van Jiperen [82], where the incorporation of styrene copolymers improved fatigue strength and slowed gentamicin release by reducing water absorption. Taddei et al. [78] demonstrated that the inclusion of vancomycin hydrochloride, as identified by Raman Spectroscopy, alters the polymerization process, impacting the crystallinity and tactility of the cement, with direct implications for the durability and wear resistance of spacers. Ammon et al. [83] highlighted that the amount of antibiotic added in the second stage was reduced to maintain mechanical strength. Furthermore, the use of irradiation to sterilize allograft bone was mentioned, with no observed negative impact on mechanical strength. Ueng et al. [84] confirmed that antibiotics such as vancomycin and oxacillin remain stable and retain their bioactivity even after exposure to the high temperatures of polymerization, ensuring their therapeutic efficacy in the post-implantation period. Emerging data indicate that while synergistic combinations of antibiotics, specifically β-lactams and aminoglycosides, increase bactericidal activity in vitro through synergistic mechanisms, clinical data on the use of these combinations in antibiotic-loaded carriers are limited. In a retrospective cohort of 252 patients with osteomyelitis and fracture-related infections, there was no significant difference in clinical outcomes between gentamicin and gentamicin plus vancomycin administered locally (8.8% vs 8.6% failure rates; Odds Ratio (OR) 1.54; Confidence Interval (CI) 0.59–4.04) [85,86]. Notably, local aminoglycoside resistance was detected in a portion of cases (∼10–24%), but did not have an association with worse outcomes (OR 0.39; CI 0.05–3.01) [85]. This highlights an important point: when antibiotic elution is prolonged, and at subtherapeutic levels from bone cement, it may create selective pressure for resistant organisms, and antibiotic resistance may occur even when there are no clinical failures, as highlighted from mechanistic, pre-clinical, and clinical studies [8,87,88]. Thus, even if in vitro synergy is pharmacologically valuable, if moving toward ALBC use, it will be important to weigh its risk for resistance, elution kinetics, and material compatibility, which supplements the need for prospective clinical trials with defined validations. The finding of the right combination of different factors, such as additional components, unconventional treatments, and antibiotics in bone cement formulations, affects the balance between enhancing antibiotic delivery and maintaining the structural integrity of bone cement. In vitro findings underscore that modifications, whether through the addition of compounds such as calcium sulphate, incorporation of functional nanoparticles, or antibiotic admixing, can significantly alter the cement matrix, affecting its mechanical strength, porosity, and ion release characteristics. Notably, the method of antibiotic incorporation (e.g., powder vs. liquid) plays a crucial role in determining the extent of these changes. Animal model studies further demonstrate the potential of advanced materials such as micro-composites, biodegradable polymers, and electrospun nanofibers in achieving effective local drug delivery, though often accompanied by trade-offs in strength or durability. Clinical investigations within the limited reported cases confirm these outcomes, revealing that while low-dose antibiotic loading typically preserves mechanical properties, manual mixing and higher concentrations can lead to porosity, irregular drug distribution, and weakened cement. Effect of biomaterials on host immune response Biomaterials play a central role in shaping the macrophage phenotype at the host-implant interface, affecting inflammation, infection, and tissue healing. Macrophages are highly plastic and can establish M1 (pro-inflammatory) or M2 (anti-inflammatory, tissue-regenerative) phenotypes influenced by their surroundings. M1 macrophages are necessary for the pathogen clearance of the site during the early stages through the expression of cytokines and phagocytosis; however, it is proposed that the macrophage must transition to the M2 phenotype rapidly, to overcome inflammation and establish osteogenesis. The use of biomaterials has the ability to drive this polarization with their surface chemistries, topographies, degradation products, and mechanical properties. For example, the influence of lithium and calcium silicate doped materials on M2 polarization was found to upregulate anti-inflammatory cytokines and osteogenic markers, allowing for bone healing while also suppressing chronic inflammation as suggested by Lin et al. [89]. In the study of bioceramics, cerium-doped mesoporous bioactive glass nanoparticles (MBGNs) were able to suppress the expression of pro-inflammatory cytokines (Tumor Necrosis Factor (TNF-α) Interleukin-1 beta (IL-1β), Interleukin-1 (IL-6)) in macrophages, while also promoting osteogenic activity by inhibiting the osteoclastogenic response [90]. Synthetic polymers were tested with tetra-Polyethylene Glycol (PEG) hydrogels to demonstrate that by integrating HA (nano)size and short-chain chitosan could repress M1 polarization and drive TLR4/NF-κB signaling while also providing preference for M2 phenotype transition and osteogenic capacity [91]. A natural polymer was tested, where a nanofibrous 9-Fluorenylmethoxycarbonyl-diphenylalanine (FmocFF)/hyaluronic acid hydrogel resulted in a significant increase in M2 macrophage populations within the regenerating tissue, and substantial increases in MC3T3-E1 pre-osteoblast osteogenic differentiation resulted in roughly 93% bone restoration in vivo [92]. In studies using biodegradable metals, an Mg–10Gd alloy had significant positive effects on macrophage behavior through suppression of TNF-α and IL-1β secretion and increased production of osteogenic signals (Oncostatin M (OSM) and Bone Morphogenetic Protein (BMP-6)) that acted on Human Umbilical Cord Perivascular (HUCPV) to facilitate bone tissue formation [93]. Lastly, in studies of non-biodegradable metals, titanium with 5 wt% copper induced M2 polarization in RAW264.7 macrophages and in vitro osteogenic differentiation and proliferation of MC3T3-E1 cells, potentially demonstrating the alloy's dual immunomodulatory and osteoconductive functions [94]. Among all biomaterials commonly used to modulate immune response a special mention is due to the PLGA, PMMA is bioinert and non-degradable and has a propensity to induce a foreign-body response, predominated by sustained M1 macrophage activation with minimal intrinsic stimulation of the reparative M2 phenotype (required for resolution of inflammation and progression to tissue repair). While Mahon et al. [95] demonstrated that PMMA particles activated human macrophages to M1 phenotype unless Interleukin (IL-4) was employed to induce M2 conversion, Bianchi et al. [96] confirmed that PMMA microparticles downregulated M2 markers in human-derived macrophages. In contrast, PLGA is biodegradable and is bioactive in nature, which suggests that its degradation products are able to actively modulate the immune microenvironment toward predominant M2 macrophages, which allows for infection resolution and bone regeneration. Long et al. [97] demonstrated that PLGA/Black Phosphorous (BP) scaffolds stimulated M2 polarization in macrophages (increased Cluster of Differentiation 163 (CD163), decreased Cluster of Differentiation (CD86)), while enhancing osteogenic signalling mechanisms via the Phosphatidylinositol 3-Kinase (PI3K/AKT)-Runt-related Transcription Factor 2 (Runx2) pathway. Likewise, Lee et al. [98] demonstrated in a rat model that a PLGA composite scaffold led to M2 polarization, decreasing inflammation, and resulting in increased gene expression of angiogenic and osteogenic factors and subsequently improved spinal fusion. The different nature and immunomodulatory profiles of PMMA and PLGA promote PLGA as a platform that can be used to not only create a better antibiotic delivery vehicle, but also can better enhance host defence, resolve infection and inflammation, and stimulate tissue integration within the unique additional challenges of orthopaedic applications that are prone to infection. Although immunomodulatory design (e.g., macrophage polarization toward pro-regenerative phenotypes and improved osseointegration) is highly compelling, most evidence remains preclinical and often relies on non-standardized infection models and surrogate immune markers. Translation is most credible where platforms have progressed to large-animal studies or early clinical evaluation, report concomitant infection-control outcomes, and quantify host response alongside mechanical performance. Key practical constraints remain: polymeric systems can generate acidic degradation microenvironments that may affect antibiotic stability and local cell function; many resorbable constructs are not suitable for load-bearing indications; and manufacturing variability (porosity, drug distribution, batch reproducibility) can shift both immune response and release kinetics. Future studies should therefore align immunomodulation endpoints with clinically meaningful outcomes (infection eradication/recurrence, osseointegration, reoperation) and standardized release/biofilm testing. Across the reviewed studies, three recurring trade-offs emerge. First, enhancing elution by increasing porosity or adding secondary phases can improve early antibacterial exposure but may penalize mechanical properties, particularly when high antibiotic loads or liquid formulations are used; conversely, low-dose approaches better preserve strength but risk shorter durations above therapeutic thresholds. Second, carrier geometry and surface area (e.g., beads vs spacers/blocks) strongly influence cumulative release and duration, complicating direct comparison across studies that use different shapes and assay conditions. Third, although several approaches improve short-term concentrations, robust pharmacokinetic confirmation of sustained levels sufficient for biofilm eradication (MBEC-relevant exposure) is still sparse, leaving an unmet need for standardized, clinically anchored testing frameworks that link elution profiles to biofilm outcomes and resistance risk during late sub-therapeutic phases. Despite the offer of novel proposed solutions in terms of biomaterials that can be employed for implant devices, PMMA remains the standard material for antibiotic-loaded bone cements and spacers; however, it presents several well-established limitations. Its non-degradable nature prevents complete integration with the host bone, and its bioinert properties do not support osteogenesis or immune modulation. Additionally, PMMA exhibits suboptimal antibiotic release kinetics, characterized by an initial burst followed by limited sustained elution. These features can contribute to antibiotic subtherapeutic levels over time and increase the risk of resistance. Mechanical degradation when highly loaded with antibiotics, and potential local cytotoxicity, further complicate its long-term performance. These drawbacks have prompted research into bioactive, resorbable alternatives capable of delivering antibiotics while supporting tissue regeneration and modulating host immune responses. Section II: After Implantation. Drug release, kinetic, and elution characteristics In vitro The reviewed literature reported similar results concerning the release behaviour of antibiotics embedded in cement matrices. A typical elution profile consists of an initial burst release, where about 40% to 80% of the embedded drug is dispersed into the surrounding environment. The duration of the initial burst stage is between 2 and 24 h. After this period, a sustained and gradual release of antibiotics occurs, characterized by a lower elution rate and an extended-release duration, often lasting up to several weeks [30,31,34,35,38,39]. Different elution kinetics were reported by Hasan et al. [37], who noticed a constant and continuous release of antibiotics from the initial hours, exhibiting no significant burst release phase. One should mention that this study is based on a novel biodegradable ABVF putty instead of traditional PMMA. This ABVF system consists of a polymer matrix made from PLGA, PEG, and Polycaprolactone (PCL), combined with an osseointegrating synthetic bone substrate. It was loaded with a combination of vancomycin and rifampicin. The unique mechanisms of polymer-controlled erosion and diffusion in this putty permitted the sustained therapeutic concentrations over a six-week period, in contrast with the rapid decay kinetics typically observed in classical monolithic acrylic cements. Lin et al. [35] compared the release behaviour of vancomycin from pristine PMMA bone cement with two modified methods: ultrasound-aided admixing and microbubbles-mediated ultrasound admixing. The US + MB method achieved a higher release of antibiotics in both the burst and sustained release phases. The authors attributed this to the oscillation and rupture of microbubbles, which increased microstreaming and shear stress, facilitating antibiotic elution and creating transient micropores in bacterial cell walls for enhanced drug uptake. Salih et al. [75] conducted a quantitative assessment of gentamicin by High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS). Indented disc spacers showed significantly higher elution of gentamicin compared to plain spacer counterparts over a nine-week elution period, further supporting the influence of surface modifications on antibiotic release profiles. In other studies, the elution times of single or multiple antibiotics mixed within the cement were compared. In in vitro experiments, the simultaneous presence of two or more drugs within the cement matrix was shown to prolong the sustained release phase. This was particularly evident with combinations like linezolid and gentamicin [38] or gentamicin-vancomycin and gentamicin-teicoplanin-loaded spacers [30], where drug interactions helped extend the duration of antibiotic release. The successful treatment of PJI relies on the relative ability to create delivery systems that are able to provide various levels of antibiotic bioavailability which achieve the target antibiotic release kinetics to penetrate the protective architecture of bacterial biofilms. Delivery systems that have an immediate burst release, ideally followed by controlled forms of sustained elution, mean that rapid antibiotic dosing can be achieved. For example, chitosan films containing different antibiotics, exhibited release profiles, characterized by temporary elution (1 day) and prolonged timeframes (6 months), depending on the structure of the antibiotic, and the characteristics of the matrix used to develop the eluting mechanisms, but also the capability to design the kinetics related to the specific application of the system [99]. In another example, thermosensitive liposomal hydrogels were able to provide vancomycin in the delivery systems for at least 21 days and provide killing effects in studies of MRSA biofilms, during the establishment and maturation phases of biofilm development [100]. The mechanistic characteristics incorporated sustained sub-MIC concentrations during the biofilm interface, which hindered quorum sensing and reduced biofilm maturation while enhancing cellular membrane permeability (changes in its physiochemistry during the temporal interface with the biofilm matrix) [101,102]. Future development of regional electrochemical delivery platforms should also consider pharmacokinetics: identifying interactions between biomaterials and biofilms, advancing the application of desired research objectives, and assessing compatibility with implants to improve biofilm eradication efficacy while reducing systemic toxicity. In vivo animal models Today, the in vivo evaluation of local drug concentrations still represents a significant challenge in obtaining reliable data. Only a few studies provide quantitative results on in vivo antibiotic release. Some of these studies rely on direct measurements of local elution [40,47,52], while others perform indirect measurements of systemic concentration of antibiotics embedded in surgically introduced implants [43,50,51]. Ingeoglu et al. [40] performed a study in which a total of 24 rabbits underwent joint arthroplasty with the implantation of a novel micro-composite cement. The in vivo experimental results showed that the micro-composite implants delivered significantly higher concentrations of vancomycin to the bone (70% of the drug payload), maintaining these higher concentrations for up to two weeks. Foster et al. [52] performed post-implantation systematic local serum extractions to measure local antibiotic concentrations. It was found that hydrogels loaded with gentamicin or vancomycin delivered 10-100 times higher local antibiotic concentrations compared to PMMA-based implants during the initial release stage, which lasted 2-3 days. Afterward, the levels became comparable, indicating a faster initial release from the hydrogel. Yan et al. [47] investigated the Continuous Wave Ultrasound (CWU)-aided vancomycin release. CWU significantly enhanced the elution of vancomycin from ALBC by 2.57-27.44% compared to controls. Both ultrasonic intensity and vancomycin loading played significant roles in increasing cumulative drug elution over 10.5 h. Additionally, in the in vivo rabbit model, CWU raised the local maximum concentration of vancomycin by 47,600 μg/mL and boosted urinary elimination of the drug by 109,560 μg (Fluorescence Polarization Immunoassay (FPIA)) compared to the control group. Heffernan et al. [51] examined dose escalation using Poly(N-isopropylacrylamide-co-Dimethyl-γ-butyrolactone acrylate-co-Jeffamine M − 1000 acrylamide) (PNDJ) gel containing 3% tobramycin and 2% vancomycin, finding that serum tobramycin concentrations remained above 5 μg/mL at 24 h and 1 μg/mL at 48 h, while vancomycin levels were disproportionately lower. Yang et al. [43] demonstrated that chlorhexidine-loaded Cemex (Liquid Chromatography-tandem Mass Spectrometry (LC-MS)/Mass Spectrometry (MS) confirmed) maintained elevated systemic and local concentrations for at least 14 days. Systemic gentamicin concentrations were monitored by Ter Boo [50] for over a week. At 3 h of post-administration, the systemic concentration of gentamicin was 2.3 μg/mL for Collagen Gen (a collagen fleece loaded with gentamicin). However, after 24 h, no detectable gentamicin levels were found in plasma for either type of ALBC, suggesting a rapid decline in systemic gentamicin concentrations after administration. In vivo clinical trials PMMA-carriers Research into antibiotic-eluting bone cements provides important insights into the drug release mechanisms and the factors influencing their efficacy. Numerous investigations [61,64,65,78,84,103,104] demonstrate a common release pattern in which antibiotics such as gentamicin, vancomycin, and meropenem exhibit an initial burst within the first 24 h, followed by a slower, sustained elution phase. This rapid release ensures high local concentrations of antibiotics, which is crucial for early infection control, while the sustained release provides prolonged therapeutic effects. Hsieh et al. [105] detected high levels of antibiotics in joint fluid immediately after implantation, with concentrations decreasing over time but remaining above therapeutic levels for several months. The release of antibiotics followed a predictable pattern, with high initial concentrations that gradually declined, ensuring sustained local antibiotic activity. Beads generally outperform spacers in terms of elution characteristics due to their larger surface area, as observed in Refs. [59,76,103], where beads release significantly higher amounts of antibiotics over extended periods. Borick et al. [81] showed that tobramycin-impregnated beads sustained high concentrations over 28 days, with therapeutic levels persisting for more than 90 days, further highlighting the advantages of bead formulations for prolonged antibiotic delivery. Despite the initial burst, studies [64,65,77] report that gentamicin and vancomycin maintain therapeutic concentrations for several weeks or even months. Kendoff et al. [65] described this release pattern as ‘flip-flop kinetics,’ reflecting the slow absorption rates into surrounding tissues and fluids. Similarly, Ammon et al. [83] noted that vancomycin elutes at high levels initially, but the concentration decreases over time, consistent with the observed flip-flop kinetics. Further, investigations such as [77,106,107] indicate that systemic absorption can persist for weeks after implantation, and measurable serum concentrations have been reported, particularly with higher loading doses, prolonged dwell times, and in patients with baseline renal vulnerability. Importantly, the absence of overt toxicity in small series should not be interpreted as universal safety; renal risk is conditional on antibiotic class (e.g., aminoglycosides vs vancomycin), total dose, elution intensity, host factors, and concomitant systemic therapy, and therefore requires monitoring and careful patient selection. Non-PMMA ceramic carriers (HA/CaP) Alternative materials, such as HA ceramic blocks, discussed by Sudo et al. [66], offer a more stable and prolonged release of antibiotics as reported by Bertazzoni et al. [80] and Kinder et al. [10]. Curtis et al. [108] highlighted that the use of aminoglycoside-impregnated bone cement allowed high local concentrations of antibiotics that exceed the minimum inhibitory concentration of pathogens, further emphasizing the therapeutic potential of optimized antibiotic-eluting materials. Factors such as cement mantle thickness and the method of antibiotic incorporation, whether manual or pre-mixed, can significantly impact both release kinetics and the mechanical integrity of the cement, as shown by van Jiperen [82]. This has direct implications for both drug delivery and the structural performance of the implant. The variation in elution profiles due to polymer matrix properties, as highlighted in Refs. [61,103,107], underscores the complexity of optimizing these cements. Balancing mechanical strength with effective, long-term antibiotic delivery remains a challenge, requiring careful consideration of cement composition, incorporation methods, and drug-eluting characteristics to maximize therapeutic outcomes. A schematic representation of the most representative consolidated or proposed solutions to enhance and fine-tune the drug release is reported in Fig. 3.Fig. 3Schematic representation of the most important consolidated or emerging strategies for improved and controlled drug release for PJI: antibiotic-loaded beads vs cement blocks, use of hydrogels as coating or composite material-based implants, mechanical pre-treatments, multiple drug combination.Fig. 3 Schematic representation of the most important consolidated or emerging strategies for improved and controlled drug release for PJI: antibiotic-loaded beads vs cement blocks, use of hydrogels as coating or composite material-based implants, mechanical pre-treatments, multiple drug combination. Biofilms create steep concentration gradients for antibiotic diffusion limiting penetration through the biofilm and initiating resistance mechanisms. Therefore, the levels of antibiotics need to be well above the MBEC (10-1000 times higher than MIC values) for a sufficient period of time to disturb the structural integrity of the biofilm and effectively kill the bacteria contained [109]. Core Pharmacokinetic–Pharmacodynamic rationale (C(t)–biofilm–MBEC): the clinical value of any local delivery platform is determined less by “release” per se and more by whether the local concentration–time profile C(t) achieves (i) sufficient penetration into biofilm microenvironments, and (ii) a coverage window above the MBEC, which is often one to three orders of magnitude higher than MIC. Accordingly, the relevant comparative question across PMMA spacers, beads, resorbable depots, and hydrogels is the duration and reproducibility of MBEC-level exposure at the implant–tissue interface, balanced against mechanical constraints and systemic leakage. In this framework, burst release is beneficial only if it contributes to rapid biofilm eradication without collapsing into prolonged sub-inhibitory tails that may promote persistence and resistance selection. A schematic representation of typical C(t) profiles for different carriers against MBEC requirements is presented in Fig. 4.Fig. 4Schematic representation of the kinetic profiles of the local concentration of eluted antibiotic for different matrix carriers.Fig. 4 Schematic representation of the kinetic profiles of the local concentration of eluted antibiotic for different matrix carriers. The drug release kinetics of antibiotic-loaded materials for periprosthetic joint infection exhibit a characteristic biphasic pattern, with an initial burst phase followed by a prolonged, sustained release. This profile has been consistently observed across in vitro, in vivo, and clinical studies, although variations arise depending on material composition, surface modifications, drug combinations, and incorporation methods. Advanced techniques such as ultrasound-assisted admixing, microbubble-mediated enhancement, and novel carriers such as hydrogels and ceramics have demonstrated superior elution efficiency and therapeutic potential. The interplay between mechanical integrity and optimized antibiotic delivery remains a pivotal point that defines the release behaviour. Antibiotic activity In vitro The use of commercially available drugs and cements ensures good antimicrobial performance due to the well-known properties of these components. Their efficacy is widely recognized by the clinician and scientific communities. Therefore, only relevant findings related to protocol variations and novel experimentations are highlighted in this review paper. Lin et al. [35] observed that vancomycin combined with ultrasound and microbubbles exhibited notably enhanced bactericidal activity against planktonic Staphylococcus aureus (S. aureus). This was evidenced by a significant reduction in colony-forming units and noticeable alterations in bacterial cell morphology, suggesting improved antibacterial efficacy. An extensive comparative study performed by Gasparini et al. [34] involving various aminoglycoside antibiotics concluded that tobramycin demonstrated the highest absolute and relative elution rates compared to gentamicin and amikacin, with no significant differences compared to streptomycin. Morrison et al. [33] investigated the addition of silver to gentamicin-impregnated PMMA as a potential antibiofilm strategy. However, the combination did not enhance efficacy against biofilm-associated Methicillin-Resistant Staphylococcus pseudintermedius (MRSP). SEM images confirmed biofilm formation on PMMA beads, with numerous staphylococci adherent to the beads and embedded within the extracellular polymeric matrix. Snir et al. [38] showed that the combination of linezolid with gentamicin significantly increased the Growth Inhibitory Time (GIT) of gentamicin against gram-negative bacteria such as Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae), both of which were resistant to linezolid alone. Similarly, Anagnostakos et al. [30] demonstrated that bi-antibiotic-impregnated hip spacers exhibited higher antibiotic release and bacteria growth inhibition in vitro compared to monoantibiotic-loaded spacers. This study recommended the use of gentamicin-vancomycin combinations for infections caused by S. epidermidis and MRSA and gentamicin-teicoplanin combinations for S. aureus and Enterococcus faecalis. Dual-antibiotic loading can be advantageous when it (i) broadens the spectrum, (ii) improves elution via altered matrix porosity/solubility interactions, and (iii) provides true pharmacodynamic synergy against biofilm-embedded organisms. However, combination strategies also require caution: prolonged low-level elution below bactericidal thresholds may increase the probability of tolerance and resistance enrichment, particularly when C(t) tails traverse the sub-inhibitory range for extended periods. Therefore, combination regimens should be interpreted through the C(t)–MBEC window (Fig. 3) and, where available, supported by endpoints that capture biofilm eradication rather than planktonic inhibition alone. Alt et al. [110] compared nano-silver embedded bone cement with gentamicin-loaded bone cement in terms of antimicrobial activity. It was demonstrated that nano-silver formulation completely inhibited the proliferation of Staphylococcus epidermidis EDCC 5245, Methicillin-Resistant Staphylococcus epidermidis (MRSE) EDCC 5130, and MRSA EDCC 5246, showing high antibacterial efficacy against these multidrug-resistant strains. In contrast, gentamicin-loaded cement failed to inhibit the proliferation of MRSE EDCC 5130 and MRSA EDCC 5246 due to the strains' high-level resistance to gentamicin. To address the recent updates in antibacterial methods in the treatment of PJI, an array of novel materials has been introduced. These include novel metal coatings, Antimicrobial Peptides (AMPs), chitosan-based materials, and nano-antibacterial delivery systems. The use of metals such as silver and zinc in coating implants creates a broad-spectrum antimicrobial effect; however, biocompatibility should be considered, as silver has been shown to have reduced osteoblast viability at higher concentrations [111]. Chitosan is an inherently biocompatible, naturally occurring biopolymer that has been used in combination with metal nanoparticles to achieve greater antibacterial efficacy as well as requisite cytocompatibility [112]. AMPs like the Synthetic, Cationic, α-Helical Antimicrobial Decapeptide (KSL) and the 23-Residue Cationic Antimicrobial Peptide (Dadapin-1) may be developing as ascending antibiotic-free techniques that target specific bacterial species without compromising host cell function [113]. Nano-antibacterials are increasing the surface area to volume ratio while dispensing required active ingredients as well as penetrating biofilms. Further, there are further capabilities for surface functionalization of these platforms. These findings suggest that while traditional antibiotics remain the general standard approach, the inclusion of novel materials such as nano-silver or combinations of antibiotics, or AMPs, may enhance treatment outcomes, particularly against resistant strains and biofilm-related infections. In vivo animal model The in vivo animal studies considered in this section provide evidence for the efficacy of various antibiotic-loaded materials in controlling bone infections, particularly osteomyelitis, while preventing bacterial colonization and biofilm formation. Quantitative methods, including bacterial counts, imaging techniques, and inflammation markers, were employed to assess the antibacterial effectiveness of these materials, thereby establishing their utility in treating complex bone infections. Several studies [37,41,43,48] demonstrated that ABVF and vancomycin-loaded PMMA spacers effectively reduced bacterial loads in animal models of osteomyelitis. For instance, Hasan et al. [48] proved that ABVF putty achieved a 3-log reduction in bacterial growth, indicating a strong antibacterial effect. Similarly, vancomycin-loaded PMMA spacers analysed by Carli et al. [41] eluted antibiotics for 144 h, killing 90% of Xen36 S. aureus at concentrations between 300 and 600 μg/mL (microdilution assay). These materials also prevented biofilm formation, with SEM imaging showing no bacterial colonies on treated spacers. Additionally, reductions in serum amyloid-A levels - a marker of inflammation - confirmed the efficacy of these treatments in reducing infection and related inflammatory complications. In other studies, gentamicin-loaded and chlorhexidine-loaded silica nanoparticles embedded in PMMA matrices [43], as well as gentamicin-loaded hyaluronic acid-based hydrogels [50,51] showed sustained antibacterial activity. Yang et al. [43] showed that bacterial counts significantly decreased after 14 days, with the antibacterial effect persisting up to 28 days, as demonstrated by micro-computed tomography (micro-CT), which revealed fewer bone lesions and voids compared to control groups. Similarly, Ter Boo [50] demonstrated that gentamicin-loaded hydrogels completely prevented bacterial colonization at the implant site, with bacteriological analysis confirming the absence of infection in treated animals. Heffernan et al. [51] proved that antimicrobial-loaded PNDJ hydrogels outperformed controls, with no infections observed in the treated animals. The CWU-aided approach of Yan et al. [47] showed that at day 30 post-implantation, rabbits treated with ultrasound showed significantly improved clinical outcomes versus controls (p < 0.05): while all control animals exhibited signs of chronic infection (malaise, pain on palpation, and pus in two cases), no clinical signs of infection were observed in two rabbits in the ultrasound group. Consistently, Enhanced Magnetic Resonance Imaging (EMRI) revealed a weaker femoral inflammatory signal and a smaller inflammatory area in the hip in the ultrasound group. Bacteriology and histology confirmed these findings, with chronic infection features and S. aureus growth in the control group (infection score 3–10; bacterial growth detected in six rabbits), whereas no bacterial growth was detected in ultrasound-treated rabbits, and two showed no inflammation; overall infection scores were significantly lower with ultrasound (p < 0.01). Innovative formulations such as Cu-TiO2-coated PMMA [114], minocycline- and rifampin-impregnated bioresorbable coatings [57], and PLGA nanofibers loaded with fusidic acid and rifampicin [58] also showed significant antibacterial effects. Mauerer et al. [114] showed that the Cu-TiO2 coating reduced infection rates from 90% to 41.7%, while gentamicin-PMMA chains further decreased infection rates to 33.3%. Planet et al. [57] proved that minocycline- and rifampin-loaded coatings significantly reduced bacterial biofilm formation on K-wires, as confirmed by SEM, which showed fewer bacterial colonies. Gilchrist et al. [58] demonstrated that PLGA nanofibers reduced bacterial colonization on titanium implants by 99.9% after seven days, further underscoring their antibacterial efficacy. Enzyme-enhanced antibiotic treatments, such as the serratiopeptidase and antibiotic combination in a study made by Mecikoglu et al. [54], demonstrated even greater bacterial reduction. Microbiological testing revealed that infection persisted in only 5.6% of animals in the serratiopeptidase-and-antibiotic group, compared to 37.5% in the antibiotic-only group and 63.2% in the no-treatment group, confirming the enzyme's role in enhancing bacterial clearance. Quantitative analyses consistently showed lower bacterial loads, reduced inflammation, and improved bone healing in treated groups compared to controls. Boot et al. [56] loaded hydrogel coatings with 2% and 5% vancomycin, which significantly decreased CFU. In addition, the 5% vancomycin group showed the lowest bacterial counts, supporting the strong antibacterial effect. However, some models noted that local antibiotic treatments alone were insufficient to completely eradicate infections without the addition of systemic antibiotics. In summary, the reported studies demonstrated that antibiotic-loaded biomaterials, including PMMA spacers, hydrogels, nanoparticle composites, and enzyme-enhanced formulations, were, in most cases, effective in reducing bacterial loads, preventing biofilm formation, and promoting bone healing. In vivo – clinical trials Surgical strategy: one-stage vs two-stage revision Clinical evidence on ALBCs and spacers predominantly arises from two-stage revision arthroplasty protocols, where infected prostheses are explanted, debridement is performed, and temporary antibiotic-loaded spacers are implanted prior to reimplantation. Studies employing vancomycin–gentamicin-loaded PMMA spacers [59,60,63,80] consistently demonstrate infection control rates exceeding 85–95% at follow-up durations ranging from 12 to 60 months. One-stage revisions, though less common, have reported comparable infection eradication in select patient cohorts with susceptible organisms and limited biofilm formation. In such cases, the use of high-dose ALBCs during reimplantation, combined with systemic antibiotic therapy, achieved eradication rates near 90% [61,106]. Debridement, Antibiotics, and Implant Retention strategies (DAIR) are less represented in this literature but have been applied for acute infections where biofilm is immature. The use of local antimicrobial carriers in debridement, antibiotics, and implant retention DAIR procedures marks an important advancement in clinical practice. Unlike two-stage revisions, where the main objective is to maintain joint space and ensure systemic elution of medication, the goal of DAIR is to eliminate early-stage biofilms that form on retained hardware. A major challenge in improving the success rates of DAIR procedures is the current ineffectiveness of standard PMMA carriers. These carriers often fail to deliver the sustained high concentrations needed to effectively penetrate established biofilms. Studies made by Ammon et al. and Ma et al. [83,115] indicate partial success, though recurrence rates are higher (up to 25–30%), particularly in methicillin-resistant staphylococcal infections. Removal and staged reconstruction remain the preferred method for chronic PJI due to the mature biofilm's resistance to antibiotics. Systemic antibiotic co-therapy Most studies report the concurrent use of systemic antibiotics for 4–12 weeks postoperatively, guided by microbiological results. The combination of local and systemic therapy enhances bactericidal activity and reduces recurrence. Typical regimens included intravenous vancomycin or cefazolin for Gram-positive coverage and gentamicin, tobramycin, or ceftazidime for Gram-negative pathogens [63,102,104]. Where multi-drug resistance was suspected, linezolid or daptomycin were incorporated, though data remain limited. Combined local and systemic delivery ensured local concentrations above the MIC while maintaining safe systemic levels. Key outcomes Infection eradication rates across ALBC studies typically ranged from 85 to 96%, with reinfection rates between 5 and 15% during follow-ups from 6 months to 5 years [63,81,104]. Reoperation rates were highest among DAIR and one-stage cases involving resistant bacteria. Complications were mostly mechanical (spacer fracture, loosening) or biological (delayed wound healing). Few studies noted nephrotoxicity when aminoglycoside levels were closely monitored. Explanted spacers in the investigation of Griffin et al. [116] showed no biofilm presence, while Ma et al. [115] identified persistent bacterial cells embedded within the biofilm matrix, emphasizing variability related to pathogen type and biofilm maturity. Across clinical trials, two-stage revision with antibiotic-loaded spacers remains the gold standard for chronic PJI management, ensuring high rates of infection control and implant survival. One-stage and implant-retaining procedures may be appropriate in early or low-virulence infections but require precise pathogen identification and systemic co-therapy to prevent recurrence. The integration of traditional and novel antibiotic strategies across in vitro, in vivo animal, and clinical studies demonstrates consistent progress in combating PJI. In vitro findings confirm that antibiotic combinations and advanced materials such as nano-silver and enzyme-enhanced systems significantly enhance bactericidal activity, especially against resistant and biofilm-forming pathogens. Clinical data further validate the efficacy of dual-antibiotic-loaded bone cements, particularly vancomycin-gentamicin formulations highlighting their broad-spectrum activity and sustained release profiles. However, persistent challenges, such as biofilm tolerance and reinfections by resistant strains, underscore the need for a combination approach involving both local and systemic therapies. In vivo – clinical trials: antibiotic-resistant strains in PJI Surgical strategy Management of resistant infections, particularly MRSA and MDR Gram-negative PJIs, generally necessitates two-stage revision and complete implant removal. Clinical registry data demonstrate that gentamicin-loaded cements, when used repeatedly in revisions, are associated with an increased incidence (up to 8 × ) of gentamicin-resistant isolates [117]. For MRSA, one-stage retention procedures have shown limited success due to high biofilm tolerance, with concentrations required for eradication often 10–1000 × the MIC (MBEC range) [118]. Consequently, two-stage exchange combined with systemic therapy remains standard for these cases. Systemic antibiotic co-therapy Resistant strain management typically integrates long-term systemic therapy—commonly intravenous vancomycin, linezolid, or daptomycin for Gram-positive organisms, and carbapenems or colistin for resistant Gram-negatives. Maintaining drug exposure above both MIC and the Mutant Prevention Concentration (MPC) is crucial to avoid the “mutant selection window” [119,120]. Combination regimens (e.g., vancomycin plus rifampicin) have shown synergy against biofilm-embedded MRSA, although systemic toxicity risk necessitates individualized dosing strategies. Key outcomes Clinical series report infection eradication rates between 70 and 90% for resistant PJI treated with two-stage protocols, though recurrence is more common in polymicrobial or immunocompromised patients. Follow-up durations of 12–48 months reveal that late recurrence typically correlates with subtherapeutic elution from PMMA spacers or inadequate systemic exposure. Complications include renal impairment from aminoglycosides and delayed wound healing, but are generally reversible with early intervention. Infections caused by resistant pathogens demand aggressive surgical and pharmacological management. Two-stage exchange and combination antibiotic therapy remain essential to overcome biofilm tolerance and prevent resistance amplification. Future strategies should aim to optimize elution kinetics and sustain bactericidal concentrations above MBEC thresholds. A schematic representation of the most representative strategies against biofilm formation and planktonic bacteria is represented in Fig. 5.Fig. 5Schematic representation of the most representative consolidated or emerging strategies against 1) biofilm formation: materials alternative to PMMA (PLGA, mesoporous silica, calcium phosphate cements), surface functionalization (polypeptides, enzymes). 2) planktonic bacteria: broad-spectrum antibiotics, multiple drug combinations.Fig. 5 Schematic representation of the most representative consolidated or emerging strategies against 1) biofilm formation: materials alternative to PMMA (PLGA, mesoporous silica, calcium phosphate cements), surface functionalization (polypeptides, enzymes). 2) planktonic bacteria: broad-spectrum antibiotics, multiple drug combinations. Section III: Implantation and after explantation follow-up. Local and systemic antibiotic levels, cytotoxicity and nephrotoxicity In vitro Demineralized bone matrix was used as a carrier for gentamicin-loaded cement by Lewis et al. [39]. The study found that the incorporation of gentamicin into the DBM did not negatively impact the attachment, proliferation, or alkaline phosphatase activity of osteoblasts. These findings are significant as they suggest that the antibiotic does not compromise the osteoconductive properties of the DBM, which is critical for bone regeneration and healing. The osteoblasts, essential for bone formation, maintained their functional capacity despite the presence of the antibiotic, ensuring that the DBM retained its potential to support new bone growth while simultaneously providing localized infection control. Furthermore, the study highlights the potential of DBM as a dual-function material—acting both as an osteoconductive scaffold and a localized drug delivery system. This could be especially beneficial in the treatment of bone infections such as osteomyelitis, where both bone regeneration and infection management are critical. In vivo animal model The in vivo animal studies explored in the literature reveal varying outcomes concerning the biocompatibility of different antibiotic-loaded materials and treatments, particularly with respect to systemic toxicity and inflammatory responses. Multiple studies [37,47,48,52,114] highlighted the absence of significant nephrotoxicity, with markers of renal function, such as serum creatinine levels, remaining within normal ranges after the local delivery of antibiotics via materials like vancomycin-soaked PRO OSTEON 500R putty, ABVF putty, and hydrogels. Similarly, authors [43,49,56] reported minimal inflammatory responses or fibrous encapsulation, suggesting that hydrogel and nanocomposite materials show no adverse effects on tissues and the immune system. In studies [41,50] and [58], systemic health indicators, including body weight monitoring and inflammatory markers such as C-Reactive Protein (CRP) and serum amyloid-A, showed that antibiotic-loaded materials did not induce prolonged systemic inflammation, reinforcing their suitability for long-term application. These studies also noted reductions in infection severity and systemic inflammation without evidence of chronic toxicity. Furthermore, Matsuno et al. [53] and Boot et al. [56] demonstrated that gentamicin-containing hyaluronic acid gels and hydrogels were well tolerated in animal models, with no evidence of chronic toxicity or adverse haematological responses over extended observation periods. However, some studies revealed potential localized adverse effects. For instance, while no systemic side effects were observed by Mecikoglu et al. [54], serratiopeptidase caused localized cartilage erosion and fibrous tissue formation, raising concerns about its suitability for joint treatments. Similarly, Heffernan et al. [51] reported transient hepatotoxicity and mild tubular injury in renal tissues, consistent with aminoglycoside toxicity, though these effects were reversible and did not result in long-term damage. In contrast, Mauerer et al. [114] and Gilchrist et al. [58] confirmed that other treatments, such as Cu-TiO2 coatings and PLGA nanofibers, did not cause significant liver or kidney impairment, as blood tests remained within normal ranges and inflammatory responses were minimal. Across animal and clinical evidence, local antibiotic delivery is frequently reported as clinically tolerable, but safety cannot be stated in absolute terms. Systemic exposure and adverse events depend on drug class and combinations (vancomycin and aminoglycosides being the most relevant for renal risk), total loading dose, carrier type and surface area (beads vs spacers vs coatings), dwell time, baseline renal function, and co-administered systemic antibiotics. While multiple studies report stable renal indices, Acute Kidney Injury (AKI) cases and detectable systemic levels have also been described, particularly under high-dose or prolonged exposure scenarios [81,107,108,121,122]. Therefore, the evidence supports a conditional safety statement: local delivery can reduce systemic dosing requirements and improve local exposure, but it requires standardized dosing guidance, renal monitoring, and clearer thresholds that account for patient risk stratification and carrier-specific pharmacokinetics. In vivo clinical trials Surgical strategy Clinical evaluation of toxicity and systemic antibiotic levels has been most extensively documented in two-stage revision procedures using antibiotic-loaded spacers. ALBCs (vancomycin, gentamicin, or tobramycin) implanted temporarily during infection eradication consistently produced high local concentrations while keeping systemic levels below toxicity thresholds [59,63,65,106]. Implant retention or one-stage revisions carry a slightly higher risk of systemic absorption due to prolonged exposure of vascularized tissue to cement interfaces. Removal of spacers in the second stage generally prevents cumulative toxicity. Systemic antibiotic co-therapy Systemic co-therapy durations varied between 2 and 12 weeks, depending on pathogen sensitivity and renal function. Vancomycin or cefazolin were standard for Gram-positive infections, while tobramycin, amikacin, or ceftazidime were used for Gram-negatives. Several studies highlighted the need for renal monitoring during aminoglycoside therapy, particularly in elderly or pre-renal impairment patients [81,121,123]. Key outcomes Most studies confirmed that systemic levels of gentamicin or vancomycin following ALBC implantation remained below nephrotoxic thresholds, and no sustained renal or hepatic impairment occurred in more than 90% of patients [61,77,80,104]. Isolated cases of acute kidney injury (AKI) have been reported, [81,121,123], predominantly in patients with pre-existing renal compromise or high-dose aminoglycoside spacers. Follow-up durations of 12–60 months confirmed no late systemic sequelae in the majority of cohorts. Complications were mainly transient (mild AKI, reversible hepatotoxicity), with no correlation between antibiotic dose and permanent organ damage when appropriate monitoring was implemented. Summary In clinical settings, antibiotic-loaded spacers demonstrate a strong safety profile when used in staged revisions. Systemic co-therapy should be adjusted according to renal reserve and infection complexity to prevent toxicity. Long-term outcomes indicate that controlled local delivery can achieve infection eradication while minimizing systemic side effects. In vivo clinical trials. Beyond nephrotoxicity: hepatotoxic and gastrointestinal toxicities In addition to nephrotoxicity, antibiotics can induce clinically significant hepatotoxic and Gastrointestinal (GI) toxicities, which merit consideration in implant-related antibacterial strategies. Hepatotoxicity from antibiotics is often idiosyncratic but can occur with several commonly prescribed antibiotics like β-lactams (e.g., amoxicillin-clavulanate), macrolides, tetracyclines, and sulfonamides. Trimethoprim-Sulfamethoxazole (TMP-SMX) has been shown to result in acute liver injury, causing jaundice, elevated hepatocellular enzymes, or hepatic failure in both adults and children [121]. The risk of liver injury can increase with duration of therapy, co-prescriptions, or pre-existing hepatic steatosis because prolonged use of antibiotics can worsen metabolic liver disorders like Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) [122]. GI toxicity is more frequent (but may not always be clinically or symptomatically significant) and has clear manifestations including, nausea, vomiting, diarrhea, and mucosal inflammation with steatosis/colitis as a common method of antibiotic toxicity, mainly due to the dysbiosis of gut microbiota. For example, clindamycin, cephalosporins, and fluoroquinolones are associated with Clostridioides difficile-associated diarrhea, which can lead to pseudomembranous colitis. Other experimental models of antibiotic-associated GI toxicity also demonstrate that targeted agents such as vancomycin may also impact commensal gut flora outside their anticipated spectrums [124]. Recent advances in the research of antibiotic-induced GI toxicity using intestinal organoid models suggest that systemic GI toxicity may not solely be the result of gut dysbiosis, but also benefit from altered serotonin signalling, which regulates intestinal motility and secretion. For instance, in addition to microbial dysbiosis, some tyrosine kinase inhibitors and other pharmaceuticals inhibit serotonin reuptake transporters, resulting in GI distress [125]. Taking into consideration the cumulative burden of hepatic and GI toxicity, and especially to pharmacologically complex or vulnerable patients the strategy of antibacterial implants should be identified in developed designs (e.g., implantable controlled-delivery countermeasures) to limit exposure to systemic antibiotics, thus minimizing drug (off-target) organ toxicity. A schematic representation of local and systemic concentrations (levels) of antibiotics at different after-implantation stages is represented in Fig. 6.Fig. 6Schematic representation of local and systemic concentrations (levels) of antibiotics at different after-implantation stages and possible toxic side effects. Aside from local cytotoxicity, acute kidney failure represents the most severe effect.Fig. 6 Schematic representation of local and systemic concentrations (levels) of antibiotics at different after-implantation stages and possible toxic side effects. Aside from local cytotoxicity, acute kidney failure represents the most severe effect. Implants Biodegradability - osseointegration – bone volume analysis In vivo animal model The in vivo animal studies demonstrate the effectiveness of various biomaterials in promoting bone healing, osseointegration, and tissue regeneration while also managing infection and minimizing inflammation. These studies examine how advanced materials such as ABVF putty, PMMA spacers, and hydrogels enhance tissue repair in orthopaedic applications. Hasan et al. [37,48] and Jones et al. [49] showed that Micro-Computed Tomography (μ-CT) imaging and histological evaluations revealed that ABVF putty significantly increased bone volume and promoted osseointegration. Treatment groups showed healed bone with cortical bridging and new bone growth, whereas control groups experienced persistent infection and fibrous tissue development, underscoring the putty's ability to support bone healing and eliminate infection. Moreover, Jones et al. [49] reported active mineralization and osteoblast activity without signs of inflammation or fibrous encapsulation. The material's ability to degrade over time, supporting the new bone formation, further highlights its biocompatibility and effectiveness in orthopaedic use, as depicted in Fig. 7.Fig. 7(a) The μ-CT images of the drill-hole rat control group demonstrated signs of osteomyelitis through signs of infection, decreased bone formation, and formation of the sinus tract. Infection seemed to have spread to the posterior of the bone. (b) The drill-hole treatment group showed no signs of osteomyelitis, and the bone appeared to be healed with new bone formation and cortical bone bridging. Bone seemed to be undergoing remodeling. (c) The μ-CT images of K-wire rat control group demonstrated signs of osteomyelitis through signs of infection, decreased bone formation and formation of sinus tract. (d) The K-wire treatment group showed no signs of osteomyelitis and the bone appeared to be healed with new bone formation. Bone seemed to be undergoing remodeling. Reproduced from Ref. [32] under the Common Creative Licence.Fig. 7 (a) The μ-CT images of the drill-hole rat control group demonstrated signs of osteomyelitis through signs of infection, decreased bone formation, and formation of the sinus tract. Infection seemed to have spread to the posterior of the bone. (b) The drill-hole treatment group showed no signs of osteomyelitis, and the bone appeared to be healed with new bone formation and cortical bone bridging. Bone seemed to be undergoing remodeling. (c) The μ-CT images of K-wire rat control group demonstrated signs of osteomyelitis through signs of infection, decreased bone formation and formation of sinus tract. (d) The K-wire treatment group showed no signs of osteomyelitis and the bone appeared to be healed with new bone formation. Bone seemed to be undergoing remodeling. Reproduced from Ref. [32] under the Common Creative Licence. Similarly, Matsuno et al. [53] and Boot et al. [56] focused on titanium implants coated with hydrogel or HA gel. Both μ-CT and histological analyses confirmed that these coatings did not negatively impact bone growth around the implants. There was no significant inflammatory reaction, and the HA gel was completely resorbed over a 12-week period. These findings suggest that hydrogels and HA gels are effective for use in orthopaedic implants, promoting osseointegration without causing adverse tissue reactions. The μ-CT micrographs are reported in Fig. 8.Fig. 8Infection effect on bone architecture and bone-implant contact. (a) Overview of representative 3D μCT images of the left tibia showing the destruction of the cortex (red arrows) and visual growth of periosteal bone (blue stars). The titanium rod is removed from the images, allowing for visualisation of the bone on the implant surface. The anterior tibia was removed for bacteriology and is missing from these images. (b) Regions of Interest (ROIs) were generated to enable measuring the bone-implant contact. The implant was detected by global thresholding and defined ROI1 (inner yellow circle 1). ROI1 was radially expanded by 2 pixels, which resulted in ROI2 (middle yellow circle, 2). Then, ROI2 was enlarged by 3 pixels (outer yellow circle, 3). The enlarged region was defined as ROI3 and represented the region of bone-implant contact. (c) Percentages of bone-implant contact measured at the implant surface. The symbol “∗” indicates a significant difference when compared to the Gel group (p < 0.05). Reproduced from Ref. [50] under the Common Creative Licence.Fig. 8 Infection effect on bone architecture and bone-implant contact. (a) Overview of representative 3D μCT images of the left tibia showing the destruction of the cortex (red arrows) and visual growth of periosteal bone (blue stars). The titanium rod is removed from the images, allowing for visualisation of the bone on the implant surface. The anterior tibia was removed for bacteriology and is missing from these images. (b) Regions of Interest (ROIs) were generated to enable measuring the bone-implant contact. The implant was detected by global thresholding and defined ROI1 (inner yellow circle 1). ROI1 was radially expanded by 2 pixels, which resulted in ROI2 (middle yellow circle, 2). Then, ROI2 was enlarged by 3 pixels (outer yellow circle, 3). The enlarged region was defined as ROI3 and represented the region of bone-implant contact. (c) Percentages of bone-implant contact measured at the implant surface. The symbol “∗” indicates a significant difference when compared to the Gel group (p < 0.05). Reproduced from Ref. [50] under the Common Creative Licence. Studies on PMMA and its modifications further highlighted the safety and efficacy of bone cements in orthopaedic treatments. Carli et al. [41] and Foster et al. [52] showed that PMMA spacers preserved tissue structure and prevented further damage in the treated animals, while control groups displayed severe osteomyelitis, bone destruction, and distorted soft-tissue planes. Niska et al. [126] used X-ray imaging and histologic analysis to assess bone changes, indicating that the vancomycin-rifampin combination therapy was effective in preserving bone structure compared to vancomycin alone, further supporting the benefits of combination antibiotic therapy in orthopaedic applications. A modified version of PMMA, PMMA bone cement loaded with Hydroxypropyltrimethyl Ammonium Chloride Chitosan (HACC), was studied by Tan et al. [45], showing superior osseointegration and enhanced new bone formation compared to other variants of the material. Fluorescence labelling confirmed significant new bone growth, while SEM analysis at the bone-cement interface revealed minimal local toxicity, indicating good biocompatibility. Furthermore, Yang et al. [43] and Ter Boo et al. [50] investigated cement and collagen-based scaffolds, which facilitated the formation of organized fibrocartilage and collagen fibers, crucial for endochondral ossification and bone regeneration. Histological analysis showed a physiological response at the implant interface, with early signs of muscle regeneration and no significant inflammatory response. In vivo clinical trials Unfortunately, none of the reviewed papers reporting clinical cases of antibiotic-loaded spacers used in single- or two-stage revision procedures provide data regarding implant biodegradability, osseointegration, or bone volume analysis. The vast majority of implants used in clinical arthroplasty today are made of acrylic cements, particularly PMMA, which is the first generation of biomaterials. This class of materials is favoured due to its well-established mechanical properties and stability. In conclusion, preclinical in vivo studies demonstrate promising outcomes with emerging biodegradable materials such as ABVF putty, hydrogel/HA-coated titanium implants, and modified PMMA formulations. These materials show enhanced osseointegration, bone regeneration, and infection control, with minimal inflammatory responses. The μ-CT and histological analyses consistently reveal increased bone volume and integration, underscoring their potential in orthopaedic applications. However, current clinical practices predominantly rely on non-resorbable PMMA spacers, which lack osteoinductivity and integration capacity, posing limitations for long-term use. This translational lack underlines the urgent need for clinical validation of next-generation biomaterials that combine antimicrobial efficacy with biodegradability and regenerative capabilities. In vivo clinical trials: a step away from clinical translation Despite promising preclinical outcomes, the clinical translation of degradable antibiotic-loaded materials such as hydrogels, surface coatings, and bioceramics faces persistent challenges that limit their routine integration into orthopaedic practice. Hydrogels have promising release kinetics and mechanical properties that could mimic tissue; however, the often low levels of strength and emerging evidence that hydrogels rapidly degrade in physiologically loaded scenarios (especially for weight-bearing) have limited their construct and clinical application [[127], [128], [129]]. The method of sterilization for hydrogels is usually via gamma-irradiation, which could deform the shape of the hydrogel and stability of the drugs. Furthermore, gamma-irradiation and hydrogel sterilization require manual controls and inventoried storage that complicate clinical practice [130]. Surface coatings (such as antibiotic-loaded dip or plasma-sprayed layers) will have limited and specific antimicrobial activity following medical device implantation; additionally, there are studies that show surface coatings had limited physical adhesion on titanium or stainless steel implant substrates, and only under shear or abraded applications, especially during implantation. Moreover, regulatory bodies would demand extensive validation on coating material uniformity, elution kinetics, and delamination, which would typically require multiple implants in expensive long-term in vivo clinical studies that few manufacturers would invest in Ref. [131]. Bioceramics, such as calcium phosphates or HA-based ceramics with bioactive and osteoconductive properties, are limited as a practical route due to constraints in mechanical strength, erratic degradation, and loading efficiency (if it is lower than 10% for any biological target previously established in bone), production, development, and monitoring of delivery methods [132,133]. A major hurdle is regulatory ambiguity, especially for combination products that integrate biomaterials and pharmacological agents. These are often subject to dual or conflicting regulatory oversight, complicating approval timelines and increasing development costs. Furthermore, preclinical models often do not replicate the multifactorial mechanical, microbial, and immunological environments presented in the orthopaedic setting in humans, thus limiting the translational potential of efficacy and safety data [130,134]. The manufacturing issue is also nontrivial when considering scalability. For example, someone considering electrospun scaffolds or wet polymer precipitation will need significant infrastructure to ensure that they maintain batch-to-batch consistency and standardization, particularly when considering non-dimensional systems approaching nanofibers or microparticles [135]. Cost remains a barrier as well. Most of these biomaterials are relatively expensive to produce, and there is little clarity about whether reimbursement mechanisms will be available for these products. As a result, unless companies can demonstrate a clear advantage over current standards, it is challenging to secure investment or gain buy-in from hospitals. Additionally, for biodegradable devices, post-market surveillance guidelines are still developing, which increases liability concerns and hesitancy among surgeons to try new devices. As such, while research and scientific advancement in antibiotic delivery are proliferating, true translational advances will require collaboration among regulators to consolidate guidance, industry players to improve scale, and stakeholders to align health economics drivers with needs [136,137]. Fig. 9 shows a proposed decisional diagram outlining the flowchart for preparing adequate implants for PJI management, starting with the clinical stage of infection, and ending with manufacturing and regulatory readiness.Fig. 9Proposed decisional scheme (for material scientists and surgeons) based on a based on an overall consideration on infection control, mechanical support, biodegradability, osteoconductivity, and host safety profile.Fig. 9 Proposed decisional scheme (for material scientists and surgeons) based on a based on an overall consideration on infection control, mechanical support, biodegradability, osteoconductivity, and host safety profile. Clinical safety thresholds and monitoring implications High-quality observational data (Kang et al.122], Ma et al. [113]) showed that safety is not completely guaranteed, especially in the case of the vulnerable population. Regarding the high-risk patient profile, the clinical caution process is compulsory when high-dose-antibiotic-loaded bone cement is used for the following patient categories: pre-existing renal insufficiency - patients with a baseline Estimated Glomerular Filtration Rate (eGFR) lower than 60 mL/min/1.73 m2 are at a significantly higher risk for AKI after spacer implantation; synergistic nephrotoxicity - this risk occurs when local vancomycin or aminoglycosides are combined with systemic therapies such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Angiotensin-Converting Enzyme (ACE) inhibitors, and diuretics; old age and low Body Mass Index (BMI) - these factors often correlate with reduced volume of distribution and declining clearance rates. Based on the studies by Edelstein et al. [107] and Kendoff et al. [65], the following monitoring framework is proposed for the above-mentioned high-risk groups. Firstly, the serum trough levels should be monitored within 24-48 h for patients who are treated with a quantity of vancomycin or aminoglycosides higher than 4g in the spacer, especially if systemic therapy is initiated. Secondly, serial renal function tests must be applied, so as a consequence, daily serum creatinine and electrolyte monitoring for the first 72 h is mandatory (Janssen et al. [76]). And last but not least, the local drainage management must be correlated, because it is well known that rapid drainage of joint fluid may decrease local concentrations, but also potentially alter the systemic absorption profile. To end this discussion, it is worth mentioning that the “inefficiency” of the standard PMMA cement, characterized by high-dose drug loading to overcome poor elution, is one of the most important phenomena in this safety concern framework. Nano-engineered delivery systems (Ashbaugh et al. [141]) offer a “safety-by-design” approach, utilizing highly efficient release mechanisms that achieve therapeutic efficacy with a lower total drug mass, thereby inherently reducing the systemic burden for high-risk patients. To offer a clear view for surgical teams and clinicians, we have developed a clinical-use table (Table 3) with devoted attention to actionable clinical takeaways, risk-stratification for high-risk groups, and monitoring implications. The cumulative evidence from studies presented in Table 1 indicates a consistent performance gap in current PMMA-based delivery. Whether measured by mechanical degradation, temporal decay, spatial limitation, or chemical sequestration, the “inefficiency” of the gold standard is statistically and clinically evident. This robust evidence base justifies the exploration of the nano-engineered alternatives. Table S2 in the supplementary file provides an extensive audit of the key studies presented in the paper.Table 3Clinical-use summary table.Table 3Patient Risk ProfileIntervention StrategyMonitoring RequirementClinical RationaleLow risk (normal renal function, <65 years)Standard ALBC spacers/beadsRoutine clinical follow-up; Standard inflammatory markers (C-Reactive Protein (CRP)/Erythrocyte Sedimentation Rate (ESR)).High safety margin; peak elution typically remains sub-toxic (Kendof et al. [65]).High risk (eGFR <60 mL/min/1.73m2, old age, BMI <20)Optimized low-dose spacers/nano-carriers24-48h serum troughs; Daily Creatinine for 72h.Risk of AKI is compounded by burst elution (Edelstein et al. [107]).Complex infection (biofilm/Gram-Negative)High-surface area carriers (beads/nanofibers)Extended serum monitoring; eGFR surveillance.Maximizes surface-area elution to overcome high MICs (Anagnostakos et al. [30]).Long-term managementsurface-modified implants/porous implantsBaseline renal/hepatic profile; Long-term radiographic stability.Addresses the “72-h decay” by providing sustained, low-level release. Table 3Clinical-use summary table.Table 3Patient Risk ProfileIntervention StrategyMonitoring RequirementClinical RationaleLow risk (normal renal function, <65 years)Standard ALBC spacers/beadsRoutine clinical follow-up; Standard inflammatory markers (C-Reactive Protein (CRP)/Erythrocyte Sedimentation Rate (ESR)).High safety margin; peak elution typically remains sub-toxic (Kendof et al. [65]).High risk (eGFR <60 mL/min/1.73m2, old age, BMI <20)Optimized low-dose spacers/nano-carriers24-48h serum troughs; Daily Creatinine for 72h.Risk of AKI is compounded by burst elution (Edelstein et al. [107]).Complex infection (biofilm/Gram-Negative)High-surface area carriers (beads/nanofibers)Extended serum monitoring; eGFR surveillance.Maximizes surface-area elution to overcome high MICs (Anagnostakos et al. [30]).Long-term managementsurface-modified implants/porous implantsBaseline renal/hepatic profile; Long-term radiographic stability.Addresses the “72-h decay” by providing sustained, low-level release. Clinical-use summary table. Future perspectives An important equilibrium state between the therapeutic effect and biological safety highly influences the efficiency of the local antimicrobial agent delivery. The literature studies analysed in this review paper highlight the fact that although the local delivery process is an important tool in PJI management, it is always followed by some possible risks. The work of Kendoff et al. [65] and Regis et al. [63] showed that local drug concentration can be safely maintained below the systemic threshold in standard patient health states. On the other hand, a large retrospective analysis by Kang et al. [122] proved that the risk of important complications such as nephrotoxicity remains a multifactorial challenge as a function of patient-specific risk profile (preexisting renal disease) and cumulative dose-load resulting usually after the combination of local and systemic treatments. Additionally, the “inefficiency” of the most used in practice PMMA cements consists not only of their rapid elution decay but also of their lack of release control. So, as a direct consequence, an unpredictable systemic absorption phenomenon could occur for high-risk patients. A transition toward a ‘precision delivery’ process based on nano-engineered and bio-responsive carriers represents a future trend, in which the antimicrobial efficiency combined with minimal systemic effects is foreseen. Biofilm-targeting nanoplatforms integrating PLGA composites, exosome systems, and biofilm-penetrating antimicrobials such as engineered peptides and D-amino-acid derivatives represent a convergent and highly adaptable approach to PJI management. Methodologically, PLGA-based scaffolds offer remarkable control over degradation and release kinetics through tunable lactic: glycolic ratios, supporting sustained and programmable antibiotic delivery [138,139]. Their modular synthesis via emulsion evaporation, spray drying, or nanoprecipitation allows customization of size, porosity, and surface charge to optimize penetration within infected tissues. Recent developments have introduced core–shell PLGA nanocomposites embedding metal nanostructures (Ag, ZnO, Cu) and electrospun nanofiber coatings that enable multi-drug co-delivery and spatially resolved elution [[140], [141], [142]]. In parallel, exosome-based carriers combine natural biocompatibility with the ability to deliver genetic and protein cargoes across biological barriers. When immobilized on polymeric scaffolds such as Polylactic Acid (PLA) or Polyether Ether Ketone (PEEK), exosomes promote osteogenesis, angiogenesis, and immunomodulation, sustaining regenerative signalling at implant sites [[143], [144], [145]]. Despite these advances, major methodological limitations remain, particularly low drug loading efficiency (<1 %), burst release of hydrophilic agents, and a lack of standardized biofilm models, which hinder interstudy comparison and reproducibility [139,142]. From a clinical translation perspective, the safety of PLGA systems already FDA-approved for several parenteral products offers an encouraging foundation [146]. Early exosome-functionalized scaffolds have achieved over 65 % wound closure in large animal models, while engineered antimicrobial peptides such as Engineered Cationic Antimicrobial Peptide (PLG0206) and Synthetic Antimicrobial and Antibiofilm Peptide-148 (SAAP-148) have produced greater than 4-log10 bacterial reductions in chronic implant biofilms and demonstrated safety in early DAIR irrigation trials [[147], [148], [149]]. The incorporation of AMPs or D-amino acids into bone cement, calcium phosphate carriers, and polymer coatings has further reduced colonization and improved bacterial clearance in preclinical PJI models [[150], [151], [152]]. Nevertheless, translation remains constrained by proteolytic degradation, pharmacokinetic instability, and batch variability of biologic cargoes, as well as limited harmonization of manufacturing and potency assays for exosome therapeutics [153]. Comparative assessments reveal complementary strengths among these modalities. PLGA scaffolds ensure prolonged and localized release, while metal- or polyphenol-modified versions enhance antibiofilm and anti-inflammatory efficacy [[140], [141], [142]]. Exosomes, in contrast, excel at reprogramming the immune milieu, promoting M2 macrophage polarization and regulatory T-cell activation, thereby facilitating bone healing and mitigating chronic inflammation [[143], [144], [145]]. Engineered peptides extend this functional landscape: SAAP-148, 37-Amino Acid Cationic, Amphipathic Peptide (LL-37) analogues, and β-clamp-targeting AlkB homologue 2 PCNA-interacting motif (APIM) peptides eradicate persist within mature Staphylococcus biofilms, and PLG0206 displays rapid bactericidal action across Gram-positive and Gram-negative PJI pathogens [147,148,151,152,154]. The most promising outcomes arise from hybrid PLGA-exosome or peptide-polymer combinations, which achieve both antibacterial and osteoregenerative functions in infected bone models [148,151]. Despite growing evidence, critical research gaps impede full clinical translation. The mechanistic interface between PLGA nanoparticles and mature biofilm matrices remains poorly understood, as do their behaviors under physiological flow or in mucus-embedded infection sites [139]. Peptide stability, immune tolerance, and exosome heterogeneity complicate scalability and reproducibility, while chronic and multispecies PJI models that accurately reflect human infection dynamics are still lacking [150,153,155,156]. Addressing these issues through rational peptide engineering, standardized preclinical protocols, and integrated clinical trials combining local peptide delivery with conventional antibiotics will be essential for transforming these multifunctional biomaterials from promising prototypes into clinically validated anti-biofilm therapeutics for orthopaedic infections. Next-generation local antibacterial strategies for PJI are converging toward multifunctional platforms that combine (i) controllable degradation and osteoconductivity, (ii) delivery profiles designed to maximize the MBEC coverage window at the implant–tissue interface, and (iii) surface or payload designs that reduce biofilm resilience while supporting host repair. Among emerging directions, polymer–ceramic composites (e.g., PLGA-, PCL-, and calcium phosphate–based constructs), hydrogel-enabled delivery, and biofilm-penetrating agents (including engineered antimicrobial peptides) show promise, but translation remains limited by heterogeneous biofilm models, non-standardized release testing, and incomplete pharmacokinetic validation of local exposure in clinically relevant geometries. A practical priority is harmonization of test conditions (biofilm maturity, flow conditions, implant-relevant substrates) and reporting standards (drug loading, surface area, porosity, sampling strategy) to enable meaningful cross-study comparison. Conclusions In the frame of this review, research literature devoted to antibacterial strategies against PJI has been explored. The specific purpose of this meta-research was to focus on antibiotic-loaded cement-based solutions (spacers, blocks, beads, etc) used in single or two-stage revisions of joint arthroplasty. Different approaches have been adopted to contrast infections arising from joint arthroplasty surgical procedures. Though each author explored an almost unique way to cover direct or indirect aspects of PJI, some conclusions and similarities can be underlined. In vivo clinical trials, in vivo animal models, and in vitro experiments can constitute the three major macro-categories, where the novelty of proposed solutions decreases from the former to the latter. In vivo clinical trials on human patients make use of consolidated protocols that involve commercial products, such as cement spacers, blocks, or beads. Antibacterial agents employed in the analysed studies consist of routinely approved and used antibiotics. Cement-drug admixing conditions and the use of single or combined use of multiple antibiotics define the limited degree of novelty and experimentation in modern clinical trials. A wider window of options has been explored for in vivo animal models and in vitro assays. Biodegradable, osteoconductive materials that can release antibiotics over an extended period while maintaining mechanical stability have been applied to build cement matrices with improved features. Bioresorbable polymers, multifunctional nanocomposites, and antibacterial hybrid materials are all potential approaches to managing PJI. Mechanical performance remains a pivotal parameter to take into account, as the joints (constituted mainly by the terminal sides of the connected bones) are the main target of these implants. Along with antibacterial efficacy and mechanical performance, the review highlights other significant aspects as follows. Release kinetics, which is directly connected to infection control, due to the fact that local concentrations of antibiotics should respond to a tailored and personalized release curve, able to manage the infection risk in the early stage, mid-term, and long-term release after implantation. Antibiotic release should be sustained for the necessary therapeutic period and should be comprised of a range of toxicity levels and MIC. Local and systemic antibiotic levels and the way antibiotics interact with tissues and fluids during the early stages of implantation and with the systemic distribution within the animal or human body in the mid-term period, and the possibilities to be correctly elaborated and/or eliminated by kidney and urine. Several studies highlighted the possibilities for antibacterial agents to achieve toxic levels and provoke an inflammatory state or AKI in the most severe cases. On the other hand, some experimental papers proposed reliable solutions to manage and contrast the cyto- and nephrotoxicity. Lastly, the possibility of improved osseointegration has been explored in in vivo animal model papers. The principal condition to achieve integration between implanted devices and host tissue is using biomaterials that are able to integrate within the surrounding tissues within a reasonable period. Materials that facilitate local antibiotic release, such as ceramic-based materials, cement calcium phosphate, and hydrogels, are particularly useful in meeting the combined objectives of infection control and implant durability while also promoting osseointegration and tissue healing. Unfortunately, almost all clinically approved implant devices are composed of PMMA cement, which is recognized as not being biodegradable or osteoinductive at any level. This aspect remains a serious concern in orthopaedic surgery, and novel techniques are needed to improve patient outcomes. The development of novel biomaterials and drug delivery systems provides encouraging results in vitro and in animal models. However, more clinical trials are required to determine their effectiveness and safety in patients. Besides the general conclusions, prospective cohort studies (Mutimer et al. [103]; Regis et al. [63] and randomized clinical trials (Ueng et al. [85]) showed that although antibiotic-loaded carriers attain high initial concentrations, these concentrations decrease below therapeutic thresholds within 48-72 h. It was proven that PMMA-based delivery systems are efficient, but in most cases, they are characterized by a transient antimicrobial activity. From the long-term elution efficacy point of view, the analysis of Klinder et al. [10] performed on explanted spacers gave evidence that over 90% of the antimicrobial payload remains sequestered and clinically unavailable. By analysing the relation between systemic safety and multi-organ risk, it is worth mentioning that large-scale retrospective cohorts (Kang et al. [122]) and focused prospective safety studies (Oe et al. [77]) proved a reduced risk of acute systemic toxicity from local treatments. While local antibiotic delivery is linked to a low acute systemic toxicity in comparison with intravenous administration, an emerging moderate-quality study by Kang et al. [122] showed potential cardiovascular damage associated with metabolic changes due to a prolonged time of antibiotic treatment. So, as a direct consequence, the development of localized carriers minimizes systemic burden, but long-term longitudinal follow-up is necessary. An in vitro study that is based on bias evaluation by considering the 5 criteria solution confirmed that antibiotic loading acts as a structural contaminant when it is used in conjunction with living tissue [28]. There is strong laboratory evidence that adding bulk antibiotics to PMMA reduces its mechanical fatigue life and fracture toughness. This creates a fundamental efficiency gap, as the biological need for a high drug dose conflicts with the mechanical requirement for implant stability. This conflict highlights the urgent need for a shift towards surface-modified and nano-engineered drug delivery systems. The contemporary policy analysis performed by Gargate et al. [136] identifies a stagnant trend for new systemic Gram-negative antibiotics. Due to economic and regulatory challenges in antibiotic research, investigations indicate that optimizing the delivery of existing treatments is a critical clinical priority. The literature presents a paradox: although clinical success is often achieved in two-stage revisions, the evidence supported by methods such as microdialysis (Webb et al. [64]) and ELISA analysis (Janssen et al. [76]) indicates that traditional carriers are both pharmacokinetically and mechanically inefficient. Therefore, the shift toward nanotechnology-based solutions is not intended to replace current standards definitively; rather, it represents a methodologically supported evolution aimed at addressing the identified limitations of monolithic PMMA. Even though the analysed literature does not make explicit mention of new emerging solutions, recently PJI has benefited from novel and effective solutions. Antimicrobial peptides, bacteriophage therapy, and immunotherapy are among the most promising emerging tactics for the management of resistant, implant-associated infections. AMPs, including LL-37 and defensins, are naturally occurring host defence molecules with strong, broad-spectrum antimicrobial activity and immune-modulatory properties. The overall clinical adoption and use of AMPs is limited due to poor in vivo stability, potential high-dose cytotoxicity, and costs of production. Phage therapy, which targets specific bacterial pathogens, has promise for eliminating biofilm-related and multidrug-resistant PJI, particularly when used in conjunction with antibiotics. Nonetheless, issues associated with regulatory approval, phage-host specificity, and a limited supply of well-characterized phage banks prevent commercialization and widespread application. On the other hand, approaches to immunotherapy, including immune checkpoint modulators and cytokine therapies, are emerging as a potential to modulate host response to chronic infection, with the caveat that immunotherapy options engender immune-related side effects that can be systemic to the host. Clinical outcomes associated with translating to future clinical use will depend on overcoming biological and regulatory issues, in addition to efficacy, cost-effectiveness, and scaling considerations related to delivery platforms. Moreover, in recent years, machine learning and artificial intelligence have established itself as a valuable tool to find the best combinations of antibiotics and also decrease the time to discover peptide antibiotics. One prime example is that there were developed deep learning models that predict antimicrobial peptide activity to pathogens, such as Escherichia coli, with accuracies greater than 90% by utilizing the physicochemical properties (which are then used by the neural networks) [157]. The Simple Application Messaging Protocol (SAMP) model has been established since and has some additional features, including split amino acid composition, and provides improved predictions of AMPs over the previous models also demonstrating a better sensitivity and sequence specificity [158]. The tools will not only decrease experimental effort, but they also permit in silico screening of possible candidate peptides against whole bacteria, especially multidrug-resistant pathogens. One avenue could be built on moving forward in translating our Machine Learning (ML)-informed predictions to potential therapeutic candidates would be to incorporate datasets from clinical sources for resistance and important host toxicity profiles. In conclusion, this review maps local antibacterial strategies for PJI across PMMA-based antibiotic-loaded constructs, resorbable depots, hydrogels, coatings/nanomaterials, and emerging antibiofilm agents. The clinical evidence base remains strongest for PMMA-based spacers/cements as part of established staged-revision workflows, while resorbable carriers and advanced biomaterials are best supported as adjuncts or investigational solutions, with limited head-to-head outcome data against PMMA in two-stage revision settings. Key unmet needs include: (1) standardized release testing linked to clinically relevant geometries and dwell times; (2) standardized biofilm models and agreed endpoints beyond planktonic MIC; (3) comparative clinical studies with adequate follow-up reporting recurrence, reoperation, and complications; and (4) clearer safety frameworks that stratify renal risk by antibiotic class, dose, carrier, and patient baseline function. Addressing these gaps will enable clinically actionable selection of local antibacterial strategies and more defensible recommendations. CRediT authorship contribution statement Marco Fosca: Writing – review & editing, Writing – original draft, Visualization, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Veronica Manescu: Writing – review & editing, Writing – original draft, Visualization, Supervision, Methodology, Investigation, Conceptualization. Iulian Antoniac: Writing – review & editing, Validation, Supervision, Methodology, Conceptualization. Julietta V. Rau: Writing – review & editing, Validation, Supervision, Methodology, Data curation, Conceptualization. Ethics approval and consent to participate Not applicable. Founding sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest Julietta V. Rau is an associate editor and Iulian Antoniac is an editorial board members for Bioactive Materials and was not involved in the editorial review or the decision to publish this article. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.